Behavioral and Developmental Neuroscience

Kati Caro

Colby Gooch

First Edition, 2012

ISBN 978-81-323-1375-5

Published by:
College Publishing House
4735/22 Prakashdeep Bldg,
Ansari Road, Darya Ganj,
Delhi - 110002
Email: info@wtbooks.com

Table of Contents

Chapter 1

Behavioral Neuroscience

Behavioral neuroscience, also known as **biological psychology**, **biopsychology**, or **psychobiology** is the application of the principles of biology (in particular neurobiology), to the study of physiological, genetic, and developmental mechanisms of behavior in human and non-human animals. It typically investigates at the level of nerves, neurotransmitters, brain circuitry and the basic biological processes that underlie normal and abnormal behavior. Most typically experiments in behavioral neuroscience involve non-human animal models (such as rats and mice, and non-human primates) which have implications for better understanding of human pathology and therefore contribute to evidence based practice.

History

The study of behavioral neuroscience dates back to Avicenna (980-1037), a Persian psychologist and physician who in *The Canon of Medicine*, recognized physiological psychology in the treatment of illnesses involving emotions, and developed a system for associating changes in the pulse rate with inner feelings, which is seen as an anticipation of the word association test. Avicenna also gave psychological explanations for certain somatic illnesses, and he always linked the physical and psychological illnesses together. He explained that humidity inside the head can contribute to mood disorders, and he posited that this occurs when the amount of breath changes: happiness increases the breath, which leads to increased moisture inside the brain, but if this moisture goes beyond its limits, the brain would lose control over its rationality and lead to mental disorders.

Behavioral neuroscience as a scientific discipline later emerged from a variety of scientific and philosophical traditions in the 18th and 19th centuries. In philosophy, men like René Descartes proposed physical models to explain animal and human behavior. Descartes, for example, suggested that the pineal gland, a midline unpaired structure in the brain of many organisms, was the point of contact between mind and body. Descartes also elaborated on a theory in which the pneumatics of bodily fluids could explain reflexes and other motor behavior. This theory was inspired by moving statues in a garden in Paris.

Other philosophers also helped give birth to psychology. One of the earliest textbooks in the new field, *The Principles of Psychology* by William James (1890), argues that the scientific study of psychology should be grounded in an understanding of biology:

> “ Bodily experiences, therefore, and more particularly brain-experiences, must take a place amongst those conditions of the mental life of which Psychology need take account. The spiritualist and the associationist must both be 'cerebralists,' to the extent at least of admitting that certain peculiarities in the way of working of their own favorite principles are explicable only by the fact that the brain laws are a codeterminant of their result.
>
> Our first conclusion, then, is that a certain amount of brain-physiology must be presupposed or included in Psychology. ”

James, like many early psychologists, had considerable training in physiology. The emergence of both psychology and behavioral neuroscience as legitimate sciences can be traced from the emergence of physiology from anatomy, particularly neuroanatomy. Physiologists conducted experiments on living organisms, a practice that was distrusted by the dominant anatomists of the 18th and 19th centuries. The influential work of Claude Bernard, Charles Bell, and William Harvey helped to convince the scientific community that reliable data could be obtained from living subjects.

The term "psychobiology" has been used in a variety of contexts, but was likely first used in its modern sense by Knight Dunlap in his book *An Outline of Psychobiology (1914)*. Dunlap also founded the journal *Psychobiology*. In the announcement of that journal, Dunlap writes that the journal will publish research "...bearing on the interconnection of mental and physiological functions", which describes the field of behavioral neuroscience even in its modern sense.

Relationship to other fields of psychology and biology

In many cases, humans may serve as experimental subjects in behavioral neuroscience experiments; however, a great deal of the experimental literature in behavioral neuroscience comes from the study of non-human species, most frequently rats, mice, and monkeys. As a result, a critical assumption in behavioral neuroscience is that organisms share biological and behavioral similarities, enough to permit extrapolations across species. This allies behavioral neuroscience closely with comparative psychology, evolutionary psychology, evolutionary biology, and neurobiology. Behavioral neuroscience also has paradigmatic and methodological similarities to neuropsychology, which relies heavily on the study of the behavior of humans with nervous system dysfunction (i.e., a non-experimentally based biological manipulation).

Synonyms for behavioral neuroscience include biopsychology, behavioral neuroscience, and psychobiology. Physiological psychology is another term often used synonymously

with behavioral neuroscience, though authors would make physiological psychology a subfield of behavioral neuroscience, with an appropriately narrow definition.

Research methods

The distinguishing characteristic of a behavioral neuroscience experiment is that either the independent variable of the experiment is biological, or some dependent variable is biological. In other words, the nervous system of the organism under study is permanently or temporarily altered, or some aspect of the nervous system is measured (usually to be related to a behavioral variable).

Disabling or decreasing neural function

- **Lesions** - A classic method in which a brain-region of interest is destroyed or stimulated to observe any resulting changes such as degraded or enhanced performance on some behavioral measure. Lesions can be placed with relatively high accuracy thanks to a variety of brain 'atlases' which provide a map of brain regions in 3-dimensional stereotactic coordinates.
    - **Surgical lesions** - Neural tissue is destroyed by removing it surgically.
    - **Electrolytic lesions** - Neural tissue is destroyed through the application of electrical shock trauma.
    - **Chemical lesions** - Neural tissue is destroyed by the infusion of a neurotoxin.
    - **Temporary lesions** - Neural tissue is temporarily disabled by cooling or by the use of anesthetics such as tetrodotoxin.

- **Transcranial magnetic stimulation** - A new technique usually used with human subjects in which a magnetic coil applied to the scalp causes unsystematic electrical activity in nearby cortical neurons which can be experimentally analyzed as a functional lesion.
- **Psychopharmacological manipulations** - A chemical receptor antagonist induces neural activity by interfering with neurotransmission. Antagonists can be delivered systemically (such as by intravenous injection) or locally (intracerebrally) during a surgical procedure into the ventricles or into specific brain structures. For example, NMDA antagonist AP5 has been shown to inhibit the initiation of long term potentiation of excitatory synaptic transmission (in rodent fear conditioning) which is believed to be a vital mechanism in learning and memory.
- **optogenetic inhibition** - A light activated inhibitory protein is expressed in cells of interest. Powerful millisecond timescale neuronal inhibition is instigated upon stimulation by the appropriate frequency of light delivered via fiber optics or implanted LEDs in the case of vertebrates, or via external illumination for small, sufficiently translucent invertebrates. Bacterial Halorhodopsins or Proton pumps are the two classes of proteins used for inhibitory optogenetics, achieving inhibition by increasing cytoplasmic levels of halides (Cl-) or decreasing the cytoplasmic concentration of protons, respectively.

Enhancing neural function

- **Electrical Stimulation** - A classic method in which neural activity is enhanced by application of a small electrical current (too small to cause significant cell death).
- **Psychopharmacological manipulations** - A chemical receptor agonist facilitates neural activity by enhancing or replacing endogenous neurotransmitters. Agonists can be delivered systemically (such as by intravenous injection) or locally (intracerebrally) during a surgical procedure.
- **Transcranial magnetic stimulation** - In some cases (for example, studies of motor cortex), this technique can be analyzed as having a stimulatory effect (rather than as a functional lesion).
- **optogenetic excitation** - A light activated excitatory protein is expressed in select cells. Channelrhodopsin-2 (ChR2), a light activated cation channel, was the first bacterial opsin shown to excite neurons in response to light, though a number of new excitatory optogenetic tools have now been generated by improving and imparting novel properties to ChR2

Measuring neural activity

- **Optical techniques** - Optical methods for recording neuronal activity rely on methods that modify the optical properties of neurons in response to the cellular events associated with action potentials or neurotransmitter release.
    - Voltage sensitive dyes (VSDs) were among the earliest method for optically detecting action potentials. VSDs commonly become fluorescent in response to a neuron's change in voltage, rendering individual action potentials detectable. Genetically encoded voltage sensitive fluorescent proteins have also been developed.
    - Calcium imaging relies on dyes or genetically encoded proteins that fluoresce upon binding to the calcium that is transiently present during an action potential.
    - Synapto-pHluorin is a technique that relies on a fusion protein that combines a synaptic vesicle membrane protein and a pH sensitive fluorescent protein. Upon synaptic vesicle release, the chimeric protein is exposed to the higher pH of the synaptic cleft, causing a measurable change in fluorescence.
- **Single-unit recording** - A method whereby an electrode is introduced into the brain of a living animal to detect electrical activity that is generated by the neurons adjacent to the electrode tip. Normally this is performed with sedated animals but sometimes it is performed on awake animals engaged in a behavioral event, such as a thirsty rat whisking a particular sandpaper grade previously paired with water in order to measure the corresponding patterns of neuronal firing at the decision point.
- **Multielectrode recording** - The use of a bundle of fine electrodes to record the simultaneous activity of up to hundreds of neurons.
- **fMRI** - Functional magnetic resonance imaging, a technique most frequently applied on human subjects, in which changes in cerebral blood flow can be

detected in an MRI apparatus and are taken to indicate relative activity of larger scale brain regions (i.e., on the order of hundreds of thousands of neurons).
- **Electroencephalography** - Or EEG; and the derivative technique of event-related potentials, in which scalp electrodes monitor the average activity of neurons in the cortex (again, used most frequently with human subjects).
- **Functional neuroanatomy** - A more complex counterpart of phrenology. The expression of some anatomical marker is taken to reflect neural activity. For example, the expression of immediate early genes is thought to be caused by vigorous neural activity. Likewise, the injection of 2-deoxyglucose prior to some behavioral task can be followed by anatomical localization of that chemical; it is taken up by neurons that are electrically active.
- **MEG** - Magnetoencephalography shows the functioning of the human brain through the measurement of electromagnetic activity. Measuring the magnetic fields created by the electric current flowing within the neurons identifies brain activity associated with various human functions in real time, with millimeter spatial accuracy. Clinicians can noninvasively obtain data to help them assess neurological disorders and plan surgical treatments.

Genetic manipulations

- **QTL mapping** - The influence of a gene in some behavior can be statistically inferred by studying inbred strains of some species, most commonly mice. The recent sequencing of the genome of many species, most notably mice, has facilitated this technique.
- **Selective breeding** - Organisms, often mice, may be bred selectively among inbred strains to create a recombinant congenic strain. This might be done to isolate an experimentally interesting stretch of DNA derived from one strain on the background genome of another strain to allow stronger inferences about the role of that stretch of DNA.
- **Genetic engineering** - The genome may also be experimentally-manipulated; for example, knockout mice can be engineered to lack a particular gene, or a gene may be expressed in a strain which does not normally do so (the 'transgenic'). Advanced techniques may also permit the expression or suppression of a gene to occur by injection of some regulating chemical.

Limitations and advantages

Different manipulations have advantages and limitations. Neural tissue destroyed by surgery, electric shock or neurotoxcin is a permanent manipulation and therefore limits follow-up investigation. Most genetic manipulation techniques are also considered permanent. Temporary lesions can be achieved with advanced in genetic manipulations, for example, certain genes can now be switched on and off with diet. Pharmacological manipulations also allow blocking of certain neurotransmitters temporarily as the function returns to its previous state after the drug has been metabolized.

Topic areas in behavioral neuroscience

In general, behavioral neuroscientists study similar themes and issues as academic psychologists, though limited by the need to use nonhuman animals. As a result, the bulk of literature in behavioral neuroscience deals with mental processes and behaviors that are shared across different animal models such as:

- Sensation and perception
- Motivated behavior (hunger, thirst, sex)
- Control of movement
- Learning and memory
- Sleep and biological rhythms
- Emotion

However, with increasing technical sophistication and with the development of more precise noninvasive methods that can be applied to human subjects, behavioral neuroscientists are beginning to contribute to other classical topic areas of psychology, philosophy, and linguistics, such as:

- Language
- Reasoning and decision making
- Consciousness

Behavioral neuroscience has also had a strong history of contributing to the understanding of medical disorders, including those that fall under the purview of clinical psychology and biological psychopathology (also known as abnormal psychology). Although animal models do not exist for all mental illnesses, the field has contributed important therapeutic data on a variety of conditions, including:

- Parkinson's Disease, a degenerative disorder of the central nervous system that often impairs the sufferer's motor skills and speech.
- Huntington's Disease, a rare inherited neurological disorder whose most obvious symptoms are abnormal body movements and a lack of coordination. It also affects a number of mental abilities and some aspects of personality.
- Alzheimer's Disease, a neurodegenerative disease that, in its most common form, is found in people over the age of 65 and is characterized by progressive cognitive deterioration, together with declining activities of daily living and by neuropsychiatric symptoms or behavioral changes.
- Clinical depression, a common psychiatric disorder, characterized by a persistent lowering of mood, loss of interest in usual activities and diminished ability to experience pleasure.

- Schizophrenia, a psychiatric diagnosis that describes a mental illness characterized by impairments in the perception or expression of reality, most commonly manifesting as auditory hallucinations, paranoid or bizarre delusions or

disorganized speech and thinking in the context of significant social or occupational dysfunction.
- Autism, a brain development disorder that impairs social interaction and communication, and causes restricted and repetitive behavior, all starting before a child is three years old.
- Anxiety, a physiological state characterized by cognitive, somatic, emotional, and behavioral components. These components combine to create the feelings that are typically recognized as fear, apprehension, or worry.
- Drug abuse, including alcoholism

Nobel Laureates

The following Nobel Prize winners could reasonably be considered biological psychologists. (This list omits winners who were almost exclusively neuroanatomists or neurophysiologists; i.e., those that did not measure behavioral or psychological variables.)

- Charles Sherrington (1932)
- Edgar Adrian (1932)
- Walter Hess (1949)
- Egas Moniz (1949)
- Georg von Bekesy (1961)
- George Wald (1967)
- Ragnar Granit (1967)
- Konrad Lorenz (1973)
- Niko Tinbergen (1973)
- Karl von Frisch (1973)
- Roger W. Sperry (1981)
- David H. Hubel (1981)
- Torsten N. Wiesel (1981)
- Eric R. Kandel (2000)
- Arvid Carlsson (2000)
- Richard Axel (2004)
- Linda B. Buck (2004)

Chapter 2

Transcranial Magnetic Stimulation



rTMS in a rodent. From Oscar Arias-Carrión, 2008

Transcranial magnetic stimulation (**TMS**) is a noninvasive method to cause depolarization in the neurons of the brain. TMS uses electromagnetic induction to induce weak electric currents using a rapidly changing magnetic field; this can cause activity in specific or general parts of the brain with minimal discomfort, allowing the functioning and interconnections of the brain to be studied. A variant of TMS, **repetitive**

transcranial magnetic stimulation (**rTMS**), has been tested as a treatment tool for various neurological and psychiatric disorders including migraines, strokes, Parkinson's disease, dystonia, tinnitus, depression and auditory hallucinations.

Background

The principle of inductive brain stimulation with eddy currents has been noted since the 20th century. The first successful TMS study was performed in 1985 by Anthony Barker and his colleagues in Sheffield, England. Its earliest application demonstrated conduction of nerve impulses from the motor cortex to the spinal cord, stimulating muscle contractions. The use of magnets rather than a direct electric current to the brain reduced the discomfort of the procedure and research and allowed mapping of the cerebral cortex and its connections.

Effects on the brain

The exact details of how TMS functions are still being explored. The effects of TMS can be divided into two types depending on the mode of stimulation:

- Single or paired pulse TMS causes neurons in the neocortex under the site of stimulation to depolarise and discharge an action potential. If used in the primary motor cortex, it produces muscle activity referred to as a motor evoked potential (MEP) which can be recorded on electromyography. If used on the occipital cortex, 'phosphenes' (flashes of light) might be perceived by the subject. In most other areas of the cortex, the participant does not consciously experience any effect, but his or her behaviour may be slightly altered (e.g. slower reaction time on a cognitive task), or changes in brain activity may be detected using sensing equipment.

- Repetitive TMS produces longer-lasting effects which persist past the initial period of stimulation. rTMS can increase or decrease the excitability of the corticospinal tract depending on the intensity of stimulation, coil orientation and frequency. The mechanism of these effects is not clear although it is widely believed to reflect changes in synaptic efficacy akin to long-term potentiation (LTP) and long-term depression (LTD).

Risks

Although TMS is often regarded as safe, the greatest acute risk of TMS is the rare occurrence of induced seizures and syncope. More than 16 cases of TMS-related seizure have been reported in the literature, with at least seven reported before the publication of safety guidelines in 1998, and more than nine reported afterwards. The seizures have been associated with single-pulse and rTMS. Reports have stated that in at least some cases, predisposing factors (medication, brain lesions or genetic susceptibility) may have contributed to the seizure. A review of nine seizures associated with rTMS that had been reported after 1998 stated that four seizures were within the safety parameters, four were

outside of those parameters, and one had occurred in a healthy volunteer with no predisposing factors. A 2009 international consensus statement on TMS that contained this review concluded that based on the number of studies, subjects and patients involved with TMS research, the risk of seizure with rTMS is considered very low.

Besides seizures, other risks include fainting, minor pains such as headache or local discomfort, minor cognitive changes and psychiatric symptoms (particularly a low risk of mania in depressed patients). Though other side effects are thought to be possibly associated with TMS (alterations to the endocrine system, altered neurotransmitter and immune system activity) they are considered investigational and lacking substantive proof.

Other adverse effects of TMS are:

- Discomfort or pain from the stimulation of the scalp and associated nerves and muscles on the overlying skin; this is more common with rTMS than single pulse TMS,
- Rapid deformation of the TMS coil produces a loud clicking sound which increases with the stimulator intensity that can affect hearing with sufficient exposure, particularly relevant for rTMS (hearing protection may be used to prevent this),
- rTMS in the presence of incompatible EEG electrodes can result in electrode heating and, in severe cases, skin burns. Non-metallic electrodes are used if concurrent EEG data is required.

Clinical uses

The uses of TMS and rTMS can be divided into diagnostic and therapeutic uses.

Diagnosis

TMS can be used clinically to measure activity and function of specific brain circuits in humans. The most robust and widely-accepted use is in measuring the connection between the primary motor cortex and a muscle to evaluate damage from strokes, spinal cord injuries, multiple sclerosis and motor neuron disease. TMS has been suggested as a means of assessing short-interval intracortical inhibition (SICI) which measures the internal pathways of the motor cortex but this use has not yet been validated.

Therapy

Studies of the use of TMS and rTMS to treat neurological and psychiatric conditions have shown only modest effects with little confirmation of results. However, publications reporting the results of reviews and statistical meta-anaylses of earlier investigations have stated that rTMS appeared to be effective in the treatment of certain types of major depression under certain specific conditions. rTMS devices are marketed for the

treatment of such disorders in Canada, Australia, New Zealand, the European Union, Israel and the United States.

There is evidence that rTMS can temporarily reduce chronic pain and change pain-related brain and nerve activity, and TMS has been used to predict the success of surgically implanted electrical brain stimulation for the treatment of pain.

Other areas of research include the rehabilitation of aphasia and motor disability after stroke, tinnitus, Parkinson's disease and the negative symptoms of schizophrenia. TMS has failed to show effectiveness for the treatment of brain death, coma, and other persistent vegetative states.

It is difficult to establish a convincing form of "sham" TMS to test for placebo effects during controlled trials in conscious individuals, due to the neck pain, headache and twitching in the scalp or upper face associated with the intervention. "Sham" TMS manipulations can affect cerebral glucose metabolism and MEPs, which may confound results. This problem is exacerbated when using subjective measures of improvement. Depending on the research question asked and the experimental design, matching this discomfort to distinguish true effects from placebo can be an important and challenging issue.

A recent multicenter trial of rTMS in depression used a "sham" placebo treatment that appeared to mimic the sound and scalp stimulation associated with active TMS treatment. The investigators concluded: "Although the treatment effect was statistically significant on a clinically meaningful variable (remission), the overall number of remitters and responders was less than one would like with a treatment that requires daily intervention for 3 weeks or more, even with a benign adverse effect profile". However, a review of the trial's report has questioned the adequacy of the placebo, noting that treaters were able to guess whether patients were receiving treatment with active or sham TMS, better than chance.

FDA actions and responses

FDA actions

In January 2007 an advisory panel of the United States Food and Drug Administration (FDA) did not recommend clearance for marketing of an rTMS device, stating that the device appeared to be reasonably safe but had failed to demonstrate efficacy in a study of people with major depression who had not benefitted from prior adequate treatment with oral antidepressants during their current major depressive episode. The panel agreed that "unblinding was greater in the active group, and considering the magnitude of the effect size, it may have influenced the study results." However, the FDA determined in December 2008 that the rTMS device was sufficiently similar to existing devices that did not require a premarket approval application and allowed the device to be marketed in accordance with Section 510(k) of the Federal Food, Drug, and Cosmetic Act for "the treatment of Major Depressive Disorder in adult patients who have failed to achieve

satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode". The user manual for the device warns that effectiveness has not been established in patients with major depressive disorder who have failed to achieve satisfactory improvement from zero and from two or more antidepressant medications in the current episode and that the device has not been studied in patients who have had no prior antidepressant medication.

Response to FDA decision

Soon after the FDA cleared the device, several members of Public Citizen stated in a letter to the editor of the medical journal *Neuropsychopharmacology* that the FDA seemed to have based its decision on a *post-hoc* analysis that did not establish the effectiveness of rTMS for the treatment of depression. The writers of the letter expressed their concern that patients would be diverted from therapies such as antidepressant medications that have an established history of effectiveness.

Technical information



TMS - Butterfly Coils

TMS uses electromagnetic induction to generate an electric current across the scalp and skull without physical contact. A plastic-enclosed coil of wire is held next to the skull and when activated, produces a magnetic field oriented orthogonally to the plane of the coil. The magnetic field passes unimpeded through the skin and skull, inducing an oppositely directed current in the brain that activates nearby nerve cells in much the same way as currents applied directly to the cortical surface. The path of this current is difficult to model because the brain is irregularly shaped and electricity and magnetism are not conducted uniformly throughout its tissues. The magnetic field penetrates only to a maximum depth of three centimeters into the brain, in the area directly adjacent to the coil.

Coil types

The design of transcranial magnetic stimulation coils used in either treatment or diagnostic/experimental studies may differ in a variety of ways. These differences should be considered in the interpretation of any study result, and the type of coil used should be specified in the study methods for any published reports.

The most important considerations include:

- the type of material used to construct the core of the coil
- the geometry of the coil configuration
- the biophysical characteristics of the pulse produced by the coil.

With regard to coil composition, the core material may be either a magnetically inert substrate (i.e., the so-called ‘air-core’coil design), or possess a solid, ferromagnetically active material (ie, the so-called ‘solid-core’ design). Solid core coil design result in a more efficient transfer of electrical energy into a magnetic field, with a substantially reduced amount of energy dissipated as heat, and so can be operated under more aggressive duty cycles often mandated in therapeutic protocols, without treatment interruption due to heat accumulation, or the use of an accessory method of cooling the coil during operation. Varying the geometric shape of the coil itself may also result in variations in the focality, shape, and depth of cortical penetration of the magnetic field.

Differences in the coil substance as well as the electronic operation of the power supply to the coil may also result in variations in the biophysical characteristics of the resulting magnetic pulse (e.g., width or duration of the magnetic field pulse). All of these features should be considered when comparing results obtained from different studies, with respect to both safety and efficacy.

A number of different types of coils exist, each of which produce different magnetic field patterns. Some examples:

- round coil: the original type of TMS coil
- figure-eight coil (i.e. butterfly coil): results in a more focal pattern of activation
- double-cone coil: conforms to shape of head, useful for deeper stimulation
- four-leaf coil: for focal stimulation of peripheral nerves

Design variations in the shape of the TMS coils allow much deeper penetration of the brain than the standard depth of 1.5 cm. Circular, H-shaped, double cone coils and other experimental variations can induce excitation or inhibition of neurons deeper in the brain including activation of motor neurons for the cerebellum, legs and pelvic floor. Though able to penetrate deeper in the brain, they are less able to produced a focused, localized response and are relatively non-focal.

Chapter 3

Functional Magnetic Resonance Imaging

Functional MRI or **functional Magnetic Resonance Imaging (FMRI)** is a type of specialized MRI scan. It measures the hemodynamic response (change in blood flow) related to neural activity in the brain or spinal cord of humans or other animals. It is one of the most recently developed forms of neuroimaging. Since the early 1990s, fMRI has come to dominate the brain mapping field due to its relatively low invasiveness, absence of radiation exposure, and relatively wide availability.



fMRI statistics (yellow) overlaid on an average of the brain anatomies of several humans (gray)

Background

Since the 1890s it has been known that changes in blood flow and blood oxygenation in the brain (collectively known as hemodynamics) are closely linked to neural activity. When neural cells are active they increase their consumption of energy from glucose and switch to less energetically effective, but more rapid aerobic glycolysis. The local response to this energy utilization is to increase blood flow to regions of increased neural activity, which occurs after a delay of approximately 1–5 seconds. This hemodynamic response rises to a peak over 4–5 seconds, before falling back to baseline (and typically undershooting slightly). This leads to local changes in the relative concentration of oxyhemoglobin and deoxyhemoglobin and changes in local cerebral blood volume and in local cerebral blood flow.

History

Blood-oxygen-level dependence (BOLD) is the MRI contrast of blood deoxyhemoglobin, first discovered in 1990 by Seiji Ogawa at AT&T Bell labs. Ogawa and colleagues had recognized the potential importance of BOLD for functional brain imaging with MRI, but the first successful fMRI study was reported by John W. Belliveau and colleagues in 1991 using an intraveneously administered paramagnetic contrast agent (Gadolinium). Using a visual stimulus paradigm, localized increases in blood volume (32 +/- 10 percent, n = 7 subjects) were detected in the primary visual cortex. In 1992, three papers were published using endogenous BOLD contrast MRI. One was submitted by Peter Bandettini at the Medical College of Wisconsin on February 5, revised March 31, accepted March 31 and published in the June 1992 issue of *Magnetic Resonance in Medicine* (MRM). The second by Kenneth Kwong and colleagues also applied BOLD to image human brain activities with MRI and was submitted on March 26 and published in the June issue of PNAS in 1992. In the same year, Dr. Ogawa submitted their result on March 31 and published in July issue of PNAS. In the following year, Dr. Ogawa published the biophysics model of BOLD contrast in Biophysical Journal. Dr. Bandettini also published a further paper in 1993 demonstrating quantitative determination of functional activation maps.

Physiology

As neurons do not have internal reserves for glucose and oxygen, more neuronal activity requires more glucose and oxygen to be delivered rapidly through the blood stream. Through a process called the hemodynamic response, blood releases glucose to neurons and astrocytes at a greater rate than in the area of inactive neurons. It results in a surplus of oxyhemoglobin in the veins of the area and distinguishable change of the local ratio of oxyhemoglobin to deoxyhemoglobin, the "marker" of BOLD for MRI.

Hemoglobin is diamagnetic when oxygenated (oxyhemoglobin) but paramagnetic when deoxygenated (deoxyhemoglobin). The magnetic resonance (MR) signal of blood is therefore slightly different depending on the level of oxygenation. Higher BOLD signal intensities arise from increases in the concentration of oxygenated hemoglobin since the blood magnetic susceptibility now more closely matches the tissue magnetic susceptibility. By collecting data in an MRI scanner with sequence parameters sensitive to changes in magnetic susceptibility one can assess changes in BOLD contrast. These changes can be either positive or negative depending upon the relative changes in both cerebral blood flow (CBF) and oxygen consumption. Increases in CBF that outstrip changes in oxygen consumption will lead to increased BOLD signal, conversely decreases in CBF that outstrip changes in oxygen consumption will cause decreased BOLD signal intensity. The signal difference is very small, but given many repetitions of a thought, action or experience, statistical methods can be used to determine the areas of the brain which reliably show more of this difference as a result, and therefore which areas of the brain are active during that thought, action or experience.

Almost all current fMRI research uses BOLD as the method for determining where activity occurs in the brain as the result of various experiences, but because the signals are relative and not individually quantitative, some question its rigor. Other methods which propose to measure neural activity more directly have been attempted (for example measurement of the Oxygen Extraction Fraction (OEF) in regions of the brain, which measures how much of the oxyhemoglobin in the blood has been converted to deoxyhemoglobin or direct detection of magnetic fields generated by neuronal currents), but because the electromagnetic fields created by an active or firing neuron are so weak, the signal-to-noise ratio is extremely low and statistical methods used to extract quantitative data have been largely unsuccessful as of yet.

Neural correlates of BOLD

The precise relationship between neural signals and BOLD is under active research. In general, changes in BOLD signal are well correlated with changes in blood flow. Numerous studies during the past several decades have identified a coupling between blood flow and metabolic rate that is, the blood supply is tightly regulated in space and time to provide the nutrients for brain metabolism. However, neuroscientists have been seeking a more direct relationship between the blood supply and the neural inputs/outputs that can be related to observable electrical activity and circuit models of brain function.

While current data indicate that local field potentials, an index of integrated electrical activity, form a marginally better correlation with blood flow than the spiking action potentials that are most directly associated with neural communication, no simple measure of electrical activity to date has provided an adequate correlation with metabolism and the blood supply across a wide dynamic range. Presumably, this reflects the complex nature of metabolic processes, which form a superset with regards to electrical activity. Some recent results have suggested that the increase in cerebral blood flow (CBF) following neural activity is not causally related to the metabolic demands of the brain region, but rather is driven by the presence of neurotransmitters, like glutamate, serotonin, nitric oxide, acetylcholine, dopamine and noradrenaline.

Some other recent results suggest that an initial small, negative dip before the main positive BOLD signal is more highly localized and also correlates with measured local decreases in tissue oxygen concentration (perhaps reflecting increased local metabolism during neuron activation). Use of this more localized negative BOLD signal has enabled imaging of human ocular dominance columns in primary visual cortex, with resolution of about 0.5 mm. One problem with this technique is that the early negative BOLD signal is small and can only be seen using larger scanners with magnetic fields of at least 3 Tesla. Further, the signal is much smaller than the normal BOLD signal, making extraction of the signal from noise more difficult. Also, this initial dip occurs within 1–2 seconds of stimulus initiation, which may not be captured when signals are recorded at long repetition (TR). If the TR is sufficiently low, increased speed of the cerebral blood flow response due to consumption of vasoactive drugs (such as caffeine) or natural differences in vascular responsiveness may further obscure observation of the initial dip.

The BOLD signal is composed of CBF contributions from larger arteries and veins, smaller arterioles and venules, and capillaries. Experimental results indicate that the BOLD signal can be weighted to the smaller vessels, and hence closer to the active neurons, by using larger magnetic fields. For example, whereas about 70% of the BOLD signal arises from larger vessels in a 1.5 tesla scanner, about 70% arises from smaller vessels in a 7 tesla scanner. Furthermore, the size of the BOLD signal increases roughly as the square of the magnetic field strength. Hence there has been a push for larger field scanners to both improve localization and increase the signal. A few 7 tesla commercial scanners have become operational, and experimental 8 and 9 tesla scanners are under development.

Technique

BOLD effects are measured using rapid volumetric acquisition of images with contrast weighed by T1 or T2*. Such images can be acquired with moderately good spatial and temporal resolution; images are usually taken every 1–4 seconds, and the voxels in the resulting image typically represent cubes of tissue about 2–4 millimeters on each side in humans. Recent technical advancements, such as the use of high magnetic fields and multichannel RF reception, have advanced spatial resolution to the millimeter scale. Although responses to stimuli presented as close together as one or two seconds can be distinguished from one another, using a method known as event-related fMRI, the full time course of a BOLD response to a briefly presented stimulus lasts about 15 seconds for the robust positive response.

fMRI studies draw from many disciplines

fMRI is a highly interdisciplinary research area and many studies draw on knowledge in several fields:

- Physics: Physical principles underlie fMRI signals and many studies require an understanding of these underlying principles.
- Psychology: Almost all fMRI studies are essentially cognitive psychological, cognitive psychophysiological, and/or psychophysical experiments in which the MRI scanner is used to obtain an extra set of measurements in addition to behavioral or electroencephalographic measurements.
- Neuroanatomy: The fMRI signals can be put into the context of previous knowledge only with an understanding of the neuroanatomy.
- Statistics: Correct application of statistics is essential to "tease out" observations and avoid false-positive results.
- Electrophysiology: Familiarity with neuronal behavior at the electrophysiological level can help investigators design a useful fMRI study.

Advantages and Disadvantages of fMRI

Like any technique, fMRI has advantages and disadvantages, and in order to be useful, the experiments that employ it must be carefully designed and conducted to maximize its strengths and minimize its weaknesses.

Advantages of fMRI

- It can noninvasively record brain signals without risks of radiation inherent in other scanning methods, such as CT or PET scans.
- It has high spatial resolution. 2–3 mm is typical but resolution can be as good as 1mm.
- It can record signal from all regions of the brain, unlike EEG/MEG which are biased towards the cortical surface.
- fMRI is widely used and standard data-analysis approaches have been developed which allow researchers to compare results across labs.
- fMRI produces compelling images of brain "activation".

Disadvantages of fMRI

- The images produced must be interpreted carefully, since correlation does not imply causality, and brain processes are complex and often non-localized.
- Statistical methods must be used carefully because they can produce false positives. One team of researchers studying reactions to pictures of human emotional expressions reported a few activated voxels in the brain of a dead salmon when no correction for multiple comparisons was applied, illustrating the need for rigorous statistical analyses.
- The BOLD signal is only an indirect measure of neural activity, and is therefore susceptible to influence by non-neural changes in the body. This also means that it is difficult to interpret positive and negative BOLD responses
- BOLD signals are most strongly associated with the input to a given area rather than with the output. It is therefore possible (although unlikely) that a BOLD signal could be present in a given area even if there is no single unit activity.
- fMRI has poor temporal resolution. The BOLD response peaks approximately 5 seconds after neuronal firing begins in an area. This means that it is hard to distinguish BOLD responses to different events which occur within a short time window. Careful experimental design can reduce this problem. Also, some research groups are attempting to combine fMRI signals that have relatively high spatial resolution with signals recorded with other techniques, electroencephalography (EEG) or magnetoencephalography (MEG), which have higher temporal resolution but worse spatial resolution.
- fMRI has often been used to show activation localized to specific regions, thus minimizing the distributed nature of processing in neural networks. Several recent multivariate statistical techniques work around this issue by characterizing interactions between "active" regions found via traditional univariate techniques.

- The BOLD response can be affected by a variety of factors, including: drugs/substances; age, brain pathology; local differences in neurovascular coupling; attention; amount of carbon dioxide in the blood; etc.

For these reasons, Functional imaging provides insights into neural processing that are complementary to insights of other studies in neurophysiology.

Scanning in practice



Berkeley's 4T fMRI scanner

Subjects participating in a fMRI experiment are asked to lie still and are usually restrained with soft pads to prevent movement from disturbing measurements. Some labs also employ bite bars to reduce motion, although these are unpopular as they can be uncomfortable. Small head movements can be corrected for in post-processing of the data, but large transient motion cannot be corrected. Motion in excess of around 3 millimeters results in unusable data. Motion is an issue for all populations, but most especially problematic for subjects with certain medical conditions (e.g. Alzheimer's Disease or schizophrenia) or with young children. Participants can be habituated to the scanning environment and trained to remain still in an MRI simulator.

An fMRI experiment usually lasts between 15 minutes and an hour. Depending on the purpose of study, subjects may view movies, hear sounds, smell odors, perform cognitive

tasks such as n-back, memorization or imagination, press a few buttons, or perform other tasks. Researchers are required to give detailed instructions and descriptions of the experiment plan to each subject, who must sign a consent form before the experiment.

Safety is an important issue in all experiments involving MRI. Potential subjects must ensure that they are able to enter the MRI environment. The MRI scanner is built around an extremely strong magnet (1.5 teslas or more), so potential subjects must be thoroughly examined for any ferromagnetic objects (e.g. watches, glasses, hair pins, pacemakers, bone plates and screws, etc.) before entering the scanning environment.

Related techniques

Aside from BOLD fMRI, there are other related ways to probe brain activity using magnetic resonance properties:

Diffusion based functional MRI

Neuronal activity produces some immediate physical changes in cell shape that can be detected because they affect the compartment shape and size for water diffusion. A much improved spatial and temporal resolution for fMRI data collection has now been achieved by using diffusion MRI methodology that can detect these changes in neurons. The abrupt onset of increased neuron cell size occurs before the metabolic response commences, is shorter in duration and does not extend significantly beyond the area of the actual cell population involved. This technique is a diffusion weighted technique (DWI). There is some evidence that similar changes in axonal volume in white matter may accompany activity and this has been observed using a DTI (diffusion tensor imaging) technique. The future importance of diffusion-based functional techniques relative to BOLD techniques is not yet clear.

Contrast MR

An injected contrast agent such as an iron oxide that has been coated by a sugar or starch (to hide from the body's defense system), causes a local disturbance in the magnetic field that is measurable by the MRI scanner. The signals associated with these kinds of contrast agents are proportional to the cerebral blood volume. While this semi-invasive method presents a considerable disadvantage in terms of studying brain function in normal subjects, it enables far greater detection sensitivity than BOLD signal, which may increase the viability of fMRI in clinical populations. Other methods of investigating blood volume that do not require an injection are a subject of current research, although no alternative technique in theory can match the high sensitivity provided by injection of contrast agent.

Arterial spin labeling

Arterial Spin Labelling (ASL), also known as arterial spin tagging, is an MRI technique capable of measuring cerebral blood flow (CBF) *in vivo*. ASL is capable of providing

cerebral perfusion maps, without requiring the administration of a contrast agent or the use of ionising radiation, as it uses magnetically-labelled endogenous blood water as a freely-diffusible tracer. It was first proposed in 1992 and has since benefited from a number of modifications aimed at improving its robustness. ASL can monitor changes in CBF with activation and fMRI studies can therefore be conducted using ASL instead of relying on the BOLD effect. ASL fMRI is less popular than BOLD, as it suffers from a lower signal to noise ratio, can be less sensitive to weak stimuli and its temporal resolution is poorer than in BOLD studies. On the plus side, it can provide quantitative measures of a single well-defined parameter, CBF, whose baseline value can also be determined in the same experiment. It has also been found to outperform BOLD in terms of stability to slow signal drifts and localization of the activation area. The ASL activation signal is believed to be dominated by changes in the capillary bed of the activated area of the cortex, wheareas the BOLD signal is likely to be dominated by changes in the oxygenation of nearby veins.

Magnetic resonance spectroscopic imaging

Magnetic resonance spectroscopic imaging (MRS) is another, NMR-based process for assessing function within the living brain. MRS takes advantage of the fact that protons (hydrogen atoms) residing in differing chemical environments depending upon the molecule they inhabit (H_2O vs. protein, for example) possess slightly different resonant properties (chemical shift). For a given volume of brain (typically > 1 cubic cm), the distribution of these H resonances can be displayed as a spectrum.

The area under the peak for each resonance provides a quantitative measure of the relative abundance of that compound. The largest peak is composed of H_2O. However, there are also discernible peaks for choline, creatine, *N*-acetylaspartate (NAA) and lactate. Fortuitously, NAA is mostly inactive within the neuron, serving as a precursor to glutamate and as storage for acetyl groups (to be used in fatty acid synthesis) — but its relative levels are a reasonable approximation of neuronal integrity and functional status. Brain diseases (schizophrenia, stroke, certain tumors, multiple sclerosis) can be characterized by the regional alteration in NAA levels when compared to healthy subjects. Creatine is used as a relative control value since its levels remain fairly constant, while choline and lactate levels have been used to evaluate brain tumors.

Diffusion tensor imaging

Diffusion tensor imaging (DTI) is a related use of MR to measure anatomical connectivity between areas. Although it is not strictly a functional imaging technique because it does not measure dynamic changes in brain function, the measures of inter-area connectivity it provides are complementary to images of cortical function provided by BOLD fMRI. White matter bundles carry functional information between brain regions. The diffusion of water molecules is hindered across the axes of these bundles, such that measurements of water diffusion can reveal information about the location of large white matter pathways. Illnesses that disrupt the normal organization or integrity of

cerebral white matter (such as multiple sclerosis) have a quantitative impact on DTI measures.

fMRI and EEG

Functional MRI has high spatial resolution but relatively poor temporal resolution (of the order of several seconds). Electroencephalography (EEG) directly measures the brain's electrical activity, giving high temporal resolution (~milliseconds) but low spatial resolution. The two techniques are therefore complementary and may be used simultaneously to record brain activity.

Recording an EEG signal inside an MRI system is technically challenging. The MRI system introduces artifacts into the EEG recording by inducing currents in the EEG leads via Faraday induction. This can happen through several different mechanisms. An imaging sequence applies a series of short radiofrequency pulses which induce a signal in the EEG system. The pulses are short and relatively infrequent, so interference may be avoided by blanking (switching off) the EEG system during their transmission. Magnetic field gradients used during imaging also induce a signal, which is harder to remove as it is in a similar frequency range to the EEG signal. Current is also induced when EEG leads move inside the magnet bore (i.e. when the patient moves during the exam). Finally, pulsed blood flow in the patient in the static magnetic field also induces a signal (called a ballistocardiographic artifact), which is also within the frequency range of interest. The EEG system also affects the MRI scan. Metal in the EEG leads and electrodes can introduce susceptibility artifacts into MR images. Care must also be taken to limit currents induced in the EEG leads via the MRI RF system, which could heat the leads sufficiently to burn the subject.

Having simultaneously recorded EEG and fMRI data, the final hurdle is to co-register the two datasets, as each is reconstructed using a different algorithm, subject to different distortions.

Nuclear neuroimaging

Before the advent of fMRI functional neuroimaging was typically performed with positron emission tomography (PET) scanners or more rarely with SPECT scanners. Niels A. Lassen and his coworkers lead the earliest efforts of functional neuroimaging, using radioactive gases to construct images of the working brain.

These nuclear imaging techniques do not use the nuclear magnetic resonance property and employ entirely different scanners.

Approaches to fMRI data analysis

The ultimate goal of fMRI data analysis is to detect correlations between brain activation and the task the subject performs during the scan. The BOLD signature of activation is relatively weak, however, so other sources of noise in the acquired data must be carefully

controlled. This means that a series of processing steps must be performed on the acquired images before the actual statistical search for task-related activation can begin.

For a typical fMRI scan, the 3D volume of the subject's head is imaged every one or two seconds, producing a few hundred to a few thousand complete images per scanning session. The nature of MRI is such that these images are acquired in Fourier transform space, so they must be transformed back to image space to be useful. Because of practical limitations of the scanner the Fourier samples are not acquired on a grid, and scanner imperfections like thermal drift and spike noise introduce additional distortions. Small motions on the part of the subject and the subject's pulse and respiration will also affect the images.

The most common situation is that the researcher uses a pulse sequence supplied by the scanner vendor, such as an echo-planar imaging (EPI) sequence that allows for relatively rapid acquisition of many images. Software in the scanner platform itself then performs the reconstruction of images from Fourier transform space. During this stage some information is lost (specifically the complex phase of the reconstructed signal). Some types of artifacts, for example spike noise, become more difficult to remove after reconstruction, but if the scanner is working well these artifacts are thought to be relatively unimportant. For pulse sequences not provided by the vendor, for example spiral EPI, reconstruction may have to be done by software running on a separate platform.

After reconstruction the output of the scanning session consists of a series of 3D images of the brain. The most common corrections performed on these images are motion correction and correction for physiological effects. Outlier correction and spatial and/or temporal filtering may also be performed. If the task performed by the subject is thought to produce bursts of activation which are short compared to the BOLD response time (on the order of 6 seconds), temporal filtering may be performed at this stage to attempt to deconvolve out the BOLD response and recover the temporal pattern of activation.

At this point the data provides a time series of samples for each voxel in the scanned volume. A variety of methods are used to correlate these voxel time series with the task in order to produce maps of task-dependent activation.

There are many software packages available for analysing fMRI data.

Reconstruction of MRI data needs to be tested, calibrated and confirmed. MRI can suffer from numerous artifacts that include, geometric distortions, Nyquist ghosting, and signal dropout. Medical Imaging Phantoms are used to provide a consistent geometrical source for calibration and testing purposes. Minute tumor changes can require recalibration by use of a phantom to quantify the change.

Cost of fMRI

The major cost of an fMRI experiment is the MR scanner itself. New 1.5 tesla scanners often cost between $1,000,000 USD and $1,500,000 USD. New 3.0 tesla scanners often cost between $2,000,000 and $2,300,000 USD. Construction of MRI suites can cost $500,000 USD.

MRI procedures themselves can vary considerably in cost but generally fall somewhere between $400 and $3,500, depending on the facility and which region of the body is being scanned. Extremity scans (feet, hands, etc.) tend to be lower in price while body scans (including the brain) tend to be higher.

Commercial use

Most fMRI scans are for research or clinical use. Commercial use is limited. However, a few companies have been set up that attempt to sell fMRI specific hardware or services for research or clinical use.

At least two companies have been set up to use fMRI in lie detection (*No Lie MRI, Inc* and *Cephos Corporation*).

In using fMRI techniques for use in lie detection, activated areas of the brain are observed while the subject is making a statement. Depending on what regions are the most active, the technician might determine whether a subject is telling the truth or not. Since a specific combination of brain functions are needed in order to tell a lie, the simultaneous activation of these regions often indicates deception. This technology is in its early stages of development, and many of its proponents hope to replace older lie detection techniques.

In clinical trials, the usage of fMRI as a method of lie detection has appeared reliable, with studies from 2005 by Kozel et al. indicating a 90% to 93% success rate.

However, there is still a fair amount of controversy over whether these techniques are reliable enough to be used in a legal setting. Some studies indicate that while there is an overall positive correlation, there is a great deal of variation between findings and in some cases considerable difficulty in replicating the findings.

Chapter 4

Magnetoencephalography

Magnetoencephalography (**MEG**) is a technique for mapping brain activity by recording magnetic fields produced by electrical currents occurring naturally in the brain, using arrays of SQUIDs (superconducting quantum interference devices). Applications of MEG include basic research into perceptual and cognitive brain processes, localizing regions affected by pathology before surgical removal, determining the function of various parts of the brain, and neurofeedback.

History of MEG

MEG signals were first measured by University of Illinois physicist David Cohen in 1968, before the availability of the SQUID, using a copper induction coil as the detector. To reduce the magnetic background noise, the measurements were made in a magnetically shielded room. The coil detector was barely sensitive enough, resulting in poor, noisy MEG measurements that were difficult to use. Later, Cohen built a better shielded room at MIT, and used one of the first SQUID detectors, just developed by James E. Zimmerman, a researcher at Ford Motor Company, to again measure MEG signals. This time the signals were almost as clear as those of EEG. This stimulated the interest of physicists who had been looking for uses of SQUIDs. Subsequently, various types of spontaneous and evoked MEGs began to be measured.

At first, a single SQUID detector was used to successively measure the magnetic field at a number of points around the subject's head. This was cumbersome, and in the 1980s, MEG manufacturers began to arrange multiple sensors into arrays to cover a larger area of the head. Present-day MEG arrays are set in helmet-shaped dewar that typically contain 300 sensors, covering most of the head. In this way, MEGs of a subject or patient can now be accumulated rapidly and efficiently.

The basis of the MEG signal



Patient undergoing an MEG

Synchronized neuronal currents induce weak magnetic fields. At 10 femtotesla (fT) for cortical activity and 10^3 fT for the human alpha rhythm, the brain's magnetic field is considerably smaller than the ambient magnetic noise in an urban environment, which is on the order of 10^8 fT or 10 μT. The essential problem of biomagnetism is thus the weakness of the signal relative to the sensitivity of the detectors, and to the competing environmental noise.



Origin of the brain's magnetic field. The electric current also produces the EEG signal.

The MEG (and EEG) signals derive from the net effect of ionic currents flowing in the dendrites of neurons during synaptic transmission. In accordance with Maxwell's equations, any electrical current will produce an orthogonally oriented magnetic field. It is this field which is measured. The net currents can be thought of as electric dipoles, i.e. currents with a position, orientation, and magnitude, but no spatial extent. According to the right-hand rule, a current dipole gives rise to a magnetic field that flows around the axis of its vector component.

To generate a signal that is detectable, approximately 50,000 active neurons are needed. Since current dipoles must have similar orientations to generate magnetic fields that reinforce each other, it is often the layer of pyramidal cells, which are situated perpendicular to the cortical surface, that give rise to measurable magnetic fields. Bundles of these neurons that are orientated tangentially to the scalp surface project measurable portions of their magnetic fields outside of the head, and these bundles are typically located in the sulci. Researchers are experimenting with various signal processing methods in the search for methods that detect deep brain (i.e., non-cortical) signal, but no clinically useful method is currently available.

It is worth noting that action potentials do not usually produce an observable field, mainly because the currents associated with action potentials flow in opposite directions and the magnetic fields cancel out. However, action fields have been measured from peripheral nerves.

Magnetic shielding

Since the magnetic signals emitted by the brain are on the order of a few femtoteslas, shielding from external magnetic signals, including the Earth's magnetic field, is necessary. Appropriate magnetic shielding can be obtained by constructing rooms made of aluminium and mu-metal for reducing high-frequency and low-frequency noise, respectively.

Entrance to MSR, showing the separate shielding layers

Magnetically shielded room (MSR)

A magnetically shielded room (MSR) model consists of three nested main layers. Each of these layers is made of a pure aluminium layer, plus a high permeability ferromagnetic layer, similar in composition to molybdenum permalloy. The ferromagnetic layer is supplied as 1 mm sheets, while the innermost layer is composed of four sheets in close contact, and the outer two layers are composed of three sheets each. Magnetic continuity is maintained by overlay strips. Insulating washers are used in the screw assemblies to ensure that each main layer is electrically isolated. This helps eliminate radio frequency radiation, which would degrade SQUID performance. Electrical continuity of the aluminium is also maintained by aluminium overlay strips to ensure AC eddy-current shielding, which is important at frequencies greater than 1 Hz. The junctions of the inner layer are often electroplated with silver or gold to improve conductivity of the aluminium layers.

Active shielding system

Active systems are designed for three dimensional noise cancellation. To implement an active system, low-noise fluxgate magnetometers are mounted at the center of each surface and oriented orthogonally to it. This negatively feeds a DC amplifier through a low-pass network with a slow falloff to minimize positive feedback and oscillation. Built into the system are shaking and degaussing wires. Shaking wires increase the magnetic permeability, while the permanent degaussing wires are applied to all surfaces of the inner main layer to degauss the surfaces. Moreover, noise cancellation algorithms can reduce both low-frequency and high-frequency noise. Modern systems have a noise floor of around 2–3 $fT/Hz^{0.5}$ above 1 Hz.

Source localization

The inverse problem

The challenge posed by MEG is to determine the location of electric activity within the brain from the induced magnetic fields outside the head. Problems such as this, where model parameters (the location of the activity) have to be estimated from measured data (the SQUID signals) are referred to as *inverse problems* (in contrast to *forward problems* where the model parameters (e.g. source location) are known and the data (e.g. the field at a given distance) is to be estimated.) The primary difficulty is that the inverse problem does not have a unique solution (i.e., there are infinite possible "correct" answers), and the problem of defining the "best" solution is itself the subject of intensive research. Possible solutions can be derived using models involving prior knowledge of brain activity.

The source models can be either over-determined or under-determined. An over-determined model may consist of a few point-like sources ("equivalent dipoles"), whose locations are then estimated from the data. Under-determined models may be used in cases where many different distributed areas are activated ("distributed source solutions"): there are infinitely many possible current distributions explaining the measurement results, but the most likely is selected. Localization algorithms make use of given source and head models to find a likely location for an underlying focal field generator.

Localization algorithms using overdetermined models operate by expectation-maximization: the system is initialized with a first guess. A loop is started, in which a forward model is used to simulate the magnetic field that would result from the current guess. The guess is adjusted to reduce the discrepancy between the simulated field and the measured field. This process is iterated until convergence.

The extent to which the constraint-free MEG inverse problem is ill-posed cannot be overemphasized. If one's goal is to estimate the current density within the human brain with say a 5mm resolution then it is well established that the vast majority of the information needed to perform a unique inversion must come not from the magnetic field measurement but rather from the constraints applied to the problem. Furthermore, even when a unique inversion is possible in the presence of such constraints said inversion can be unstable. These conclusions are easily deduced from published works

Magnetic source imaging

The estimated source locations can be combined with magnetic resonance imaging (MRI) images to create magnetic source images (MSI). The two sets of data are combined by measuring the location of a common set of fiducial points marked during MRI with lipid markers and marked during MEG with electrified coils of wire that give off magnetic fields. The locations of the fiducial points in each data set are then used to define a

common coordinate system so that superimposing the functional MEG data onto the structural MRI data ("coregistration") is possible.

A criticism of the use of this technique in clinical practice is that it produces colored areas with definite boundaries superimposed upon an MRI scan: the untrained viewer may not realize that the colors do not represent a physiological certainty, because of the relatively low spatial resolution of MEG, but rather a probability cloud derived from statistical processes. However, when the magnetic source image corroborates other data, it can be of clinical utility.

Dipole model source localization

A widely accepted source-modeling technique for MEG involves calculating a set of equivalent current dipoles (ECDs), which assumes the underlying neuronal sources to be focal. This dipole fitting procedure is non-linear and over-determined, since the number of unknown dipole parameters is smaller than the number of MEG measurements. Automated multiple dipole model algorithms such as MUSIC (MUltiple SIgnal Classification) and MSST (MultiStart Spatial and Temporal) modeling are applied to the analysis of MEG responses. The limitations of dipole models for characterizing neuronal responses are (1) difficulties in localizing extended sources with ECDs, (2) problems with accurately estimating the total number of dipoles in advance, and (3) dependency on dipole location, especially depth in the brain.

Distributed Source Models

Unlike multiple-dipole modeling, distributed source models divide the source space into a grid containing a large number of dipoles. The inverse problem is to obtain the dipole moments for the grid nodes. As the number of unknown dipole moments is much greater than the number of MEG sensors, the inverse solution is highly underdetermined, so additional constraints are needed to reduce ambiguity of the solution. The primary advantage of this approach is that no prior specification of the source model is necessary. However, the resulting distributions may be difficult to interpret, because they only reflect a "blurred" (or even distorted) image of the true neuronal source distribution. The matter is complicated by the fact that spatial resolution depends strongly on several parameters such as brain area, depth, orientation, number of sensors etc.

Independent component analysis (ICA)

Independent component analysis (ICA) is another signal processing solution that separates different signals that are statistically independent in time. It is primarily used to remove artifacts such as blinking, eye muscle movement, facial muscle artifacts, cardiac artifacts, etc. from MEG and EEG signals that may be contaminated with outside noise. However, ICA has poor resolution of highly correlated brain sources.

MEG use in the field

In research, MEG's primary use is the measurement of time courses of activity. MEG can resolve events with a precision of 10 milliseconds or faster, while functional MRI (fMRI), which depends on changes in blood flow, can at best resolve events with a precision of several hundred milliseconds. MEG also accurately pinpoints sources in primary auditory, somatosensory and motor areas. For creating functional maps of human cortex during more complex cognitive tasks, MEG is most often combined with fMRI, as the methods complement each other. Neuronal (MEG) and hemodynamic (fMRI) data do not necessarily agree, in spite of the tight relationship between local field potentials (LFP) and blood oxygenation level dependent (BOLD) signals. MEG and BOLD signals may originate from the same source (though the BOLD signals are filtered through the hemodynamic response).

Recent studies have reported successful classification of patients with multiple sclerosis, Alzheimer's disease, schizophrenia, Sjögren's syndrome, chronic alcoholism, and facial pain. MEG can be used to distinguish these patients from healthy control subjects, suggesting a future role of MEG in diagnostics.

Focal epilepsy

The clinical uses of MEG are in detecting and localizing pathological activity in patients with epilepsy, and in localizing eloquent cortex for surgical planning in patients with brain tumors or intractable epilepsy. The goal of epilepsy surgery is to remove the epileptogenic tissue while sparing healthy brain areas. Knowing the exact position of essential brain regions (such as the primary motor cortex and primary sensory cortex, visual cortex, and areas involved in speech production and comprehension) helps to avoid surgically induced neurological deficits. Direct cortical stimulation and somatosensory evoked potentials recorded on ECoG are considered the gold standard for localizing essential brain regions. These procedures can be performed either intraoperatively or from chronically indwelling subdural grid electrodes. Both are invasive.

Noninvasive MEG localizations of the central sulcus obtained from somatosensory evoked magnetic fields show strong agreement with these invasive recordings. MEG studies assist in clarification of the functional organization of primary somatosensory cortex and to delineate the spatial extent of hand somatosensory cortex by stimulation of the individual digits. This agreement between invasive localization of cortical tissue and MEG recordings shows the effectiveness of MEG analysis and indicates that MEG may substitute invasive procedures in the future.

Fetal MEG

MEG has been used to study cognitive processes such as vision, audition and language processing in fetuses and newborns.

Comparison with related techniques

MEG has been in development since the 1960s but has been greatly aided by recent advances in computing algorithms and hardware, and promises improved spatial resolution coupled with extremely high temporal resolution (better than 1 ms). Since the MEG signal is a direct measure of neuronal activity, its temporal resolution is comparable with that of intracranial electrodes.

MEG complements other brain activity measurement techniques such as electroencephalography (EEG), positron emission tomography (PET), and fMRI. Its strengths consist in independence of head geometry compared to EEG (unless ferromagnetic implants are present) and non-invasiveness, as opposed to PET.

MEG vs. EEG

Although EEG and MEG signals originate from the same neurophysiological processes, there are important differences. Magnetic fields are less distorted than electric fields by the skull and scalp, which results in a better spatial resolution of the MEG. Whereas scalp EEG is sensitive to both tangential and radial components of a current source in a spherical volume conductor, MEG detects only its tangential components. MEG therefore measures activity in the sulci selectively, whereas scalp EEG measures activity both in the sulci and at the top of the cortical gyri. EEG is therefore sensitive to activity in more brain areas, but activity that is visible in MEG can also be localized with more accuracy.

Scalp EEG is sensitive to extracellular volume currents produced by postsynaptic potentials. MEG primarily detects intracellular currents associated with these synaptic potentials because the field components generated by volume currents tend to cancel out in a spherical volume conductor The decay of magnetic fields as a function of distance is more pronounced than for electric fields. MEG is therefore more sensitive to superficial cortical activity, which makes it useful for the study of neocortical epilepsy. Finally, MEG is reference-free, while scalp EEG relies on a reference that, when active, makes interpretation of the data difficult.

Chapter 5

Electroencephalography



An EEG recording net (Electrical Geodesics, Inc.) being used on a participant in a brain wave study



Epileptic spike and wave discharges monitored with EEG

Electroencephalography (**EEG**) is the recording of electrical activity along the scalp produced by the firing of neurons within the brain. In clinical contexts, EEG refers to the recording of the brain's spontaneous electrical activity over a short period of time, usually 20–40 minutes, as recorded from multiple electrodes placed on the scalp. In neurology, the main diagnostic application of EEG is in the case of epilepsy, as epileptic activity can create clear abnormalities on a standard EEG study. A secondary clinical use of EEG is in the diagnosis of coma, encephalopathies, and brain death. EEG used to be a first-line method for the diagnosis of tumors, stroke and other focal brain disorders, but this use has decreased with the advent of anatomical imaging techniques such as MRI and CT.

Derivatives of the EEG technique include evoked potentials (EP), which involves averaging the EEG activity time-locked to the presentation of a stimulus of some sort (visual, somatosensory, or auditory). Event-related potentials (ERPs) refer to averaged EEG responses that are time-locked to more complex processing of stimuli; this technique is used in cognitive science, cognitive psychology, and psychophysiological research.

Source of EEG activity

The brain's electrical charge is maintained by billions of neurons. Neurons are electrically charged (or "polarized") by membrane transport proteins that pump ions across their membranes. When a neuron receives a signal from its neighbor via an action potential, it responds by releasing ions into the space outside the cell. Ions of like charge repel each other, and when many ions are pushed out of many neurons at the same time, they can push their neighbors, who push their neighbors, and so on, in a wave. This process is known as volume conduction. When the wave of ions reaches the electrodes on the scalp, they can push or pull electrons on the metal on the electrodes. Since metal conducts the push and pull of electrons easily, the difference in push, or voltage, between any two electrodes can be measured by a voltmeter. Recording these voltages over time gives us the EEG.

The electric potentials generated by single neurons are far too small to be picked by EEG or MEG. EEG activity therefore always reflects the summation of the synchronous activity of thousands or millions of neurons that have similar spatial orientation. If the cells do not have similar spatial orientation, their ions do not line up and create waves to be detected. Pyramidal neurons of the cortex are thought to produce most EEG signal because they are well-aligned and fire together. Because voltage fields fall off with the square of the distance, activity from deep sources is more difficult to detect than currents near the skull.

Scalp EEG activity shows oscillations at a variety of frequencies. Several of these oscillations have characteristic frequency ranges, spatial distributions and are associated with different states of brain functioning (e.g., waking and the various sleep stages). These oscillations represent synchronized activity over a network of neurons. The neuronal networks underlying some of these oscillations are understood (e.g., the thalamocortical resonance underlying sleep spindles), while many others are not (e.g., the system that generates the posterior basic rhythm). Research that measures both EEG and neuron spiking finds the relationship between the two is complex with the power of surface EEG only in two bands that of gamma and delta relating to neuron spike activity.

Clinical use

A routine clinical EEG recording typically lasts 20–30 minutes (plus preparation time) and usually involves recording from scalp electrodes. Routine EEG is typically used in the following clinical circumstances:

- to distinguish epileptic seizures from other types of spells, such as psychogenic non-epileptic seizures, syncope (fainting), sub-cortical movement disorders and migraine variants.
- to differentiate "organic" encephalopathy or delirium from primary psychiatric syndromes such as catatonia
- to serve as an adjunct test of brain death
- to prognosticate, in certain instances, in patients with coma

- to determine whether to wean anti-epileptic medications

At times, a routine EEG is not sufficient, particularly when it is necessary to record a patient while he/she is having a seizure. In this case, the patient may be admitted to the hospital for days or even weeks, while EEG is constantly being recorded (along with time-synchronized video and audio recording). A recording of an actual seizure (i.e., an ictal recording, rather than an inter-ictal recording of a possibly epileptic patient at some period between seizures) can give significantly better information about whether or not a spell is an epileptic seizure and the focus in the brain from which the seizure activity emanates.

Epilepsy monitoring is typically done:

- to distinguish epileptic seizures from other types of spells, such as psychogenic non-epileptic seizures, syncope (fainting), sub-cortical movement disorders and migraine variants.
- to characterize seizures for the purposes of treatment
- to localize the region of brain from which a seizure originates for work-up of possible seizure surgery

Additionally, EEG may be used to monitor certain procedures:

- to monitor the depth of anesthesia
- as an indirect indicator of cerebral perfusion in carotid endarterectomy
- to monitor amobarbital effect during the Wada test

EEG can also be used in intensive care units for brain function monitoring:

- to monitor for non-convulsive seizures/non-convulsive status epilepticus
- to monitor the effect of sedative/anesthesia in patients in medically induced coma (for treatment of refractory seizures or increased intracranial pressure)
- to monitor for secondary brain damage in conditions such as subarachnoid hemorrhage (currently a research method)

If a patient with epilepsy is being considered for resective surgery, it is often necessary to localize the focus (source) of the epileptic brain activity with a resolution greater than what is provided by scalp EEG. This is because the cerebrospinal fluid, skull and scalp *smear* the electrical potentials recorded by scalp EEG. In these cases, neurosurgeons typically implant strips and grids of electrodes (or penetrating depth electrodes) under the dura mater, through either a craniotomy or a burr hole. The recording of these signals is referred to as electrocorticography (ECoG), subdural EEG (sdEEG) or intracranial EEG (icEEG)--all terms for the same thing. The signal recorded from ECoG is on a different scale of activity than the brain activity recorded from scalp EEG. Low voltage, high frequency components that cannot be seen easily (or at all) in scalp EEG can be seen clearly in ECoG. Further, smaller electrodes (which cover a smaller parcel of brain

surface) allow even lower voltage, faster components of brain activity to be seen. Some clinical sites record from penetrating microelectrodes.

Research use



The first human EEG recording obtained by Hans Berger in 1924. The upper tracing is EEG, and the lower is a 10 Hz timing signal.

EEG, and its derivative, ERPs, are used extensively in neuroscience, cognitive science, cognitive psychology, and psychophysiological research. Many techniques used in research contexts are not standardized sufficiently to be used in the clinical context.

A different method to study brain function is functional magnetic resonance imaging (fMRI). Some benefits of EEG compared to fMRI include:

- Hardware costs are significantly lower for EEG sensors versus an fMRI machine
- EEG sensors can be deployed into a wider variety of environments than can a bulky, immobile fMRI machine
- EEG enables higher temporal resolution, on the order of milliseconds, rather than seconds
- EEG is relatively tolerant of subject movement versus an fMRI (where the subject must remain completely still)
- EEG is silent, which allows for better study of the responses to auditory stimuli
- EEG does not aggravate claustrophobia

Limitations of EEG as compared with fMRI include:

- Significantly lower spatial resolution
- ERP studies require relatively simple paradigms, compared with block-design fMRI studies

EEG recordings have been successfully obtained simultaneously with fMRI scans, though successful simultaneous recording requires that several technical issues be overcome, such as the presence of ballistocardiographic artifact, MRI pulse artifact and the induction of electrical currents in EEG wires that move within the strong magnetic fields of the MRI.

EEG also has some characteristics that compare favorably with behavioral testing:

- EEG can detect covert processing (i.e., processing that does not require a response)

- EEG can be used in subjects who are incapable of making a motor response
- Some ERP components can be detected even when the subject is not attending to the stimuli
- As compared with other reaction time paradigms, ERPs can elucidate stages of processing (rather than just the final end result)

Method



Computer Electroencephalograph *Neurovisor-BMM 40*

In conventional scalp EEG, the recording is obtained by placing electrodes on the scalp with a conductive gel or paste, usually after preparing the scalp area by light abrasion to reduce impedance due to dead skin cells. Many systems typically use electrodes, each of which is attached to an individual wire. Some systems use caps or nets into which electrodes are embedded; this is particularly common when high-density arrays of electrodes are needed.

Electrode locations and names are specified by the International 10–20 system for most clinical and research applications (except when high-density arrays are used). This system ensures that the naming of electrodes is consistent across laboratories. In most clinical applications, 19 recording electrodes (plus ground and system reference) are used. A smaller number of electrodes are typically used when recording EEG from neonates. Additional electrodes can be added to the standard set-up when a clinical or research application demands increased spatial resolution for a particular area of the brain. High-density arrays (typically via cap or net) can contain up to 256 electrodes more-or-less evenly spaced around the scalp.

Each electrode is connected to one input of a differential amplifier (one amplifier per pair of electrodes); a common system reference electrode is connected to the other input of each differential amplifier. These amplifiers amplify the voltage between the active electrode and the reference (typically 1,000–100,000 times, or 60–100 dB of voltage gain). In analog EEG, the signal is then filtered (next paragraph), and the EEG signal is output as the deflection of pens as paper passes underneath. Most EEG systems these days, however, are digital, and the amplified signal is digitized via an analog-to-digital converter, after being passed through an anti-aliasing filter. Analog-to-digital sampling typically occurs at 256–512 Hz in clinical scalp EEG; sampling rates of up to 20 kHz are used in some research applications.

During the recording, a series of activation procedures may be used. These procedures may induce normal or abnormal EEG activity that might not otherwise be seen. These procedures include hyperventilation, photic stimulation (with a strobe light), eye closure, mental activity, sleep and sleep deprivation. During (inpatient) epilepsy monitoring, a patient's typical seizure medications may be withdrawn.

The digital EEG signal is stored electronically and can be filtered for display. Typical settings for the high-pass filter and a low-pass filter are 0.5-1 Hz and 35–70 Hz, respectively. The high-pass filter typically filters out slow artifact, such as electrogalvanic signals and movement artifact, whereas the low-pass filter filters out high-frequency artifacts, such as electromyographic signals. An additional notch filter is typically used to remove artifact caused by electrical power lines (60 Hz in the United States and 50 Hz in many other countries). As part of an evaluation for epilepsy surgery, it may be necessary to insert electrodes near the surface of the brain, under the surface of the dura mater. This is accomplished via burr hole or craniotomy. This is referred to variously as "electrocorticography (ECoG)", "intracranial EEG (I-EEG)" or "subdural EEG (SD-EEG)". Depth electrodes may also be placed into brain structures, such as the amygdala or hippocampus, structures, which are common epileptic foci and may not be "seen" clearly by scalp EEG. The electrocorticographic signal is processed in the same manner as digital scalp EEG (above), with a couple of caveats. ECoG is typically recorded at higher sampling rates than scalp EEG because of the requirements of Nyquist theorem—the subdural signal is composed of a higher predominance of higher frequency components. Also, many of the artifacts that affect scalp EEG do not impact ECoG, and therefore display filtering is often not needed.

A typical adult human EEG signal is about 10μV to 100 μV in amplitude when measured from the scalp and is about 10–20 mV when measured from subdural electrodes.

Since an EEG voltage signal represents a difference between the voltages at two electrodes, the display of the EEG for the reading encephalographer may be set up in one of several ways. The representation of the EEG channels is referred to as a *montage.*

Bipolar montage

Each channel (i.e., waveform) represents the difference between two adjacent electrodes. The entire montage consists of a series of these channels. For example,

the channel "Fp1-F3" represents the difference in voltage between the Fp1 electrode and the F3 electrode. The next channel in the montage, "F3-C3," represents the voltage difference between F3 and C3, and so on through the entire array of electrodes.

Referential montage
: Each channel represents the difference between a certain electrode and a designated reference electrode. There is no standard position for this reference; it is, however, at a different position than the "recording" electrodes. Midline positions are often used because they do not amplify the signal in one hemisphere vs. the other. Another popular reference is "linked ears," which is a physical or mathematical average of electrodes attached to both earlobes or mastoids.

Average reference montage
: The outputs of all of the amplifiers are summed and averaged, and this averaged signal is used as the common reference for each channel.

Laplacian montage
: Each channel represents the difference between an electrode and a weighted average of the surrounding electrodes.

When analog (paper) EEGs are used, the technologist switches between montages during the recording in order to highlight or better characterize certain features of the EEG. With digital EEG, all signals are typically digitized and stored in a particular (usually referential) montage; since any montage can be constructed mathematically from any other, the EEG can be viewed by the electroencephalographer in any display montage that is desired.

The EEG is read by a neurologist, optimally one who has specific training in the interpretation of EEGs. This is done by visual inspection of the waveforms, called graphoelements. The use of computer signal processing of the EEG—so-called quantitative EEG—is somewhat controversial when used for clinical purposes (although there are many research uses).

Limitations

EEG has several limitations. Most important is its poor spatial resolution. EEG is most sensitive to a particular set of post-synaptic potentials: those generated in superficial layers of the cortex, on the crests of gyri directly abutting the skull and radial to the skull. Dendrites, which are deeper in the cortex, inside sulci, in midline or deep structures (such as the cingulate gyrus or hippocampus), or producing currents that are tangential to the skull, have far less contribution to the EEG signal.

The meninges, cerebrospinal fluid and skull "smear" the EEG signal, obscuring its intracranial source.

It is mathematically impossible to reconstruct a unique intracranial current source for a given EEG signal, as some currents produce potentials that cancel each other out. This is referred to as the inverse problem. However, much work has been done to produce

remarkably good estimates of, at least, a localized electric dipole that represents the recorded currents.

EEG vs fMRI and PET

EEG has several strong points as a tool for exploring brain activity. EEG's can detect changes within a millisecond timeframe, excellent considering an action potential takes approximately 0.5-130 milliseconds to propagate across a single neuron, depending on the type of neuron. Other methods of looking at brain activity, such as PET and fMRI have time resolution between seconds and minutes. EEG measures the brain's electrical activity directly, while other methods record changes in blood flow (e.g., SPECT, fMRI) or metabolic activity (e.g., PET), which are indirect markers of brain electrical activity. EEG can be used simultaneously with fMRI so that high-temporal-resolution data can be recorded at the same time as high-spatial-resolution data, however, since the data derived from each occurs over a different time course, the data sets do not necessarily represent exactly the same brain activity. There are technical difficulties associated with combining these two modalities, including the need to remove the *MRI gradient artifact* present during MRI acquisition and the ballistocardiographic artifact (resulting from the pulsatile motion of blood and tissue) from the EEG. Furthermore, currents can be induced in moving EEG electrode wires due to the magnetic field of the MRI.

EEG vs MEG

EEG reflects correlated synaptic activity caused by post-synaptic potentials of cortical neurons. The ionic currents involved in the generation of fast action potentials may not contribute greatly to the averaged field potentials representing the EEG. More specifically, the scalp electrical potentials that produce EEG are generally thought to be caused by the extracellular ionic currents caused by dendritic electrical activity, whereas the fields producing magnetoencephalographic signals are associated with intracellular ionic currents.

EEG can be recorded at the same time as MEG so that data from these complementary high-time-resolution techniques can be combined.

Normal activity



One second of EEG signal

The EEG is typically described in terms of (1) rhythmic activity and (2) transients. The rhythmic activity is divided into bands by frequency. To some degree, these frequency bands are a matter of nomenclature (i.e., any rhythmic activity between 8–12 Hz can be described as "alpha"), but these designations arose because rhythmic activity within a certain frequency range was noted to have a certain distribution over the scalp or a certain biological significance. Frequency bands are usually extracted using spectral methods (for instance Welch) as implemented for instance in freely available EEG software such as EEGLAB.

Most of the cerebral signal observed in the scalp EEG falls in the range of 1–20 Hz (activity below or above this range is likely to be artifactual, under standard clinical recording techniques).

Comparison table

Comparison of EEG bands

Type	Frequency (Hz)	Location	Normally	Pathologically
Delta	up to 4	frontally in adults, posteriorly in children; high amplitude waves	• adults slow wave sleep • in babies • Has been found during some continuous attention tasks (Kirmizi-Alsan et al. 2006)	• subcortical lesions • diffuse lesions • metabolic encephalopathy hydrocephalus • deep midline lesions
Theta	4 – 7	Found in locations not related to task at hand	• young children • drowsiness or arousal in older children and adults • idling • Associated with inhibition of elicited responses (has been found to spike in situations where a person is actively trying to repress a response or action) (Kirmizi-Alsan et al. 2006).	• focal subcortical lesions • metabolic encephalopathy • deep midline disorders • some instances of hydrocephalus
Alpha	8 – 12	posterior regions of	• relaxed/reflecting • closing the eyes	• coma

		head, both sides, higher in amplitude on dominant side. Central sites (c3-c4) at rest.	• Also associated with inhibition control, seemingly with the purpose of timing inhibitory activity in different locations across the brain (Klimesch, Sauseng, & Hanslmayr 2007; Coan & Allen 2008).	
Beta	12 – 30	both sides, symmetrical distribution, most evident frontally; low amplitude waves	• alert/working • active, busy or anxious thinking, active concentration	• benzodiazepines
Gamma	30 – 100+	Somatosensory cortex	• Displays during cross-modal sensory processing (perception that combines two different senses, such as sound and sight) (Kisley & Cornwell 2006; Kanayama, Sato, & Ohira 2007; Nieuwenhuis, Yeung, & Cohen 2004) • Also is shown during short term memory matching of recognized objects, sounds, or tactile sensations (Herrmann, Frund, & Lenz 2009)	• A decrease in gamma band activity may be associated with cognitive decline, especially when related the theta band; however, this has not been proven for use as a clinical diagnostic measurement yet (Moretti et al. 2009).
Mu	8 – 13	Sensorimotor cortex	• Shows rest state motor neurons (Gastaut, 1952).	• Mu suppression could be indicative for motor mirror neurons working, and deficits in Mu

suppression, and thus in mirror neurons, might play a role in autism. (Oberman et al., 2005)

It should be noted that while these are the universally recognized ranges, they are not concrete definitions of the range of brain-waves. While researchers tend to follow these guidelines, many scholars use their own specific boundaries depending on the range they choose to focus on. Additionally, some researchers define the bands using decimal values rather than rounding to whole numbers (for example, one researcher may define the lower Beta band cut-off as 12.1, while another may use the value 13), while still others sometimes divide the bands into sub-bands. Generally, this is only done for the sake of analysis.

Wave patterns



Delta waves

- Delta is the frequency range up to 4 Hz. It tends to be the highest in amplitude and the slowest waves. It is seen normally in adults in slow wave sleep. It is also seen normally in babies. It may occur focally with subcortical lesions and in general distribution with diffuse lesions, metabolic encephalopathy hydrocephalus or deep midline lesions. It is usually most prominent frontally in adults (e.g. FIRDA - Frontal Intermittent Rhythmic Delta) and posteriorly in children (e.g. OIRDA - Occipital Intermittent Rhythmic Delta).



Theta waves

- Theta is the frequency range from 4 Hz to 7 Hz. Theta is seen normally in young children. It may be seen in drowsiness or arousal in older children and adults; it can also be seen in meditation. Excess theta for age represents abnormal activity. It can be seen as a focal disturbance in focal subcortical lesions; it can be seen in generalized distribution in diffuse disorder or metabolic encephalopathy or deep midline disorders or some instances of hydrocephalus. On the contrary this range has been associated with reports of relaxed, meditative, and creative states.



Alpha waves

- Alpha is the frequency range from 8 Hz to 12 Hz. Hans Berger named the first rhythmic EEG activity he saw as the "alpha wave". This was the "posterior basic rhythm" (also called the "posterior dominant rhythm" or the "posterior alpha rhythm"), seen in the posterior regions of the head on both sides, higher in amplitude on the dominant side. It emerges with closing of the eyes and with relaxation, and attenuates with eye opening or mental exertion. The posterior basic rhythm is actually slower than 8 Hz in young children (therefore technically in the theta range).



sensorimotor rhythm aka mu rhythm

In addition to the posterior basic rhythm, there are other normal alpha rhythms such as the mu rhythm (alpha activity in the contralateral sensory and motor cortical areas that emerges when the hands and arms are idle; and the "third rhythm" (alpha activity in the temporal or frontal lobes). Alpha can be abnormal; for example, an EEG that has diffuse alpha occurring in coma and is not responsive to external stimuli is referred to as "alpha coma".



Beta waves

- Beta is the frequency range from 12 Hz to about 30 Hz. It is seen usually on both sides in symmetrical distribution and is most evident frontally. Beta activity is closely linked to motor behavior and is generally attenuated during active movements. Low amplitude beta with multiple and varying frequencies is often associated with active, busy or anxious thinking and active concentration. Rhythmic beta with a dominant set of frequencies is associated with various pathologies and drug effects, especially benzodiazepines. It may be absent or reduced in areas of cortical damage. It is the dominant rhythm in patients who are alert or anxious or who have their eyes open.



Gamma waves

- Gamma is the frequency range approximately 30–100 Hz. Gamma rhythms are thought to represent binding of different populations of neurons together into a network for the purpose of carrying out a certain cognitive or motor function.

- Mu ranges 8–13 Hz., and partly overlaps with other frequencies. It reflects the synchronous firing of motor neurons in rest state. Mu suppression is thought to reflect motor mirror neuron systems, because when an action is observed, the pattern extinguishes, possibly because of the normal neuronal system and the mirror neuron system "go out of sync", and interfere with each other.

"Ultra-slow" or "near-DC" activity is recorded using DC amplifiers in some research contexts. It is not typically recorded in a clinical context because the signal at these frequencies is susceptible to a number of artifacts.

Some features of the EEG are transient rather than rhythmic. Spikes and sharp waves may represent seizure activity or interictal activity in individuals with epilepsy or a predisposition toward epilepsy. Other transient features are normal: vertex waves and sleep spindles are seen in normal sleep.

Note that there are types of activity that are statistically uncommon, but not associated with dysfunction or disease. These are often referred to as "normal variants." The mu rhythm is an example of a normal variant.

The normal Electroencephalography (EEG) varies by age. The neonatal EEG is quite different from the adult EEG. The EEG in childhood generally has slower frequency oscillations than the adult EEG.

The normal EEG also varies depending on state. The EEG is used along with other measurements (EOG, EMG) to define sleep stages in polysomnography. Stage I sleep (equivalent to drowsiness in some systems) appears on the EEG as drop-out of the posterior basic rhythm. There can be an increase in theta frequencies. Santamaria and Chiappa cataloged a number of the variety of patterns associated with drowsiness. Stage II sleep is characterized by sleep spindles—transient runs of rhythmic activity in the 12–14 Hz range (sometimes referred to as the "sigma" band) that have a frontal-central maximum. Most of the activity in Stage II is in the 3–6 Hz range. Stage III and IV sleep are defined by the presence of delta frequencies and are often referred to collectively as "slow-wave sleep." Stages I-IV comprise non-REM (or "NREM") sleep. The EEG in REM (rapid eye movement) sleep appears somewhat similar to the awake EEG.

EEG under general anesthesia depends on the type of anesthetic employed. With halogenated anesthetics, such as halothane or intravenous agents, such as propofol, a rapid (alpha or low beta), nonreactive EEG pattern is seen over most of the scalp, especially anteriorly; in some older terminology this was known as a WAR (widespread anterior rapid) pattern, contrasted with a WAIS (widespread slow) pattern associated with high doses of opiates. Anesthetic effects on EEG signals are beginning to be understood at the level of drug actions on different kinds of synapses and the circuits that allow synchronized neuronal activity.

Artifacts

Biological artifacts

Electrical signals detected along the scalp by an EEG, but that originate from non-cerebral origin are called artifacts. EEG data is almost always contaminated by such artifacts. The amplitude of artifacts can be quite large relative to the size of amplitude of the cortical signals of interest. This is one of the reasons why it takes considerable experience to correctly interpret EEGs clinically. Some of the most common types of biological artifacts include:

- Eye-induced artifacts (includes eye blinks, eye movements and extra-ocular muscle activity)
- EKG (cardiac) artifacts
- EMG (muscle activation)-induced artifacts
- Glossokinetic artifacts

The most prominent eye-induced artifacts are caused by the potential difference between the cornea and retina, which is quite large compared to cerebral potentials. When the eyes and eyelids are completely still, this corneo-retinal dipole does not affect EEG. However, blinks occur several times per minute, the eyes movements occur several times per second. Eyelid movements, occurring mostly during blinking or vertical eye movements, elicit a large potential seen mostly in the difference between the Electrooculography (EOG) channels above and below the eyes. An established explanation of this potential regards the eyelids as sliding electrodes that short-circuit the positively charged cornea to the extra-ocular skin. Rotation of the eyeballs, and consequently of the corneo-retinal dipole, increases the potential in electrodes towards which the eyes are rotated, and decrease the potentials in the opposing electrodes. Eye movements called saccades also generate transient electromyographic potentials, known as saccadic spike potentials (SPs). The spectrum of these SPs overlaps the gamma-band, and seriously confounds analysis of induced gamma-band responses, requiring tailored artifact correction approaches. Purposeful or reflexive eye blinking also generates electromyographic potentials, but more importantly there is reflexive movement of the eyeball during blinking that gives a characteristic artifactual appearance of the EEG.

Eyelid fluttering artifacts of a characteristic type were previously called Kappa rhythm (or Kappa waves). It is usually seen in the prefrontal leads, that is, just over the eyes. Sometimes they are seen with mental activity. They are usually in the Theta (4–7 Hz) or Alpha (8–13 Hz) range. They were named because they were believed to originate from the brain. Later study revealed they were generated by rapid fluttering of the eyelids, sometimes so minute that it was difficult to see. They are in fact noise in the EEG reading, and should not technically be called a rhythm or wave. Therefore, current usage in electroencephalography refers to the phenomenon as an eyelid fluttering artifact, rather than a Kappa rhythm (or wave).

Some of these artifacts can be useful in various applications. The EOG signals, for instance, can be used to detect and track eye-movements, which are very important in polysomnography, and is also in conventional EEG for assessing possible changes in alertness, drowsiness or sleep.

EKG artifacts are quite common and can be mistaken for spike activity. Because of this, modern EEG acquisition commonly includes a one-channel EKG from the extremities. This also allows the EEG to identify cardiac arrhythmias that are an important differential diagnosis to syncope or other episodic/attack disorders.

Glossokinetic artifacts are caused by the potential difference between the base and the tip of the tongue. Minor tongue movements can contaminate the EEG, especially in parkinsonian and tremor disorders.

Environmental artifacts

In addition to artifacts generated by the body, many artifacts originate from outside the body. Movement by the patient, or even just settling of the electrodes, may cause

electrode pops, spikes originating from a momentary change in the impedance of a given electrode. Poor grounding of the EEG electrodes can cause significant 50 or 60 Hz artifact, depending on the local power system's frequency. A third source of possible interference can be the presence of an IV drip; such devices can cause rhythmic, fast, low-voltage bursts, which may be confused for spikes.

Artifact correction

Recently, independent component analysis techniques have been used to correct or remove EEG contaminates. These techniques attempt to "unmix" the EEG signals into some number of underlying components. There are many source separation algorithms, often assuming various behaviors or natures of EEG. Regardless, the principle behind any particular method usually allow "remixing" only those components that would result in "clean" EEG by nullifying (zeroing) the weight of unwanted components. Fully automated artifact rejection methods, which use ICA, have also been developed.

Abnormal activity

Abnormal activity can broadly be separated into epileptiform and non-epileptiform activity. It can also be separated into focal or diffuse.

Focal epileptiform discharges represent fast, synchronous potentials in a large number of neurons in a somewhat discrete area of the brain. These can occur as interictal activity, between seizures, and represent an area of cortical irritability that may be predisposed to producing epileptic seizures. Interictal discharges are not wholly reliable for determining whether a patient has epilepsy nor where his/her seizure might originate.

Generalized epileptiform discharges often have an anterior maximum, but these are seen synchronously throughout the entire brain. They are strongly suggestive of a generalized epilepsy.

Focal non-epileptiform abnormal activity may occur over areas of the brain where there is focal damage of the cortex or white matter. It often consists of an increase in slow frequency rhythms and/or a loss of normal higher frequency rhythms. It may also appear as focal or unilateral decrease in amplitude of the EEG signal.

Diffuse non-epileptiform abnormal activity may manifest as diffuse abnormally slow rhythms or bilateral slowing of normal rhythms, such as the PBR.

Intracortical Encephalogram electrodes and sub-dural electrodes can be used in tandem to discriminate and discretize artifact from epileptiform and other severe neurological events.

More advanced measures of abnormal EEG signals have also recently received attention as possible biomarkers for different disorders such as Alzheimer's disease.

History

A timeline of the history of EEG is given by Swartz. Richard Caton (1842–1926), a physician practicing in Liverpool, presented his findings about electrical phenomena of the exposed cerebral hemispheres of rabbits and monkeys in the British Medical Journal in 1875. In 1890, Polish physiologist Adolf Beck published an investigation of spontaneous electrical activity of the brain of rabbits and dogs that included rhythmic oscillations altered by light.

In 1912, Russian physiologist, Vladimir Vladimirovich Pravdich-Neminsky published the first animal EEG and the evoked potential of the mammalian (dog). In 1914, Napoleon Cybulski and Jelenska-Macieszyna photographed EEG-recordings of experimentally induced seizures.

German physiologist and psychiatrist Hans Berger (1873–1941) recorded the first human EEG in 1924. Expanding on work previously conducted on animals by Richard Caton and others, Berger also invented the electroencephalogram (giving the device its name), an invention described "as one of the most surprising, remarkable, and momentous developments in the history of clinical neurology". His discoveries were first confirmed by British scientists Edgar Douglas Adrian and B. H. C. Matthews in 1934 and developed by them.

In 1934, Fisher and Lowenback first demonstrated epileptiform spikes. In 1935 Gibbs, Davis and Lennox described interictal spike waves and the 3 cycles/s pattern of clinical absence seizures, which began the field of clinical electroencephalography. Subsequently, in 1936 Gibbs and Jasper reported the interictal spike as the focal signature of epilepsy. The same year, the first EEG laboratory opened at Massachusetts General Hospital.

Franklin Offner (1911–1999), professor of biophysics at Northwestern University developed a prototype of the EEG that incorporated a piezoelectric inkwriter called a Crystograph (the whole device was typically known as the Offner Dynograph).

In 1947, The American EEG Society was founded and the first International EEG congress was held. In 1953 Aserinsky and Kleitman describe REM sleep.

In the 1950s, William Grey Walter developed an adjunct to EEG called EEG topography, which allowed for the mapping of electrical activity across the surface of the brain. This enjoyed a brief period of popularity in the 1980s and seemed especially promising for psychiatry. It was never accepted by neurologists and remains primarily a research tool.

Various uses

The EEG has been used for many purposes besides the conventional uses of clinical diagnosis and conventional cognitive neuroscience. Long-term EEG recordings in epilepsy patients are used for seizure prediction. Neurofeedback remains an important extension, and in its most advanced form is also attempted as the basis of brain computer

interfaces. The EEG is also used quite extensively in the field of neuromarketing. There are many commercial products substantially based on the EEG.

Honda is attempting to develop a system to move its Asimo robot using EEG, a technology it eventually hopes to incorporate into its automobiles.

EEGs have been used as evidence in trials in the Indian state of Maharastra.

EEG and Telepathy

DARPA budgeted $4 million in 2009 to investigate technology to enable soldiers on the battlefield to communicate via computer-mediated telepathy. The aim is to analyse neural signals that exist in the brain before words are spoken.

Games

Recently a few companies have scaled back medical grade EEG technology (and in one case, NeuroSky, rebuilt the technology from the ground up) to create inexpensive devices based on EEG. Two of these companies, NeuroSky and OCZ, have even built commercial EEG devices retailing for under 100$.

- In 2007 NeuroSky released the first affordable consumer based EEG along with the game NeuroBoy. This was also the first large scale EEG device to use dry sensor technology.
- In 2008 OCZ Technology developed device for use in video games relying primarily on electromyography.
- In 2008 the Final Fantasy developer Square Enix announced that it was partnering with NeuroSky to create a game, Judecca.
- In 2009 Mattel partnered with NeuroSky to release the Mindflex, a game that used an EEG to steer a ball through an obstacle course. By far the best selling consumer based EEG to date.
- In 2009 Uncle Milton Industries partnered with NeuroSky to release the StarWars Force Trainer, a game designed to create the illusion of possessing the force.
- In 2009 Emotiv released the EPOC, a 14 channel EEG device. The EPOC is the first commercial BCI to not use dry sensor technology, requiring users to apply a saline solution to their head.
- In 2010 NeuroSky added blink an electromyography function to the MindSet.

Additional images



Person wearing electrodes for EEG

Portable recording device for EEG



EEG electroencephalophone used during a music performance in which bathers from around the world were networked together as part of a collective musical performance, using their brainwaves to control sound, lighting, and the bath environment

Chapter 6

Parkinson's Disease

Parkinson's

Illustration of Parkinson's disease by William Richard Gowers from *A Manual of Diseases of the Nervous System* in 1886

ICD-10	G20., F02.3
ICD-9	332
OMIM	168600 556500

DiseasesDB	9651
MedlinePlus	000755
eMedicine	neuro/304 neuro/635 in young pmr/99 rehab
GeneReviews	Parkinson Disease Overview

Parkinson's disease (also known as **Parkinson's**, **Parkinson disease**, or **PD**) is a degenerative disorder of the central nervous system that impairs motor skills, cognitive processes, and other functions. The most obvious symptoms are motor-related, including tremor, rigidity, slowness of movement, and postural instability. Among non-motor symptoms are autonomic dysfunction and sensory and sleep difficulties. Cognitive and behavioral problems, including dementia, are common in the advanced stages of the disease. PD usually appears around the age of 60, although there are young-onset cases.

PD is also called "primary parkinsonism" or "idiopathic PD" (meaning having no known cause), although some cases have a genetic origin. Many risk and protective factors have been investigated, showing an increased risk of PD in those exposed to pesticides; and a reduced risk in smokers. Symptoms result from insufficient formation and action of dopamine produced in the dopaminergic neurons of the midbrain (specifically the substantia nigra). Pathologically the disease is characterized by the accumulation of alpha-synuclein protein forming inclusions called Lewy bodies. Such pathology can only be demonstrated at autopsy so diagnosis is mainly clinical (based on symptoms). Some tests such as neuroimaging techniques can also aid in diagnosis.

Current treatments are effective at managing the early motor symptoms of the disease, mainly through the use of levodopa and dopamine agonists. As the disease advances, however, the continued use of medications leads to a second stage in which the patient develops motor complications called dyskinesias. Medications to treat other symptoms of PD also exist. Diet and some forms of rehabilitation have shown some effectiveness at mitigating symptoms, and surgery and deep brain stimulation may be used to reduce motor symptoms in the most extreme cases.

The disease is named after English surgeon James Parkinson, who gave the first detailed description of it in "An Essay on the Shaking Palsy" (1817). PD is a costly disease to society. Several major organizations promote research and improvement of quality of life of those with the disease and their families. Research directions include a search of new animal models of the disease, and investigations of the potential usefulness of gene therapy, stem cells transplants and neuroprotective agents. Advocacy actions include April 11, birthday of James Parkinson, as the world's Parkinson's disease day, and the use of a red tulip as the symbol of the disease. People with PD who have greatly affected public awareness include Michael J. Fox and Muhammad Ali.

Classification



Positive Alpha-Synuclein staining of a Lewy body in a patient with Parkinson's disease. Presence of Lewy bodies in the brains of those with PD has led to the classification of the disease as a synucleinopathy.

The term parkinsonism is used for a motor syndrome whose main symptoms are tremor at rest, stiffness, slowing of movement and postural instability. Parkinsonisms can be divided into four subtypes according to their origin: primary or idiopathic, secondary or acquired, hereditary parkinsonism, and parkinson plus syndromes or multiple system degeneration. Parkinson's disease is the most common form of parkinsonism, and is usually defined as "idiopathic" parkinsonism, meaning parkinsonism with no identifiable cause.

PD is usually classified as a movement disorder, although it also gives rise to several non-motor types of symptoms such as cognitive difficulties or sleep problems. Parkinson-plus diseases are primary parkinsonisms which present additional features. They include multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and dementia with Lewy bodies.

In terms of pathophysiology, PD is considered a synucleinopathy due to an abnormal accumulation of alpha-synuclein protein in the brain in the form of Lewy bodies, as opposed to other diseases such as Alzheimer's disease where the brain accumulates tau protein in the form of neurofibrillary tangles. Nevertheless there is clinical and pathological overlap between tauopathies and synucleinopathies. The most typical symptom of Alzheimer's disease, dementia, occurs in advanced stages of PD, while it is common to find neurofibrillary tangles in PD patients' brains at autopsy. Dementia with Lewy bodies is another synucleinopathy that has many similarities with PD. Thus the two diseases, especially PD with dementia, may be considered parts of the same continuum. However the relationship between the two diseases is complex and still has to be clarified.

Signs and symptoms

Parkinson's disease patient showing a flexed walking posture pictured in 1892. Photo appeared in *Nouvelle Iconographie de la Salpètrière*, vol. 5.

Parkinson's disease affects movement, producing motor symptoms. Non-motor symptoms, which include autonomic dysfunction, cognitive and behavioral problems (neuropsychiatric), and sensory and sleep difficulties, are also common.

Motor



Handwriting by a PD patient; showing micrographia in addition to other abnormal characteristics

Four motor symptoms are considered cardinal in PD: tremor, rigidity, slowness of movement, and postural instability. Tremor is the most apparent and well-known symptom. It is most commonly a rest tremor: maximal when the limb is at rest and disappearing with voluntary movement and sleep. It affects to a greater extent the most distal part of the limb, and at onset typically appears in only a single arm or leg, becoming bilateral later. Though around 30% of individuals with PD do not have tremor at disease onset, most develop it as the disease progresses. Rigidity is due to joint stiffness and increased muscle tone, which combined with a resting tremor produce a ratchety, "cogwheel rigidity" when the limb is passively moved. Rigidity may be associated with joint pain, such pain being a frequent initial manifestation of the disease. Bradykinesia (slowness of movement) is the most characteristic clinical feature of PD, and is associated with difficulties with the planning, initiation and execution of a movement. The performance of sequential and simultaneous movements is also hindered. Bradykinesia is the most disabling symptom in the early stages of the disease. In the late stages postural instability is typical, which leads to impaired balance and frequent falls. Instability is often absent in the initial stages, especially in younger patients.

Other motor symptoms include gait and posture disturbances such as decreased arm swing, a forward-flexed posture and the use of small steps when walking; speech and swallowing disturbances; and other symptoms such as a mask-like face expression or small handwriting are examples of the range of common motor problems that can appear.

Neuropsychiatric

Parkinson's disease causes neuropsychiatric disturbances, which include mainly cognition, mood and behavior problems, and can be as disabling as motor symptoms.

A high proportion of people with PD will have mild cognitive impairment as the disease advances although cognitive disturbances can also occur in the initial stages of the disease in some cases. The most common cognitive deficits in non-demented patients are executive dysfunction. The executive system is responsible for planning, cognitive flexibility, abstract thinking, rule acquisition, initiating appropriate actions and inhibiting inappropriate actions, and selecting relevant sensory information. PD patients may have problems with these cognitive processes. Fluctuations in attention and slowed cognitive speed are among other cognitive difficulties. Memory is also affected, specifically in recalling learned information. Nevertheless improvement appears when recall is aided by cues. Visuospatial difficulties are also part of the disease, which are for example seen when the individual is asked to perform tests of facial recognition and perception of the orientation of drawn lines.

Deficits tend to aggravate with time, in many cases developing into dementia. A person with PD has a sixfold increased risk of suffering dementia, and the overall rate in people with the disease is around 30%. Prevalence of dementia increases in relation to disease duration, going up to 80%. Dementia has been associated with a reduced quality of life in people with PD and their caregivers, increased mortality and a higher probability of attending a nursing home.

Cognitive problems and dementia are usually accompanied by behavior and mood alterations, although these kind of changes are also more common in those without cognitive impairment than in the general population. Most frequent mood difficulties include depression, apathy and anxiety. Impulse control behaviors such as medication overuse and craving, binge eating, hypersexuality, or pathological gambling can also appear in PD, and have been related to the medications for the disease. Psychotic symptoms—hallucinations or delusions—are common in late PD.

Other

In addition to cognitive and motor symptoms, PD can also impair other body functions. Sleep problems are a core feature of the disease, and can be worsened by medications. They can manifest as daytime somnolence, disturbances in REM sleep, or insomnia. Alterations in the autonomic nervous system can lead to orthostatic hypotension, oily skin and seborrheic dermatitis, excessive sweating, urinary incontinence, and altered sexual function. Constipation and gastric dysmotility can be severe enough to cause discomfort and even endanger health. PD is also related to several eye and vision abnormalities such as decreased blink rate and alteration in the tear film leading to irritation of the eye surface, abnormalities in ocular pursuit and saccadic movements, and difficulties in directing gaze upward. Changes in perception may include an impaired sense of smell, sensation of pain, and paresthesia.

Causes



PDB rendering of Parkin

Most people with Parkinson's disease have idiopathic Parkinson's disease (having no specific known cause). A small proportion of cases, however, can be attributed to known genetic factors. Other factors have been associated with the risk of developing PD, but no causal relationship has been proven; they will be described in the epidemiology section.

PD traditionally has been considered a non-genetic disorder, however around 15% of individuals with PD have a first-degree relative who also has the disease. At least 5% of patients are now known to have forms of the disease that occur due to a mutation of one of several specific genes.

A number of specific genetic mutations causing PD have been discovered. Genes conclusively identified include alpha-synuclein (SNCA), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), parkin (PRKN), leucine-rich repeat kinase 2 (LRRK2 or dardarin), PTEN-induced putative kinase 1 (PINK1), DJ-1 and ATP13A2. In most cases, people with these mutations will develop PD. With the exception of LRRK2, however, they account for only a small minority of cases of PD. The most extensively studied PD-related genes are SNCA and LRRK2. Mutations in genes including SNCA, LRRK2 and glucocerebrosidase (GBA), have been found to be risk factors for sporadic PD. Mutations of the third are also known to cause Gaucher's disease. Genome-wide association studies, which search for mutated alleles with low penetrance in sporadic cases, have yielded few positive results, but such studies have been few in number and their size small.

The role of the SNCA gene is important in PD because the alpha-synuclein protein is the main component of Lewy bodies. Missense mutations (mutation in which a single nucleotide is changed) of the gene, and duplications and triplications of the locus containing it, have been found in different groups with familial PD. Missense mutations are rare. On the other hand, multiplications of the SNCA locus account for around 2% of familial cases. Multiplications have also been found in asymptomatic carriers, which indicates that penetrance is incomplete or age-dependent.

The LRRK2 gene (PARK8) encodes for a protein called dardarin. The name dardarin was taken from a Basque word for tremor, because this gene was first identified in families from England and the north of Spain. Mutations in LRRK2 are the most common known cause of familial and sporadic PD, accounting for up to 10% of patients with a family history of the disease, and 3% of sporadic cases. More than 40 different mutations of the gene have been found to be related to PD.

Pathophysiology

The basal ganglia, a group of "brain structures" innervated by the dopaminergic system, are the most seriously affected brain areas in PD. The primary symptoms of Parkinson's disease result from greatly reduced activity of dopamine-secreting cells due to cell death in the pars compacta region of the substantia nigra. The most characteristic pathological finding in PD is a progressive accumulation of Lewy bodies in the substantia nigra and several other brain regions.

Physiology



Connections of the basal ganglia in the normal state



Connections of the basal ganglia in Parkinson's disease, resulting from decreased activity of the pars compacta region of the substantia nigra. Larger and smaller arrows refer to pathways with increased and decreased activity, respectively, in Parkinson's disease.
Model of the circuits of the basal ganglia in the normal state (left) and PD (right). Substantia nigra is seen at bottom right. Pictures show 2 coronal slices that have been superimposed to include the involved basal ganglia structures. + and - signs at the point of the arrows indicate respectively whether the pathway is excitatory or inhibitory in effect. Green arrows refer to excitatory glutamatergic pathways, red arrows refer to inhibitory GABAergic pathways and turquoise arrows refer to dopaminergic pathways that are excitatory on the direct pathway and inhibitory on the indirect pathway. Dis-inhibitory pathways are in effect excitatory on the feedback to the cortex, while dis-dis-inhibitory pathways are inhibitory.

There are five major pathways in the brain connecting other brain areas with the basal ganglia. These are known as the motor, oculo-motor, associative, limbic and orbitofrontal circuits, with names indicating the main projection area of each circuit. All of them are affected in PD, and their disruption explains many of the symptoms of the disease since

these circuits are involved in a wide variety of functions including movement, attention and learning. Scientifically, the motor circuit has been examined the most intensively.

A particular conceptual model of the motor circuit and its alteration with PD has been of great influence since 1980, although some limitations have been pointed out which have led to modifications. In this model, the basal ganglia normally exert a constant inhibitory influence on a wide range of motor systems, preventing them from becoming active at inappropriate times. When a decision is made to perform a particular action, inhibition is reduced for the required motor system, thereby releasing it for activation. Dopamine acts to facilitate this release of inhibition, so high levels of dopamine function tend to promote motor activity, and low levels of dopamine function, such as occur in PD, demand greater exertions of effort for any given movement. Thus the net effect of dopamine depletion is to produce hypokinesia, an overall reduction in motor output. Drugs that are used to treat PD, conversely, may produce excessive dopamine activity, allowing motor systems to be activated at inappropriate times and thereby producing dyskinesias.

Pathology



A. Schematic initial progression of Lewy body deposits in the first stages of Parkinson's disease, as proposed by Braak and colleagues. B. Localization of the area of significant brain volume reduction in initial PD compared with a group of participants without the disease in a neuroimaging study which concluded that brain stem damage may be the first identifiable stage of PD neuropathology.

The main pathological characteristic of PD is cell death in the substantia nigra and more specifically the ventral (front) part of the pars compacta, affecting up to 70% of the cells by the time the patient dies. There are several mechanisms by which the brain cells are lost. One mechanism consists of an abnormal accumulation of the protein alpha-synuclein bound to ubiquitin in the damaged cells. This protein accumulation forms inclusions called Lewy bodies. According to the Braak staging, a classification of the disease based on pathological findings, Lewy bodies first appear in the olfactory bulb, medulla oblongata and pontine tegmentum, with individuals at this stage being asymptomatic. As the disease progresses, Lewy bodies later develop in the substantia nigra, areas of the midbrain and basal forebrain, and in a last step the neocortex. Other cell-death mechanisms include proteosomal and lysosomal system dysfunction and reduced mitochondrial activity. Iron accumulation in the substantia nigra is also typically observed in conjunction with the protein inclusions. It may be related to oxidative stress, protein aggregation and neuronal death, but the mechanisms are not fully understood.

Diagnosis



PET scan of a healthy brain. A decreased dopamine activity in the basal ganglia, using an appropriate neurotracer, can aid in diagnosing Parkinson's disease.

A diagnosis of Parkinson's disease is usually made based on the medical history and neurological examination. The physician interviews and observes the patient in search of

the cardinal motor symptoms, while also attending to other possible symptoms that would exclude a diagnosis of PD. Reduction of motor impairment in response to administration of levodopa markedly increases the likelihood of PD. There is no definitive test for diagnosis, but finding Lewy bodies during autopsy has traditionally been considered the gold standard. Common presentations of the disease are usually easily diagnosed. On the other hand, diagnosis can be difficult when the symptoms are not fully typical of PD, since parkinsonism can occur due to a range of causes, and the difference with PD may be subtle, particularly in the early stages when symptoms may be mild.

Medical organizations have created diagnostic criteria to ease and standardize the diagnostic process, especially in the early stages of the disease. The most widely known come from the UK Parkinson's Disease Society Brain Bank and the US National Institute of Neurological Disorders and Stroke. The PD Society Brain Bank criteria require slowness of movement (bradykinesia) plus either rigidity, resting tremor, or postural instability. Other possible causes for these symptoms need to be ruled out. Finally, three or more of the following features are required during onset or evolution: unilateral onset, tremor at rest, progression in time, asymmetry of motor symptoms, response to levodopa during at least 5 years, clinical course of at least ten years, and appearance of dyskinesias induced by the intake of excessive levodopa. Accuracy of diagnostic criteria evaluated at autopsy is 75–90%, with specialists such as neurologists having the highest rates.

Differential diagnosis requires distinguishing PD from other kind of tremors and also other causes of parkinsonism. Other tremors include postural and action tremors or intention tremor. Other causes that can secondarily produce a parkinsonian syndrome are Alzheimer's disease, multiple cerebral infarction, and drug-induced parkinsonism. Parkinson plus syndromes such as progressive supranuclear palsy and multiple system atrophy also must be ruled out. Anti-Parkinson's medications are typically less effective at controlling symptoms in Parkinson plus syndromes. Faster progression rates, early cognitive dysfunction or postural instability, minimal tremor or symmetry at onset may also indicate a Parkinson plus disease rather than PD itself. Genetic forms are usually classified as PD, although the terms *familial Parkinson's disease* and *familial parkinsonism* are also used for disease entities with an autosomal dominant or recessive pattern of inheritance.

Computed tomography (CT) and Magnetic resonance imaging (MRI) brain scans of people with PD usually appear normal. These techniques are nevertheless useful to rule out other diseases that can be secondary causes of parkinsonism, such as basal ganglia tumors, vascular pathology and hydrocephalus. A specific technique of MRI, diffusion MRI, has been reported to be useful at discriminating between typical and atypical parkinsonism, although its exact diagnostic value is still under investigation. Dopaminergic function in the basal ganglia can be measured with the help of different PET and SPECT radiotracers. Examples are ioflupane (^{123}I) (trade name *DaTSCAN*) and iometopane (*Dopascan*) for SPECT or fludeoxyglucose (^{18}F) for PET. A pattern of reduced dopaminergic activity in the basal ganglia, can aid in diagnosing PD.

Management

At present, there is no cure for Parkinson's disease, but medications, surgery and multidisciplinary management can provide relief from the symptoms. The main families of drugs useful for treating motor symptoms are levodopa, dopamine agonists and MAO-B inhibitors. The stage of the disease determines which group is most useful. Two phases are usually distinguished: an initial phase in which the individual with PD has already developed some disability for which he needs pharmacological treatment, and a second stage in which the patient develops motor complications related to levodopa usage. Treatment in the initial state aims to attain an optimal tradeoff between good management of symptoms and side-effects resulting from enhancement of dopaminergic function. The start of L-DOPA treatment may be delayed by using other medications such as MAO-B inhibitors and dopamine agonists, in the hope of causing the onset of dyskinesias to be retarded. In the second stage the aim is to reduce symptoms while controlling fluctuations of the response to medication. Sudden withdrawals from medication, and overuse by some patients, also have to be controlled. When medications are not enough to control symptoms surgery and deep brain stimulation can be of use.

Levodopa

Stalevo, a commercial preparation combining entacapone, levodopa and carbidopa for treatment of Parkinson's disease



Circuits of the basal ganglia in treatment of Parkinson's disease. Model of the effect of medication on motor symptoms: levodopa, dopamine agonists and MAO-B inhibitors stimulate excitatory signals from the thalamus to the cortex by effects on the striatum, compensating for decreased dopaminergic signals from substantia nigra (seen at bottom right).

Levodopa (or L-DOPA) has been the most widely used treatment for over 30 years. L-DOPA is transformed into dopamine in the dopaminergic neurons by dopa-decarboxylase. Since motor symptoms are produced by a lack of dopamine in the substantia nigra the administration of L-DOPA temporarily diminishes the motor symptoms.

Only 5-10% of L-DOPA crosses the blood-brain barrier. The remaining is often metabolised to dopamine elsewhere, causing a wide variety of side effects including nausea, dyskinesias and stiffness. Carbidopa and benserazide are peripheral dopa decarboxylase inhibitors. They help to prevent the metabolism of L-DOPA before it reaches the dopaminergic neurons and therefore reduce side effects. They are generally given as combination preparations with levodopa. Existing preparations are carbidopa/levodopa (co-careldopa, trade names *Sinemet*, *Parcopa*, *Atamet*) and benserazide/levodopa (co-beneldopa, trade name *Madopar*). Levodopa has also been related to a dopamine dysregulation syndrome, which is a compulsive overuse of the medication, and punding.

Tolcapone inhibits the COMT enzyme, which degrades dopamine, thereby prolonging the effects of levodopa. It has been used to complement levodopa; however its usefulness is limited by possible side effects such as liver damage. A similarly effective drug, entacapone, has not been shown to cause significant alterations of liver function. Entacapone is available for treatment alone (*COMTan*) or combined with carbidopa and levodopa (*Stalevo*).

Levodopa results in a reduction in the endogenous formation of L-DOPA, and eventually becomes counterproductive. Levodopa preparations lead in the long term to the development of motor complications characterized by involuntary movements called dyskinesias and fluctuations in the response to medication. When this occurs PD patients change fastly from stages with good response to medication and few symptoms ("on" state) to phases with no response to medication and important motor symptoms ("off" state). For this reason levodopa doses are kept as low as possible while maintaining functionality. Delaying the initiation of dopatherapy, using instead alternatives for some time, is also common practice. A former strategy to reduce motor complications was to withdraw patients from L-DOPA for some time. This is discouraged now since it can bring dangerous side effects such as neuroleptic malignant syndrome. Most people will eventually need levodopa and later develop motor complications.

Dopamine agonists

Several dopamine agonists that bind to dopaminergic post-synaptic receptors in the brain have similar effects to levodopa. These were initially used for patients experiencing on-off fluctuations and dyskinesias as a complementary therapy to levodopa but they are now mainly used on their own as an initial therapy for motor symptoms with the aim of delaying motor complications. When used in late PD they are useful at reducing the off periods. Dopamine agonists include bromocriptine, pergolide, pramipexole, ropinirole, piribedil, cabergoline, apomorphine, and lisuride.

Dopamine agonists produce significant, although usually mild, side effects including somnolence, hallucinations, insomnia, nausea, and constipation. Sometimes side effects appear even at a the minimal clinically efficacious dose, leading the physician to search for a different drug. When compared with levodopa, dopamine agonists may delay motor complications but are not as effective at controlling symptoms. Nevertheless they are

usually effective enough to manage symptoms in the initial years. They also tend to be more expensive than levodopa. Dyskinesias with dopamine agonists are rare in younger patients, but along with other side effects, are more common in older patients. All this has led to agonists being the preferential initial treatment for younger patients as opposed to levodopa in older patients. Agonists at higher doses have also been related to a wide variety of impulse control disorders.

Apomorphine, a non-orally administered dopamine agonist, may be used to reduce off periods and dyskinesia in late PD. It is administered by intermittent injections or continuous subcutaneous infusions. Since secondary effects such as confusion and hallucinations are common, it has been recommended that patients under apomorphine treatment should be closely monitored.

MAO-B inhibitors

MAO-B inhibitors (selegiline and rasagiline) increase the level of dopamine in the basal ganglia by blocking its metabolization. They inhibit monoamine oxidase-B (MAO-B) which breaks down dopamine secreted by the dopaminergic neurons. Therefore reducing MAO-B results in higher quantities of L-DOPA in the striatum. Similarly to dopamine agonists, MAO-B inhibitors improve motor symptoms and delay the need of taking levodopa when used as monotherapy in the first stages of the disease but produce more adverse effects and are less effective than levodopa. Evidence on their efficacy in the advanced stage is reduced although it points towards them being useful to reduce fluctuations between on and off periods. Although an initial study had as result that selegiline in combination with levodopa increased the risk of death this has been later disproven.

Other drugs

Other drugs such as amantadine and anticholinergics may be useful as treatment of motor symptoms, but since quality of evidence on efficacy is reduced they are not first choice treatments. In addition to motor symptoms, PD is accompanied by a wide range of diverse symptoms. A number of compounds have been used to treat some of these problems. Examples are the use of clozapine for psychosis, cholinesterase inhibitors for dementia, and modafinil for day somnolence.

Surgery and deep brain stimulation



Illustration showing an electrode placed deep seated in the brain

Treating motor symptoms with surgery was once a common practice, but since the discovery of levodopa, the number of performed surgeries has reduced. Studies in the past few decades have led to great improvements in surgical techniques, and surgery is again being used in people with advanced PD for whom drug therapy is no longer sufficient. Deep brain stimulation (DBS) is presently the most used surgical treatment but other surgical therapies in which lesions are produced in specific subcortical areas are also effective. DBS involves the implantation of a medical device called a brain pacemaker, which sends electrical impulses to specific parts of the brain. Target areas for DBS or lesions include the thalamus, the globus pallidus (the lesion technique being

called pallidotomy) or the subthalamic nucleus. DBS is recommended in PD patients without important neuropsychiatric problems who suffer from motor fluctuations and tremor badly controlled by medication, or to those who are intolerant to medication.

Rehabilitation

There is some evidence that speech or mobility problems can improve with rehabilitation although studies are scarce and of low quality. Regular physical exercise and/or therapy can be beneficial to maintain and improve mobility, flexibility, strength, gait speed, and quality of life. Exercise may also improve constipation. One of the most widely practiced treatments for speech disorders associated with Parkinson's disease is the Lee Silverman voice treatment (LSVT), which focuses on increasing vocal loudness and has an intensive approach of one month. Speech therapy and specifically LSVT may improve voice and speech function. Occupational therapy (OT) aims to promote health and quality of life by helping people with the disease to participate in as many activities of their daily living as possible. There have been few studies on the effectiveness of OT and their quality is poor, although there is some indication that it may improve motor skills and quality of life for the duration of the therapy.

Diet

Muscles and nerves that control the digestive process may be affected by PD, resulting in constipation and gastroparesis (food remaining in the stomach for a longer period of time than normal). A balanced diet helps improve digestion. Diet should include high-fiber foods and plenty of water. As the disease advances dysphagia may appear. In such cases it may be helpful to use thickening agents for liquid intake, upright posture when eating, and gastrostomy in the worst cases.

Levodopa and proteins use the same transportation system in the intestine and the blood-brain barrier, thereby competing for access. When they are taken together, this results in a reduced effectiveness of the drug. Therefore when levodopa is introduced excessive protein consumption is discouraged. In advanced stages additional intake of low-protein products such as bread or pasta is recommended for similar reasons. To minimize interaction with proteins, levodopa is recommended to be taken 30 minutes before meals. At the same time, regimens for PD restrict proteins during breakfast and lunch and are usually taken at dinner.

Other treatments

Repetitive transcranial magnetic stimulation temporarily improves levodopa-induced dyskinesias. Its usefulness in PD is an open research topic. Several nutrients have been proposed as possible treatments; however there is no strong evidence that vitamins or food additives improve symptoms. There is also not enough evidence to substantiate that acupuncture, and practice of Qigong, or Tai chi have any effect on symptoms. Fava beans and velvet beans are natural sources of levodopa and are eaten by many people with PD. While they have shown some effectiveness in clinical trials, their intake is not free of

risks. Life threatening adverse reactions have been described, such as the neuroleptic malignant syndrome.

Prognosis



Global burden of Parkinson's disease, measured in disability-adjusted life years per 100,000 inhabitants in 2004.

- no data
- < 5
- 5-12.5
- 12.5-20
- 20-27.5
- 27.5-35
- 35-42.5
- 42.5-50
- 50-57.5
- 57.5-65
- 65-72.5
- 72.5-80
- > 80

PD invariably progresses with time. Motor symptoms, if not treated, advance aggressively in the early stages of the disease and more slowly later. Untreated patients are expected to lose independent ambulation after an average of 8 years and be bedridden after 10 years. However it is uncommon to find untreated people nowadays, and medication has improved the prognosis of motor symptoms, while at the same time it is also a new source of disability due to the undesired effects of levodopa after years of use. In people taking L-DOPA, the mean progression of symptoms to a stage of high dependency takes around 15 years. However it is hard to predict what course the disease will take for a given individual. Age is the best predictor of disease progression. The rate of motor decline is greater in those with less impairment at the time of diagnosis, while

cognitive impairment is more frequent in those who are over 70 years of age at symptom onset.

Since current therapies improve motor symptoms, disability at present is mainly related to non-motor features of the disease. Nevertheless the relationship between disease progression and disability is not linear. At first disability is related to motor symptoms and specially motor complications, which appear in up to 50% of the patients after 5 years of L-DOPA usage. As the disease advances disability is more related to motor symptoms that have a bad response to medication such as swallowing and speech difficulties and gait and balance problems. Finally after ten years most people with the disease have autonomic disturbances, sleep problems, mood alterations and cognitive decline. All of them, but specially the latter, greatly increase disability.

The life expectancy of people with PD is lower than for people who do not have the disease. Mortality ratios are around twice those of unaffected people. Cognitive decline and dementia, old age at onset, a more advanced disease state, and presence of swallowing problems are all mortality risk factors. On the other hand a disease mainly characterized by tremor as opposed to rigidity predicts an improved survival. One specific cause of death twice as common in individuals with PD than in the healthy population is aspiration pneumonia.

Epidemiology

PD is the most common neurodegenerative disorder after Alzheimer's disease. Two main measures are used in epidemiological studies: incidence and prevalence. Incidence is the number of new cases per unit of person–time at risk (usually number of new cases per thousand person–years); prevalence is the total number of cases of the disease in the population at a given time. The prevalence is estimated at 0.3% of the whole population in industrialized countries, rising to 1% in those over 60 years of age and to 4% of the population over 80. The mean age of onset is around 60 years, although 5-10% of cases, classified as young onset, begin between the ages of 20 and 50. PD may be less prevalent in those of African and Asian ancestry, although this finding is controversial. Some studies have proposed that it is more common in men than women, but others failed to detect any differences between the two sexes. The incidence of PD is between 8 and 18 per 100,000 person-years.

Many risk factors and protective factors have been proposed, sometimes in relation to theories concerning possible mechanisms of the disease, however none have been conclusively related to PD by empirical evidence. When epidemiological studies have been carried out in order to test the relationship between a given factor and PD, they have frequently been biased, and their results have in some cases been contradictory. The most frequently replicated relationships are an increased risk of PD in those exposed to pesticides and a reduced risk in smokers.

Risk factors

U.S. Army Huey helicopter spraying Agent Orange over Vietnamese agricultural land. Agent Orange has been associated to PD.

Injections of the synthetic neurotoxin MPTP produce a range of symptoms similar to those of PD as well as selective damage to the dopaminergic neurons in the substantia nigra. This observation has led to theorizing that exposure to some environmental toxins may increase the risk of having PD. Toxins that have been consistently related to the disease are certain pesticides and herbicides, with exposure increasing the risk by as much as a factor of two. Conversely indirect measures of exposure, such as living in rural environments, have also been found to increase the risk of PD. Limited evidence suggests that exposure to Agent Orange and other herbicides used during the Vietnam War is associated with an increased chance of developing Parkinson's disease. In 2010 the United States Department of Veterans Affairs issued a regulation which presumed an association between exposure to agent orange and other herbicides and PD in veterans. Vietnam veterans with PD are eligible for several benefits from the department. Heavy metals exposure has also been proposed to be a risk factor, through possible accumulation in the substantia nigra, however studies on the issue have been inconclusive.

Protective factors

Tobacco has a protective effect against PD. The basis for this effect is not known, but possibilities include an effect of nicotine as a dopamine stimulant. Caffeine consumption

also protects against PD. Antioxidants, such as vitamin C and D, have been proposed to protect against the disease but results of studies have been contradictory and no positive effect has been proven. Regarding fat and fatty acids, the results have also been contradictory, with protective effects, risk-enhancing effects, and no effects reported by various studies. Finally there have also been preliminary indications of a possible protective role of estrogens and anti-inflammatory drugs.

History



AN

ESSAY

ON THE

SHAKING PALSY.

CHAPTER I.

DEFINITION–HISTORY–ILLUSTRATIVE CASES.

SHAKING PALSY. *(Paralysis Agitans.)*

Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported; with a propensity to bend the trunk forward, and to pass from a walking to a running pace: the senses and intellects being uninjured.

First page of Parkinson's classical essay on the Shaking palsy

The disease was not formally recognized and its symptoms were not documented until 1817, when British apothecary James Parkinson published *An Essay on the Shaking Palsy*. PD was then known as *paralysis agitans* (shaking palsy in English). The term "Parkinson's disease" was coined several decades later by Jean-Martin Charcot.

Early descriptions

Several early sources describe symptoms resembling those of PD. An Egyptian papyrus from the 12th century B.C mentions a king drooling with age, and the Bible contains a number of references to tremor. An Ayurvedic medical treatise from the 10th century B.C describes a disease that evolves with tremor, lack of movement, drooling and other symptoms of PD. Moreover, this disease was treated with remedies derived from the mucuna family, which is rich in L-DOPA. Galen wrote about a disease that almost certainly was PD, describing tremors that occur only at rest, postural changes and paralysis.

After Galen there are no references unambiguously related to PD until the 17th century. In this and the following century several authors wrote about elements of the disease, preceding the description by Parkinson. Franciscus Sylvius, like Galen, distinguished tremor at rest from other tremors, and Johannes Baptiste Sagar and Hieronymus David

Gaubius described festination, a term for the gait abnormalities characteristic of PD. John Hunter provided a thorough description of the disease, which may have given Parkinson the idea of collecting and describing patients with "paralysis agitans". Finally, Auguste François Chomel in his pathology treatise, which was contemporary to Parkinson's essay, included several descriptions of abnormal movements and rigidity matching those seen in PD.

19th century

Jean-Martin Charcot (pictured) made important contributions to the understanding of the disease and proposed its current name honoring James Parkinson.

In 1817 James Parkinson published his essay reporting 6 cases of paralysis agitans. "An Essay on the Shaking Palsy" described the characteristic resting tremor, abnormal posture and gait, paralysis and diminished muscle strength, and the way that the diseases progresses over time. He also acknowledged the contributions of many of the previously mentioned authors to the understanding of PD. Although the article was later considered

the seminal work on the disease, it received little attention for the next forty years. Nevertheless early neurologists who made further additions to the knowledge of the disease include Trousseau, Gowers, Kinnier Wilson and Erb, and most notably Charcot, whose studies between 1868 and 1881 were a landmark in the understanding of the disease. Among other advances he made the distinction between rigidity, weakness and bradykinesia. He also championed the renaming of the disease in honor of James Parkinson.

20th century

The first speculations concerning the anatomical substrate of PD were made 80 years after Parkinson's essay, when Édouard Brissaud proposed that it had its origin in the subthalamus or cerebral peduncle and might be caused by an ischemic lesion. In 1912 Frederic Lewy described a pathologic finding in affected brains, later named "Lewy bodies". In 1919 Konstantin Tretiakoff reported that the substantia nigra was the main cerebral structure affected, but this finding was not widely accepted until it was confirmed by further studies published by Rolf Hassler in 1938. The underlying biochemical changes in the brain were identified in the 1950s, due largely to the work of Arvid Carlsson on the neurotransmitter dopamine and its role on PD. Carlsson was eventually awarded a Nobel Prize for this work.

Levodopa was first synthesized in 1911 by Casimir Funk, but it received little attention until the mid 20th century. It entered clinical practice in 1967, and the first large study reporting improvements in patients with Parkinson's disease resulting from treatment with levodopa was published in 1968. Levodopa brought about a revolution in the management of PD. Surgery for tremor was first tried in 1939, and was improved over the following 20 years, but the arrival of levodopa reduced its use dramatically. By the late 1980s deep brain stimulation emerged as a possible treatment, and it was approved for clinical use by the FDA in 1997.

Research directions

Parkinson's disease is better understood than most other neurological disorders, in that its main symptoms are known to be caused by loss of a specific group of cells in a specific part of the brain. What is not known, for most cases, is the mechanism that causes those specific cells to be lost. Research on PD, therefore, is directed mainly at two key questions: (1) What happens that causes dopamine cells in the substantia nigra to die, and how might this cell death be prevented? (2) How might those cells be replaced or their loss compensated for? There is little prospect of dramatic new PD treatments expected in a short time frame, but several lines of research are aimed at answering the critical questions. Currently active research directions include the search of new animal models of the disease, and studies of the potential usefulness of gene therapy, stem cells transplants and neuroprotective agents.

Animal models

PD is not known to occur naturally in any species other than humans. However, the tragedy of a group of drug addicts in California in the early 1980s who consumed a contaminated and illicitly produced batch of the synthetic opiate MPPP led to the discovery of the chemical MPTP as an agent that causes a parkinsonian syndrome in non-human primates as well as in humans. Other predominant toxin-based models employ the insecticide rotenone, the herbicide paraquat and the fungicide maneb. Models based on toxins are most commonly used in primates. Transgenic rodent models that replicate various aspects of PD have also been developed.

Gene therapy

Gene therapy is currently under investigation. It involves the use of a non-infectious virus to shuttle a gene into a part of the brain. The gene used leads to the production of an enzyme which helps to manage PD symptoms or protects the brain from further damage. As of 2010 there are four clinical trials using gene therapy in PD. There have not been important adverse effects in these trials although the clinical usefulness of gene therapy is still unknown.

Neuroprotective treatments



While several chemical compounds such as GNDF (chemical structure pictured) have been proposed as neuroprotectors in PD, none has proven its efficacy.

Investigations on neuroprotection are at the forefront of PD research. Several molecules have been proposed as potential treatments. However none of them has been conclusively demonstrated to reduce degeneration. Agents currently under investigation include anti-apoptotics (TCH346, CEP-1347), antiglutamatergics, monoamine oxidase inhibitors (selegiline, rasagiline), promitochondrials (coenzyme Q10, creatine), calcium channel blockers (isradipine) and growth factors (GDNF). Preclinical research also targets alpha-synuclein.

Neural transplantation

Since early in the 1980s, fetal, porcine, carotid or retinal tissues have been used in cell transplants, in which dissociated cells are injected into the substantia nigra in the hope that they will incorporate themselves into the brain in a way that replaces the dopamine cells that have been lost. Although there was initial evidence of mesencephalic dopamine-producing cell transplants being beneficial, the best constructed studies up to date indicate that cell transplants produce no demonstrable long-term benefit. An additional significant problem was the excess release of dopamine by the transplanted tissue, leading to dystonias. Stem cells transplants are a recent main research target, because stem cells are easy to manipulate, and stem cells transplanted into the brains of rodents and monkeys have been found to survive and to reduce behavioral abnormalities. Nevertheless use of fetal stem cells is controversial. It has been proposed that effective treatments may be developed in a less controversial way by use of induced pluripotent stem cells taken from adults.

Society and culture

Cost

The costs of PD to society are high, but difficult to calculate exactly due to methodological difficulties in research and differences between countries. The annual cost in the United Kingdom is estimated to be between 449 million pounds and 3.3 billions, while the cost per individual per year in the US is probably around $10,000 and the total burden around 23 billion dollars. The largest share of direct cost comes from inpatient care and nursing homes, while the share coming from medications is substantially lower. Indirect costs are also important, including losses from reduced productivity and burden on caregivers. In addition to economic costs, PD also reduces quality of life of those with the disease and their caregivers.

Advocacy



A red tulip, considered the symbol of PD

April 11, the birthday of James Parkinson, has been designated as the world's Parkinson's disease day. A red tulip was chosen by several international organizations as the symbol of the disease in 2005: it represents the James Parkinson Tulip cultivar, registered in 1981 by a Dutch horticulturalist. Advocacy organizations on the disease include the Parkinson's Disease Foundation, which has provided more than $85 million for research and $34 million for education and advocacy programs since its founding in 1957 by William Black; the American Parkinson Disease Association, founded in 1961; and the European Parkinson's Disease Association, founded in 1992.

Notable cases

Muhammad Ali is considered one of the most famous people with PD. Picture is of the boxer in 2006, 26 years after his diagnosis.

Among the many famous people with PD, one who has greatly increased the public awareness of the disease has been actor Michael J. Fox. Fox was diagnosed in 1991 when he was 30, but kept his condition secret from the public for seven years. His first book, *Lucky Man*, focused on how after seven years of denial of the disease he set up the Michael J. Fox Foundation, stopped drinking, and began to be an advocate for those with PD. His second book, *Always Looking Up: The Adventures Of An Incurable Optimist*, describes his life between 1999 and 2009, with much of the book centered on how Fox began to advocate for stem cell research. The Michael J. Fox Foundation aims to develop

a cure for Parkinson's disease. In recent years it has been the major Parkinson's fundraiser in the US, providing 140 million dollars in research funding between 2001 and 2008. In 2010, the Fox foundation launched the first large-scale clinical study on genetic biomarkers of the disease, at a cost of 40 million dollars over 5 years. Michael J. Fox also appeared before the United States Congress without medication to illustrate the effects of the disease. His work led him to be named one of the 100 people "whose power, talent or moral example is transforming the world" in 2007 by the Time magazine, and he received an honorary doctorate in medicine from Karolinska Institutet for his contributions to research in Parkinson's disease.

Another foundation that supports Parkinson's research was established by professional cyclist Davis Phinney. The Davis Phinney Foundation strives to improve the lives of those living with Parkinson's disease by providing them with information and tools.

Muhammad Ali has been called the "world's most famous Parkinson's patient". He was 42 at diagnosis although he already showed signs of parkinsonism when he was 38. Nevertheless whether he truly has PD or a parkinsonian syndrome due to boxing is still an open question.

Chapter 7

Huntington's Disease

Huntington's disease



A microscope image of Medium spiny neurons (yellow) with nuclear inclusions (orange), which occur as part of the disease process, image width 360 µm

ICD-10	G10., F02.2
ICD-9	333.4, 294.1
OMIM	143100

DiseasesDB	6060
MedlinePlus	000770
eMedicine	article/1150165 article/792600 article/289706
MeSH	D006816

Huntington's disease, **chorea**, or **disorder** (**HD**), is a neurodegenerative genetic disorder that affects muscle coordination and leads to cognitive decline and dementia. It typically becomes noticeable in middle age. HD is the most common genetic cause of abnormal involuntary writhing movements called chorea and is much more common in people of Western European descent than in those from Asia or Africa. The disease is caused by an autosomal dominant mutation on either of an individual's two copies of a gene called Huntingtin, which means any child of an affected parent has a 50% risk of inheriting the disease. In rare situations where both parents have an affected copy this risk increases to 75%, and when either parent has two affected copies, the risk is 100% (all children will be affected). Physical symptoms of Huntington's disease can begin at any age from infancy to old age, but usually begin between 35 and 44 years of age. About 6% of cases start before the age of 21 years with an akinetic-rigid syndrome; they progress faster and vary slightly. The variant is classified as **juvenile**, **akinetic-rigid** or **Westphal variant HD**.

The Huntingtin gene normally provides the genetic information for a protein that is also called "Huntingtin". The mutation of the Huntingtin gene codes for a different form of the protein, whose presence results in gradual damage to specific areas of the brain. The exact way this happens is not fully understood. Genetic testing can be performed at any stage of development, even before the onset of symptoms. This raises several ethical debates regarding the age at which an individual is considered mature enough to choose testing, the right of parents to test their children, and confidentiality and disclosure of test results. Genetic counseling has developed to inform and aid individuals considering genetic testing and has become a model for other genetically dominant diseases.

Symptoms of the disease can vary between individuals and even members of the same family, but the symptoms progress predictably for most individuals. The earliest symptoms are a general lack of coordination and an unsteady gait. As the disease advances, uncoordinated, jerky body movements become more apparent, along with a decline in mental abilities and behavioral and psychiatric problems. Physical abilities are gradually impeded until coordinated movement becomes very difficult, and mental abilities generally decline into dementia. Complications such as pneumonia, heart disease, and physical injury from falls reduce life expectancy to around twenty years after symptoms begin. There is no cure for HD, and full-time care is required in the later stages of the disease, but there are emerging treatments to relieve some of its symptoms.

Self-help support organizations, first founded in the 1960s and increasing in number, have been working to increase public awareness, to provide support for individuals and their families, and to promote research. The Hereditary Disease Foundation, a research group born out of the first support organization, was instrumental in finding the gene in 1993. Since that time there have been important discoveries every few years and understanding of the disease is improving. Current research directions include determining the exact mechanism of the disease, improving animal models to expedite research, clinical trials of pharmaceuticals to treat symptoms or slow the progression of the disease, and studying procedures such as stem cell therapy with the goal of repairing damage caused by the disease.

Signs and symptoms

Symptoms of Huntington's disease commonly become noticeable between the ages of 35 and 44 years, but they can begin at any age from infancy to old age. In the early stages, there are subtle changes in personality, cognition, and physical skills. The physical symptoms are usually the first to be noticed, as cognitive and psychiatric symptoms are generally not severe enough to be recognized on their own at the earlier stages. Almost everyone with Huntington's disease eventually exhibits similar physical symptoms, but the onset, progression and extent of cognitive and psychiatric symptoms vary significantly between individuals.

The most characteristic initial physical symptoms are jerky, random, and uncontrollable movements called chorea. Chorea may be initially exhibited as general restlessness, small unintentionally initiated or uncompleted motions, lack of coordination, or slowed saccadic eye movements. These minor motor abnormalities usually precede more obvious signs of motor dysfunction by at least three years. The clear appearance of symptoms such as rigidity, writhing motions or abnormal posturing appear as the disorder progresses. These are signs that the system in the brain that is responsible for movement is affected. Psychomotor functions become increasingly impaired, such that any action that requires muscle control is affected. Common consequences are physical instability, abnormal facial expression, and difficulties chewing, swallowing and speaking. Eating difficulties commonly cause weight loss and may lead to malnutrition. Sleep disturbances are also associated symptoms. Juvenile HD differs from these symptoms in that it generally progresses faster and chorea is exhibited briefly, if at all, with rigidity being the dominant symptom. Seizures are also a common symptom of this form of HD.

Reported prevalences of behavioral and psychiatric symptoms in Huntington's disease

Irritability	38–73%
Apathy	34–76%
Anxiety	34–61%
Depressed mood	33–69%
Obsessive and compulsive	10–52%
Psychotic	3–11%

Cognitive abilities are impaired progressively. Especially affected are executive functions which include planning, cognitive flexibility, abstract thinking, rule acquisition, initiating appropriate actions and inhibiting inappropriate actions. As the disease progresses, memory deficits tend to appear. Reported impairments range from short-term memory deficits to long-term memory difficulties, including deficits in episodic (memory of one's life), procedural (memory of the body of how to perform an activity) and working memory. Cognitive problems tend to worsen over time, ultimately leading to dementia. This pattern of deficits has been called a subcortical dementia syndrome to distinguish it from the typical effects of cortical dementias e.g. Alzheimer's disease.

Reported neuropsychiatric manifestations are anxiety, depression, a reduced display of emotions (blunted affect), egocentrism, aggression, and compulsive behavior, the latter of which can cause or worsen addictions, including alcoholism, gambling, and hypersexuality. Difficulties in recognizing other people's negative expressions have also been observed. Prevalence of these symptoms is also highly variable between studies, with estimated rates for lifetime prevalence of psychiatric disorders between 33% and 76%. For many sufferers and their families these symptoms are among the most distressing aspects of the disease, often affecting daily functioning and constituting reason for institutionalisation. Suicidal thoughts and suicide attempts are more common than in the general population.

Mutant Huntingtin is expressed throughout the body and associated with abnormalities in peripheral tissues that are directly caused by such expression outside the brain. These abnormalities include muscle atrophy, cardiac failure, impaired glucose tolerance, weight loss, osteoporosis and testicular atrophy.

Genetics

All humans have the Huntingtin gene (*HTT*), which codes for the protein Huntingtin (Htt). Part of this gene is a repeated section called a trinucleotide repeat, which varies in length between individuals and may change length between generations. When the length of this repeated section reaches a certain threshold, it produces an altered form of the protein, called mutant Huntingtin protein (mHtt). The differing functions of these proteins are the cause of pathological changes which in turn cause the disease symptoms. The Huntington's disease mutation is genetically dominant and almost fully penetrant: mutation of either of a person's *HTT* genes causes the disease. It is not inherited according to sex, but the length of the repeated section of the gene, and hence its severity, can be influenced by the sex of the affected parent.

Genetic mutation

HD is one of several trinucleotide repeat disorders which are caused by the length of a repeated section of a gene exceeding a normal range. The *HTT* gene is located on the short arm of chromosome 4 at 4p16.3. *HTT* contains a sequence of three DNA bases—cytosine-adenine-guanine (CAG)—repeated multiple times (i.e. ... CAGCAGCAG ...), known as a trinucleotide repeat. CAG is the genetic code for the amino acid glutamine, so

a series of them results in the production of a chain of glutamine known as a polyglutamine tract (or polyQ tract), and the repeated part of the gene, the *PolyQ region*.

Classification of the trinucleotide repeat, and resulting disease status, depends on the number of CAG repeats

Repeat count	Classification	Disease status
<28	Normal	Unaffected
28–35	Intermediate	Unaffected
36–40	Reduced Penetrance	+/- Affected
>40	Full Penetrance	Affected

Generally, people have fewer than 36 repeated glutamines in the polyQ region which results in production of the cytoplasmic protein Huntingtin. However, a sequence of 36 or more glutamines results in the production of a protein which has different characteristics. This altered form, called mHtt (mutant Htt), increases the decay rate of certain types of neuron. Regions of the brain have differing amounts and reliance on these type of neurons, and are affected accordingly. Generally, the number of CAG repeats is related to how much this process is affected, and accounts for about 60% of the variation of the age of the onset of symptoms. The remaining variation is attributed to environment and other genes that modify the mechanism of HD. 36–40 repeats result in a reduced-penetrance form of the disease, with a much later onset and slower progression of symptoms. In some cases the onset may be so late that symptoms are never noticed. With very large repeat counts, HD has full penetrance and can occur under the age of 20, when it is then referred to as juvenile HD, akinetic-rigid, or Westphal variant HD. This accounts for about 7% of HD carriers.

Inheritance



Huntington's disease is inherited in an autosomal dominant fashion. The probability of each offspring inheriting an affected gene is 50%. Inheritance is independent of gender, and the gene does not skip generations.

Huntington's disease has autosomal dominant inheritance, meaning that an affected individual typically inherits one copy of the gene with an expanded trinucleotide repeat (the mutant allele) from an affected parent. Since penetrance of the mutation is very high those who have a mutated copy of the gene will have the disease. In this type of inheritance pattern, each offspring of an affected individual has a 50% risk of inheriting the mutant allele and therefore being affected with the disorder (see figure). This probability is sex-independent.

Trinucleotide CAG repeats over 28 are unstable during replication and this instability increases with the number of repeats present. This usually leads to new expansions as generations pass (dynamic mutations) instead of reproducing an exact copy of the trinucleotide repeat. This causes the number of repeats to change in successive generations, such that an unaffected parent with an "intermediate" number of repeats (28–35), or "reduced penetrance" (36–40), may pass on a copy of the gene with an increase in the number of repeats that produces fully penetrant HD. Such increases in the number of

repeats (and hence earlier age of onset and severity of disease) in successive generations is known as genetic anticipation. Instability is greater in spermatogenesis than oogenesis; maternally inherited alleles are usually of a similar repeat length, whereas paternally inherited ones have a higher chance of increasing in length. It is rare for Huntington's disease to be caused by a new mutation, where neither parent has over 36 CAG repeats.

Individuals with both genes affected are rare, except in large consanguineous families. For some time HD was thought to be the only disease for which possession of a second mutated gene did not affect symptoms and progression, but it has since been found that it can affect the phenotype and the rate of progression. Offspring of an individual who has two affected genes will inherit one of them and therefore definitely inherit the disease. Offspring where both parents have one affected gene have a 75% risk of inheriting HD, including a 25% risk of inheriting two affected genes. Identical twins, who have inherited the same affected gene, typically have differing ages of onset and symptoms.

Mechanism

The Htt protein interacts with over 100 other proteins, and appears to have multiple biological functions. The behavior of mutated mHtt protein is not completely understood, but it is toxic to certain types of cells, particularly in the brain. Damage mainly occurs in the striatum, but as the disease progresses, other areas of the brain are also significantly affected. As the damage accumulates, symptoms associated with the functions of these brain areas appear. Planning and modulating movement are the main functions of the striatum, and difficulties with these are initial symptoms.

Htt function

Htt is expressed in all mammalian cells. The highest concentrations are found in the brain and testes, with moderate amounts in the liver, heart, and lungs. The function of Htt in humans is unclear. It interacts with proteins which are involved in transcription, cell signaling and intracellular transporting. In animals genetically modified to exhibit HD, several functions of Htt have been found. In these animals, Htt is important for embryonic development, as its absence is related to embryonic death. It also acts as an anti-apoptotic agent preventing programmed cell death and controls the production of brain-derived neurotrophic factor, a protein which protects neurons and regulates their creation during neurogenesis. Htt also facilitates vesicular transport and synaptic transmission and controls neuronal gene transcription. If the expression of Htt is increased and more Htt produced, brain cell survival is improved and the effects of mHtt are reduced, whereas when the expression of Htt is reduced, the resulting characteristics are more typical of the presence of mHtt. In humans the disruption of the normal gene does not cause the disease. It is currently concluded that the disease is not caused by inadequate production of Htt, but by a gain of toxic function of mHtt.

Cellular changes due to mHtt



A microscope image of a neuron with inclusion (stained orange) caused by HD, image width 250 μm

There are multiple cellular changes through which the toxic function of mHtt may manifest and produce the HD pathology. During the biological process of posttranslational modification of mHtt, cleavage of the protein can leave behind shorter fragments constituted of parts of the polyglutamine expansion. The polar nature of glutamine causes interactions with other proteins when it is overabundant in Htt proteins. Thus, the Htt molecule strands will form hydrogen bonds with one another, forming a protein aggregate rather than folding into functional proteins. Over time, the aggregates accumulate, ultimately interfering with neuron function because these fragments can then misfold and coalesce, in a process called protein aggregation, to form inclusion bodies within cells. Neuronal inclusions run indirect interference. The excess protein aggregates clump together at axons and dendrites in neurons which mechanically stops the transmission of neurotransmitters because vesicles (filled with neurotransmitters) can no longer move through the cytoskeleton. Ultimately, over time, less and less neurotransmitters are available for release in signaling other neurons as the neuronal inclusions grow. Inclusion bodies have been found in both the cell nucleus and cytoplasm. Inclusion bodies in cells of the brain are one of the earliest pathological changes, and some experiments have found that they can be toxic for the cell, but other experiments have shown that they may form as part of the body's defense mechanism and help protect cells.

Several pathways by which mHtt may cause cell death have been identified. These include: effects on chaperone proteins, which help fold proteins and remove misfolded ones; interactions with caspases, which play a role in the process of removing cells; the toxic effects of glutamine on nerve cells; impairment of energy production within cells; and effects on the expression of genes. The cytotoxic effects of mHtt are strongly enhanced by interactions with a protein called *Rhes*, which is expressed mainly in the striatum. Rhes was found to induce sumoylation of mHtt, which causes the protein clumps to disaggregate—studies in cell culture showed that the clumps were much less toxic than the disaggregated form.

An additional theory that explains another way cell function may be disrupted by HD proposes that damage to mitochondria in striatal cells (numerous accounts of mitochondrial metabolism deficiency have been found) and the interactions of the altered huntingtin protein with numerous proteins in neurons leads to an increased vulnerability of glutamine, which, in large amounts, has been found to be an excitotoxin. Excitotoxins may cause damage to numerous cellular structures. Although glutamine isn't found in excessively high amounts, its been postulated that because of the increased vulnerability, even normal amounts glutamine can cause excitotoxins to be expressed. Furthermore, the increase in sensitivity turn on capases are activated by the repeat expansion of polyglutamine and the increase in sensitivity. The huntingtin protein is cleaved into tiny pieces by capases; these nuclear aggregates disrupt transcription by interfering with the production of proteins by "slipping" into the nucleus of the neuron. Unfortunately, the cellular stress caused by the interference causes more huntingtin to be broken up until apoptosis occurs.

Macroscopic changes due to mHtt



Area of the brain damaged by Huntington's disease – striatum (shown in purple)

HD affects specific areas of the brain. The most prominent early effects are in a part of the basal ganglia called the neostriatum, which is composed of the caudate nucleus and putamen. Other areas affected include the substantia nigra, layers 3, 5 and 6 of the cerebral cortex, the hippocampus, purkinje cells in the cerebellum, lateral tuberal nuclei of the hypothalamus and parts of the thalamus. These areas are affected according to their structure and the types of neurons they contain, reducing in size as they lose cells. Striatal spiny neurons are the most vulnerable, particularly ones with projections towards the external globus pallidus, with interneurons and spiny cells projecting to the internal pallidum being less affected. HD also causes an abnormal increase in astrocytes.

The basal ganglia—the part of the brain most prominently affected by HD—play a key role in movement and behavior control. Their functions are not fully understood, but current theories propose that they are part of the cognitive executive system and the motor circuit. The basal ganglia ordinarily inhibit a large number of circuits that generate specific movements. To initiate a particular movement, the cerebral cortex sends a signal to the basal ganglia that causes the inhibition to be released. Damage to the basal ganglia can cause the release or reinstatement of the inhibitions to be erratic and uncontrolled, which results in an awkward start to motion or motions to be unintentionally initiated, or

a motion to be halted before, or beyond, its intended completion. The accumulating damage to this area causes the characteristic erratic movements associated with HD.

There are two ways the basal ganglia can be damaged: directly and indirectly. In the direct pathway, fewer neurotransmitters are sent the internal globus pallidus (IGP), which in turn comprehends this as a decrease in inhibition, thereby releasing a greater amount of neurotransmitters than normal. The thalamus, which receives a greater number of neurotransmitters, becomes inhibited, thus sending less neurotransmitters to the motor cortex. Ultimately, the motor cortex is understimulated and movements are slower than usual. The indirect pathway starts with the external globus pallidus receiving a lower number of neurotransmitters, and in turn, responding to this decrease as a signal of less inhibition, releases a more neurotransmitters. The subthalamic nuclei (STN), which receives the signals from the external globus pallidus, releases fewer neurotransmitters to the IGP in response to the increase of neurotransmitters received. The IGP is now considerably inhibited because the job of the STN is to excite the IGP and therefore, the IGP releases fewer neurotransmitters. In this context, the reception of less neurotransmitters by the thalamus is perceived as less inhibition. Finally, the motor cortex receives more neurotransmitters and is overstimulated, causing the jerky movements usual in chorea. Since there are two different types of neurons in the striatum, a different neuron, with different axons and dendrites targeted, is stimulated in each pathway (though neurotransmitter GABA is used in both) and thus both can run at the same time. The indirect pathway is generally affected first, which is why chorea is among the first symptoms, but eventually, both types of neurons die off and movement is severely limited.

Transcriptional dysregulation

CREB-binding protein (CBP), a transcription factor, is essential for cell function because as a coactivator at a significant number of promoters, it activates the transcription of genes for survival pathways. Furthermore, the amino acids that form CBP include a strip 18 glutamines. Thus, the glutamines on CBP interact directly with the increased numbers of glutamine on the Htt chain and CBP gets pulled away from its typical location next to the nucleus. Specifically, CRB contains a acetyltransferase domain that, in an experiment performed by Steffan and colleagues, showed that a Htt exon 1 with 51 glutamines binded to this domain in CBP. Autopsied brains of those who had Huntington's disease also have been found to have incredibly reduced amounts of CBP. Plus, when CBP is overexpressed, polyglutamine-induced death diminished, further demonstrating that CBP plays an important role in Huntington's disease and neurons in general.

Diagnosis

Medical diagnosis of the onset of HD can be made following the appearance of physical symptoms specific to the disease. Genetic testing can be used to confirm a physical diagnosis if there is no family history of HD. Even before the onset of symptoms, genetic testing can confirm if an individual or embryo carries an expanded copy of the trinucleotide repeat in the *HTT* gene that causes the disease. Genetic counseling is

available to provide advice and guidance throughout the testing procedure, and on the implications of a confirmed diagnosis. These implications include the impact on an individual's psychology, career, family planning decisions, relatives and relationships. Despite the availability of pre-symptomatic testing, only 5% of those at risk of inheriting HD choose to do so.

Clinical



Coronal section from a MR brain scan of a patient with HD showing atrophy of the heads of the caudate nuclei, enlargement of the frontal horns of the lateral ventricles, and generalised cortical atrophy.

A physical examination, sometimes combined with a psychological examination, can determine whether the onset of the disease has begun. Excessive unintentional movements of any part of the body are often the reason for seeking medical consultation. If these are abrupt and have random timing and distribution, they suggest a diagnosis of HD. Cognitive or psychiatric symptoms are rarely the first diagnosed; they are usually only recognized in hindsight or when they develop further. How far the disease has progressed can be measured using the *unified Huntington's disease rating scale* which provides an overall rating system based on motor, behavioral, cognitive, and functional assessments. Medical imaging, such as computerized tomography (CT) and magnetic resonance imaging (MRI), only shows visible cerebral atrophy in the advanced stages of the disease. Functional neuroimaging techniques such as fMRI and PET can show changes in brain activity before the onset of physical symptoms.

Genetic

Because HD is dominant, there is a strong motivation for individuals who are at risk of inheriting it to seek a diagnosis. The genetic test for HD consists of a blood test which counts the numbers of CAG repeats in each of the *HTT* alleles. A positive result is not considered a diagnosis, since it may be obtained decades before the symptoms begin. However, a negative test means that the individual does not carry the expanded copy of the gene and will not develop HD.

A pre-symptomatic test is a life-changing event and a very personal decision. The main reason given for choosing testing for HD is to aid in career and family decisions. Over 95% of individuals at risk of inheriting HD do not proceed with testing, mostly because there is no treatment. A key issue is the anxiety an individual experiences about not knowing whether they will eventually develop HD, compared to the impact of a positive result. Irrespective of the result, stress levels have been found to be lower two years after being tested, but the risk of suicide is increased after a positive test result. Individuals found to have not inherited the disorder may experience survivor guilt with regard to family members who are affected. Other factors taken into account when considering testing include the possibility of discrimination and the implications of a positive result, which usually means a parent has an affected gene and that the individual's siblings will be at risk of inheriting it. Genetic counseling in HD can provide information, advice and support for initial decision-making, and then, if chosen, throughout all stages of the testing process. Counseling and guidelines on the use of genetic testing for HD have become models for other genetic disorders, such as autosomal dominant cerebellar ataxias. Presymptomatic testing for HD has also influenced testing for other illnesses with genetic variants such as polycystic kidney disease, familial Alzheimer's disease and breast cancer.

Embryonic

Embryos produced using in vitro fertilisation may be genetically tested for HD using preimplantation genetic diagnosis. This technique, where a single cell is extracted from a 4 to 8 cell embryo and then tested for the genetic abnormality, can then be used to ensure

embryos with affected *HTT* genes are not implanted, and therefore any offspring will not inherit the disease. It is also possible to obtain a prenatal diagnosis for an embryo or fetus in the womb.

Differential diagnosis

About 90% of HD diagnoses based on the typical symptoms and a family history of the disease are confirmed by genetic testing to have the expanded trinucleotide repeat that causes HD. Most of the remaining are called HD-like disorders. Most of these other disorders are collectively labelled HD-like (HDL). The cause of most HDL diseases is unknown, but those with known causes are due to mutations in the prion protein gene (HDL1), the junctophilin 3 gene (HDL2), a recessively inherited *HTT* gene (HDL3—only found in one family and poorly understood), and the gene encoding the TATA box-binding protein (HDL4/SCA17). Other autosomal dominant diseases that can be misdiagnosed as HD are dentatorubral-pallidoluysian atrophy and neuroferritinopathy. There are also autosomal recessive disorders that resemble sporadic cases of HD. Main examples are chorea acanthocytosis, pantothenate kinase-associated neurodegeneration and X-linked McLeod syndrome.

Management



Chemical structure of tetrabenazine, an approved compound for the management of chorea in HD

There is no cure for HD, but there are treatments available to reduce the severity of some of its symptoms. For many of these treatments, comprehensive clinical trials to confirm their effectiveness in treating symptoms of HD specifically are incomplete. As the

disease progresses and a person's ability to tend to their own needs reduces, carefully managed multidisciplinary caregiving becomes increasingly necessary.

Tetrabenazine was developed specifically to reduce the severity of chorea in HD, it was approved in 2008 for this use in the US. Other drugs that help to reduce chorea include neuroleptics and benzodiazepines. Compounds such as amantadine or remacemide are still under investigation but have shown preliminary positive results. Hypokinesia and rigidity can be treated with antiparkinsonian drugs, and myoclonic hyperkinesia can be treated with valproic acid.

Psychiatric symptoms can be treated with medications similar to those used in the general population. Selective serotonin reuptake inhibitors and mirtazapine have been recommended for depression, while atypical antipsychotic drugs are recommended for psychosis and behavioural problems.

Weight loss and eating difficulties due to dysphagia and other muscle discoordination are common, making nutrition management increasingly important as the disease advances. Thickening agents can be added to liquids as thicker fluids are easier and safer to swallow. Reminding the patient to eat slowly and to take smaller pieces of food into the mouth may also be of use to prevent choking. If eating becomes too hazardous or uncomfortable, the option of using a percutaneous endoscopic gastrostomy is available. This is a feeding tube, permanently attached through the abdomen into the stomach, which reduces the risk of aspirating food and provides better nutritional management.

Although there have been relatively few studies of exercises and therapies that help rehabilitate cognitive symptoms of HD, there is some evidence for the usefulness of physical therapy, occupational therapy, and speech therapy. However, more rigorous studies are needed for health authorities to endorse them. A multidisciplinary approach may be important to limit disability. The families of individuals, who have inherited or are at risk of inheriting HD, have generations of experience of HD which may be outdated and lack knowledge of recent breakthroughs and improvements in genetic testing, family planning choices, care management, and other considerations. Genetic counseling benefits these individuals by updating their knowledge, dispelling any myths they may have and helping them consider their future options and plans.

Prognosis

The length of the trinucleotide repeat accounts for 60% of the variation in the age of onset and the rate of progression of symptoms. A longer repeat results in an earlier age of onset and a faster progression of symptoms. For example, individuals with a trinucleotide repeat greater than sixty repeats often develop the disease before twenty years of age, and those with less than forty repeats may not develop noticeable symptoms. The remaining variation is due to environmental factors and other genes that influence the mechanism of the disease.

Life expectancy in HD is generally around 20 years following the onset of visible symptoms. Most of the complications that are life-threatening result from muscle coordination issues, or to a lesser extent from behavioural changes resulting from the decline in cognitive function. The largest risk is pneumonia, which is the cause of death of one-third of those with HD. As the ability to synchronise movements deteriorates, difficulty clearing the lungs and an increased risk of aspirating food or drink both increase the risk of contracting pneumonia. The second greatest risk is heart disease, which causes almost a quarter of fatalities of those with HD. Suicide is the next greatest cause of fatalities, with 7.3% of those with HD taking their own lives and up to 27% attempting to do so. It is unclear to what extent suicidal thoughts are influenced by psychiatric symptoms, as they may be considered to be a response of an individual to retain a sense of control of their life or to avoid the later stages of the disease. Other associated risks include choking, physical injury from falls, and malnutrition.

Epidemiology

The late onset of Huntington's disease means it does not usually affect reproduction. The worldwide prevalence of HD is 5-10 cases per 100,000 persons, but varies greatly geographically as a result of ethnicity, local migration and past immigration patterns. Prevalence is similar for men and women. The rate of occurrence is highest in peoples of Western European descent, averaging around seventy per million people, and is lower in the rest of the world, e.g. one per million people of Asian and African descent. Additionally, some localized areas have a much higher prevalence than their regional average. One of the highest prevalences is in the isolated populations of the Lake Maracaibo region of Venezuela, where HD affects up to seven thousand per million people. Other areas of high localization have been found in Tasmania and specific regions of Scotland, Wales and Sweden. Increased prevalence in some cases occurs due to a local founder effect, a historical migration of carriers into an area of geographic isolation. Some of these carriers have been traced back hundreds of years using genealogical studies. Genetic haplotypes can also give clues for the geographic variations of prevalence.

Until the discovery of a genetic test, statistics could only include clinical diagnosis based on physical symptoms and a family history of HD, excluding those who died of other causes before diagnosis. These cases can now be included in statistics and as the test becomes more widely available, estimates of the prevalence and incidence of the disorder are likely to increase.

History



THE

MEDICAL AND SURGICAL REPORTER.

No. 789.] PHILADELPHIA, APRIL 13, 1872. [Vol. XXVI.—No. 15.

ORIGINAL DEPARTMENT.

Communications.

ON CHOREA.

By George Huntington, M. D.,

Of Pomeroy, Ohio.

Essay read before the Meigs and Mason Academy of Medicine at Middleport, Ohio, February 15, 1872

Chorea is essentially a disease of the nervous system. The name "chorea" is given to the disease on account of the *dancing* propensities of those who are affected by it, and it is a very appropriate designation. The disease, as it is commonly seen, is by no means a dangerous or serious affection, however distressing it may be to the one suffering from it, or to his friends. Its most marked and char-

The upper extremities may be the first affected, or both simultaneously. All the voluntary muscles are liable to be affected, those of the face rarely being exempted.

If the patient attempt to protrude the tongue it is accomplished with a great deal of difficulty and uncertainty. The hands are kept rolling—first the palms upward, and then the backs. The shoulders are shrugged, and the feet and legs kept in perpetual motion; the toes are turned in, and then everted; one foot is thrown across the other, and then suddenly withdrawn, and, in short, every conceivable attitude and expression is assumed, and so varied and irregular are the motions gone through with, that a complete description of



In 1872 George Huntington described the disorder in his first paper "On Chorea" at the age of 22

The first definite mention of HD was in a letter by Charles Oscar Waters, published in the first edition of Robley Dunglison's *Practice of Medicine* in 1842. Waters described 'a form of chorea, vulgarly called magrums', including accurate descriptions of the chorea, its progression, and the strong heredity of the disease. In 1846 Charles Gorman observed how higher prevalence seemed to occur in localized regions. Independently of Gorman and Waters, both students of Dunglison at Jefferson Medical College, Johan Christian Lund also produced an early description in 1860. He specifically noted that in Setesdalen, a secluded area in Norway, there was a high prevalence of dementia associated with a pattern of jerking movement disorders that ran in families.

The first thorough description of the disease was by George Huntington in 1872. Examining the combined medical history of several generations of a family exhibiting similar symptoms, he realized their conditions must be linked; he presented his detailed and accurate definition of the disease as his first paper. Unknowingly, Huntington described the exact pattern of inheritance of autosomal dominant disease years before the rediscovery of Mendelian inheritance. "Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.". Sir William Osler was interested in the disorder and chorea in general, and was impressed with Huntington's paper, stating that "*In the history of medicine, there are few instances in which a disease has been more accurately, more graphically or more briefly described*." Osler's continued interest in HD, combined with his influence in the field of medicine, helped to rapidly spread awareness and knowledge of the disorder throughout the medical community. Great interest was shown by scientists in Europe, including Louis Théophile Joseph Landouzy, Désiré-Magloire Bourneville, Camillo Golgi, and Joseph Jules

Dejerine, and until the end of the century, much of the research into HD was European in origin. By the end of the 19th century, research and reports on HD had been published in many countries and the disease was recognized as a worldwide condition.

During the rediscovery of Mendelian inheritance at the turn of the 20th century, HD was used tentatively as an example of autosomal dominant inheritance. The English biologist William Bateson used the pedigrees of affected families to establish that HD did have an autosomal dominant inheritance pattern. The strong inheritance pattern prompted several researchers to attempt to trace and connect family members of previous studies, one of whom was Smith Ely Jelliffe. Jelliffe collected information from across New York State and published several articles regarding the genealogy of HD in New England. Jelliffe's research roused the interest of his college friend, Charles Davenport, who commissioned Elizabeth Muncey to produce the first field study of families with HD, and construct their pedigrees, on the East Coast of the United States. Davenport used this information to document the variable age of onset and range of symptoms of HD and make the claim that most cases of HD in the USA could be traced back to a handful of individuals. This research was further embellished in 1932 by P. R. Vessie, who popularised the idea that three brothers who left England in 1630, bound for Boston were the progenators of HD in the USA. The claim that the earliest progenators had been established and eugenic bias of Muncey's, Davenport, and Vessie's work contributed to misunderstandings and prejudice about HD. Muncey and Davenport also popularised the idea that in the past some HD sufferers may have been thought to be possessed by spirits or victims of witchcraft, and were sometimes shunned or exiled by society. This idea has not been proven, and there is evidence to the contrary, for example, the community of the family studied by George Huntington openly accommodated those who exhibited symptoms of HD.

Research into the disorder continued steadily through the 20th century, reaching a major breakthrough in 1983 when the US–Venezuela Huntington's Disease Collaborative Research Project discovered the approximate location of a causal gene. This was the result of an extensive study begun in 1979, focusing on the populations of two isolated Venezuelan villages, Barranquitas and Lagunetas, where there was an unusually high prevalence of the disease. Among other innovations, the project developed DNA marking methods which were an important step in making the Human Genome Project possible. In 1993 the research group isolated the precise causal gene at 4p16.3, making this the first autosomal disease locus found using genetic linkage analysis. In the same time frame, key discoveries concerning the mechanisms of the disorder were being made, including the findings by Anita Harding's research group on the effects of the gene's length.

Modelling the disease in various types of animals, such as the transgenic mouse developed in 1996, enabled larger scale experiments. As these animals have faster metabolisms and much shorter lifespans than humans, results from experiments are received sooner, speeding research. The 1997 discovery that mHtt fragments misfold led to the discovery of the nuclear inclusions they cause. These advances have led to increasingly extensive research into the proteins involved with the disease, potential drug treatments, care methods, and the gene itself.

Society and culture

Ethics

Huntington's disease, particularly the application of the genetic test for the disease, has raised several ethical issues. The issues for genetic testing include defining how mature an individual should be before being considered eligible for testing, ensuring the confidentiality of results, and whether companies should be allowed to use test results for decisions on employment, life insurance or other financial matters. There was controversy when Charles Davenport proposed in 1910 that compulsory sterilization and immigration control be used for people with certain diseases, including HD, as part of the eugenics movement. In vitro fertilization has some issues regarding its use of embryos. Some HD research has ethical issues due to its use of animal testing and embryonic stem cells.

The development of an accurate diagnostic test for Huntington's disease has caused social, legal, and ethical concerns over access to and use of a person's results. Many guidelines and testing procedures have strict procedures for disclosure and confidentiality to allow individuals to decide when and how to receive their results and also to whom the results are made available. Financial institutions and businesses are faced with the question of whether to use genetic test results when assessing an individual, such as for life insurance or employment. The United Kingdom's insurance companies have agreed that until 2014 they will not use this information when writing most insurance policies. As with other untreatable genetic conditions with a later onset, it is ethically questionable to perform pre-symptomatic testing on a child or adolescent as there would be no medical benefit for that individual. There is consensus for only testing individuals who are considered cognitively mature, although there is a counter-argument that parents have a right to make the decision on their child's behalf. With the lack of an effective treatment, testing a person under legal age who is not judged to be competent is considered unethical in most cases.

Prenatal genetic testing or preimplantation genetic diagnosis to ensure a child is not born with a given disease has some ethical concerns. For example, prenatal testing raises the issue of selective abortion, a choice considered unacceptable by some. Using preimplantation testing for HD requires twice as many embryos to be used for in vitro fertilisation, as half of them will be positive for HD. For a dominant disease there are also difficulties in situations in which a parent does not want to know his or her own diagnosis, as this would require parts of the process to be kept secret from the parent.

Support organizations

The death of Woody Guthrie led to the foundation of the Committee to Combat Huntington's Disease



Poster of *Recent studies of Huntington's disease Marjorie Guthrie lecture in genetics*; 1985

In 1968, after experiencing HD in his wife's family, Dr. Milton Wexler was inspired to start the Hereditary Disease Foundation (HDF), with the aim of curing genetic illnesses by coordinating and supporting research. The foundation and Dr. Wexler's daughter, Nancy Wexler, were key parts of the research team in Venezuela which discovered the HD gene. At roughly the same time as the HDF formed, Marjorie Guthrie helped to found the Committee to Combat Huntington's Disease (now the Huntington's Disease Society of America), after her husband Woody Guthrie died from complications of HD. Since then, support and research organizations have formed in many countries around the world and have helped to increase public awareness of HD. A number of these collaborate in umbrella organizations, like the International Huntington Association and

the EuroHD network. Many support organizations hold an annual HD awareness event, some of which have been endorsed by their respective governments. For example, June 6 is designated "National Huntington's Disease Awareness Day" by the US senate.

Research directions

Research into the mechanism of HD has focused on identifying the functioning of Htt, how mHtt differs or interferes with it, and the brain pathology that the disease produces. Most research is conducted in animals. Appropriate animal models are critical for understanding the fundamental mechanisms causing the disease and for supporting the early stages of drug development. Mice and monkeys, chemically induced to exhibit HD-like symptoms were initially used, but they did not mimic the progressive features of the disease. Since the Huntingtin gene was identified, transgenic animals (mice, *Drosophila* fruit flies, and more recently monkeys) exhibiting HD-like syndromes can be generated by inserting a CAG repeat expansion into the gene. Nematode worms also provide a valuable model when the gene is expressed.

Genetically engineered intracellular antibody fragments called intrabodies have been shown to prevent mortality during the development stages of *Drosophila* models. Their mechanism of action was an inhibition of mHtt aggregation. As HD has been conclusively linked to a single gene, gene silencing is potentially possible and by using gene knockdown in mouse models, researchers have shown that when the influence of mHtt is reduced, symptoms improve. Stem cell therapy is the replacement of damaged neurons by transplantation of stem cells into affected regions of the brain. Experiments have yielded some positive results using this technique in animal models and preliminary human clinical trials.

Numerous drugs have been reported to produce benefits in animals, including creatine, coenzyme Q10 and the antibiotic minocycline. Some of these have then been tested by humans in clinical trials, and as of 2009 several are at different stages of these trials. In 2010, minocycline was found to be ineffective for humans in a multi-center trial.

Chapter 8

Neural Development

Neural development comprises the processes that generate, shape, and reshape the nervous system, from the earliest stages of embryogenesis to the final years of life. The study of neural development aims to describe the cellular basis of brain development and to address the underlying mechanisms. The field draws on both neuroscience and developmental biology to provide insight into the cellular and molecular mechanisms by which complex nervous systems develop. Defects in neural development can lead to cognitive, motor, and intellectual disability, as well as neurological disorders such as autism, Rett syndrome, and mental retardation.

Overview of brain development

The brain emerges during embryonic development from the neural tube, an early embryonic structure. The most anterior part of the neural tube is called the telencephalon, which expands rapidly due to cell proliferation, and eventually gives rise to the brain. Gradually some of the cells stop dividing and differentiate into neurons and glial cells, which are the main cellular components of the brain. The newly generated neurons migrate to different parts of the developing brain to self-organize into different brain structures. Once the neurons have reached their regional positions, they extend axons and dendrites, which allow them to communicate with other neurons via synapses. Synaptic communication between neurons leads to the establishment of functional neural circuits that mediate sensory and motor processing, and underlie behavior. The brain does most of its development with in the first 20 years of life.



Highly schematic flowchart of human brain development

Aspects of neural development

Some landmarks of neural development include the birth and differentiation of neurons from stem cell precursors, the migration of immature neurons from their birthplaces in the embryo to their final positions, outgrowth of axons and dendrites from neurons, guidance of the motile growth cone through the embryo towards postsynaptic partners, the generation of synapses between these axons and their postsynaptic partners, and finally the lifelong changes in synapses, which are thought to underlie learning and memory.

Typically, these neurodevelopmental processes can be broadly divided into two classes: activity-independent mechanisms and activity-dependent mechanisms. Activity-independent mechanisms are generally believed to occur as hardwired processes determined by genetic programs played out within individual neurons. These include differentiation, migration and axon guidance to their initial target areas. These processes are thought of as being independent of neural activity and sensory experience. Once axons reach their target areas, activity-dependent mechanisms come into play. Although synapse formation is an activity-independent event, modification of synapses and synapse elimination requires neural activity.

Developmental neuroscience uses a variety of animal models including mice *Mus musculus*, the fruit fly *Drosophila melanogaster*, the zebrafish *Danio rerio*, *Xenopus laevis* tadpoles and the worm *Caenorhabditis elegans*, among others.

Neural induction

During early embryonic development the ectoderm becomes specified to give rise to the epidermis (skin) and the neural plate. The conversion of undifferentiated ectoderm to neuro-ectoderm requires signals from the mesoderm. At the onset of gastrulation presumptive mesodermal cells move through the dorsal blastopore lip and form a layer in between the endoderm and the ectoderm. These mesodermal cells that migrate along the

dorsal midline give rise to a structure called the notochord. Ectodermal cells overlying the notochord develop into the neural plate in response to a diffusible signal produced by the notochord. The remainder of the ectoderm gives rise to the epidermis (skin). The ability of the mesoderm to convert the overlying ectoderm into neural tissue is called **Neural Induction**.

The neural plate folds outwards during the third week of gestation to form the neural groove. Beginning in the future neck region, the neural folds of this groove close to create the neural tube. The formation of the neural tube from the ectoderm is called **Neurulation**. The ventral part of the neural tube is called the basal plate; the dorsal part is called the alar plate. The hollow interior is called the neural canal. By the end of the fourth week of gestation, the open ends of the neural tube (the **neuropores**) close off.

Identification of neural inducers

A transplanted blastopore lip can convert ectoderm into neural tissue and is said to have an inductive effect. Neural Inducers are molecules that can induce the expression of neural genes in ectoderm explants without inducing mesodermal genes as well. Neural induction is often studied in Xenopus embryos since they have a simple body pattern and there are good markers to distinguish between neural and non-neural tissue. Examples of Neural Inducers are the molecules Noggin and Chordin.

When embryonic ectodermal cells are cultured at low density in the absence of mesodermal cells they undergo neural differentiation (express neural genes), suggesting that neural differentiation is the default fate of ectodermal cells. In explant cultures (which allow direct cell-cell interactions) the same cells differentiate into epidermis. This is due to the action of BMP4 (a TGF-β family protein) that induces ectodermal cultures to differentiate into epidermis. During neural induction, Noggin and Chordin are produced by the dorsal mesoderm (notochord) and diffuse into the overlying ectoderm to inhibit the activity of BMP4. This inhibition of BMP4 causes the cells to differentiate into neural cells.

Regionalization

Late in the fourth week, the superior part of the neural tube flexes at the level of the future midbrain—the mesencephalon. Above the mesencephalon is the prosencephalon (future forebrain) and beneath it is the rhombencephalon (future hindbrain).

The optical vesicle (which will eventually become the optic nerve, retina and iris) forms at the basal plate of the prosencephalon. The alar plate of the prosencephalon expands to form the cerebral hemispheres (the telencephalon) whilst its basal plate becomes the diencephalon. Finally, the optic vesicle grows to form an optic outgrowth.

Patterning of the nervous system

In chordates, dorsal ectoderm forms all neural tissue and the nervous system. Patterning occurs due to specific environmental conditions - different concentrations of signaling molecules

Dorsoventral axis

The ventral half of the neural plate is controlled by the notochord, which acts as the 'organiser'. The dorsal half is controlled by the ectoderm plate which flanks the neural plate on either side.

Ectoderm follows a default pathway to become neural tissue. Evidence for this comes from single, cultured cells of ectoderm which go on to form neural tissue. This is postulated to be because of a lack of BMPs, which are blocked by the organiser. The organiser may produce molecules such as follistatin, noggin and chordin which inhibit BMPs.

The ventral neural tube is patterned by Sonic Hedgehog (Shh) from the notochord, which acts as the inducing tissue. The Shh inducer causes differentiation of the floor plate. Shh-null tissue fails to generate all cell types in the ventral tube, suggesting Shh is necessary for its induction. The hypothesised mechanism suggests that Shh binds patched, relieving patched inhibition of smoothened, leading to activation of glia transcription factors.

In this context Shh acts as a morphogen - it induces cell differentiation dependent on its concentration. At low concentrations it forms ventral interneurones, at higher concentrations it induces motor neurone development, and at highest concentrations it induces floor plate differentiation. Failure of Shh-modulated differentiation causes holoprosencephaly.

The dorsal neural tube is patterned by BMPs from the epidermal ectoderm flanking the neural plate. These induce sensory interneurones by activating Sr/Thr kinases and altering SMAD transcription factor levels.

Rostrocaudal (Anteroposterior) axis

Signals that control anteroposterior neural development include FGF and retinoic acid which act in the hindbrain and spinal cord. The hindbrain, for example, is patterned by Hox genes, which are expressed in overlapping domains along the anteroposterior axis under the control of retinoic acid. The 3' genes in the Hox cluster are induced by retinoic acid in the hindbrain, whereas the 5' Hox genes are not induced by retinoic acid and are expressed more posteriorly in the spinal cord. Hoxb-1 is expressed in rhombomere 4 and gives rise to the facial nerve. Without this Hoxb-1 expression, a nerve which is similar to the trigeminal nerve arises.

Neuronal migration



Corticogenesis: younger neurons migrate past older ones using radial glia as a scaffolding. Cajal-Retzius cells (red) release reelin (orange).

Neuronal migration is the method by which neurons travel from their origin or birth place to their final position in the brain. There are several ways they can do this, e.g. by radial migration or tangential migration.



Tangential migration of interneurons from ganglionic eminence

Radial migration Neuronal precursor cells proliferate in the ventricular zone of the developing neocortex. The first postmitotic cells to migrate form the preplate which are destined to become Cajal-Retzius cells and subplate neurons. These cells do so by somal translocation. Neurons migrating with this mode of locomotion are bipolar and attach the leading edge of the process to the pia. The soma is then transported to the pial surface by nucleokinesis, a process by which a microtubule "cage" around the nucleus elongates and contracts in association with the centrosome to guide the nucleus to its final destination. Radial glia, whose fibers serve as a scaffolding for migrating cells, can itself divide or translocate to the cortical plate and differentiate either into astrocytes or neurons. Somal translocation can occur at any time during development.

Subsequent waves of neurons split the preplate by migrating along radial glial fibres to form the cortical plate. Each wave of migrating cells travel past their predecessors forming layers in an inside-out manner, meaning that the youngest neurons are the closest to the surface. It is estimated that glial guided migration represents 90% of migrating neurons in human and about 75% in rodents.

Tangential migration Most interneurons migrate tangentially through multiple modes of migration to reach their appropriate location in the cortex. An example of tangential migration is the movement of interneurons from the ganglionic eminence to the cerebral cortex. One example of ongoing tangential migration in a mature organism, observed in some animals, is the rostral migratory stream connecting subventricular zone and olfactory bulb.

Others modes of migration There is also a method of neuronal migration called **multipolar migration**. This is seen in multipolar cells, which are abundantly present in the cortical intermediate zone. They do not resemble the cells migrating by locomotion or somal translocation. Instead these multipolar cells express neuronal markers and extend multiple thin processes in various directions independently of the radial glial fibers.

Neurotrophic factors

The survival of neurons is regulated by survival factors, called trophic factors. The neurotrophic hypothesis was formulated by Victor Hamburger and Rita Levi Montalcini based on studies of the developing nervous system. Victor Hamburger discovered that implanting an extra limb in the developing chick led to an increase in the number of spinal motor neurons. Initially he thought that the extra limb was inducing proliferation of motor neurons, but he and his colleagues later showed that there was a great deal of motor neuron death during normal development, and the extra limb prevented this cell death. According to the neurotrophic hypothesis, growing axons compete for limiting amounts of target-derived trophic factors and axons that neurons that fail to receive insufficient trophic support die by apoptosis. It is now clear that factors produced by a number of sources contribute to neuronal survival.

Nerve Growth Factor (NGF): Rita Levi Montalcini and Stanley Cohen purified the first trophic factor, Nerve Growth Factor (NGF), for which they received the Nobel Prize. There are three NGF-related trophic factors: BDNF, NT3, and NT4, which regulate survival of various neuronal populations. The Trk proteins act as receptors for NGF and related factors. Trk is a receptor tyrosine kinase. Trk dimerization and phosphorylation leads to activation of various intracellular signaling pathways including the MAP kinase, Akt, and PKC pathways.

CNTF: Ciliary neurotrophic factor is another protein that acts as a survival factor for motor neurons. CNTF acts via a receptor complex that includes CNTFRα, GP130, and LIFRβ. Activation of the receptor leads to phosphorylation and recruitment of the JAK kinase, which in turn phosphorylates LIFRβ. LIFRβ acts as a docking site for the STAT

transcription factors. JAK kinase phosphorylates STAT proteins, which dissociate from the receptor and translocate to the nucleus to regulate gene expression.

GDNF: Glial derived neurotrophic factor is a member of the TGFb family of proteins, and is a potent trophic factor for striatal neurons. The functional receptor is a heterodimer, composed of type 1 and type 2 receptors. Activation of the type 1 receptor leads to phosphorylation of Smad proteins, which translocate to the nucleus to activate gene expression.

Synapse formation

Neuromuscular junction Much of our understanding of synapse formation comes from studies at the neuromuscular junction. The transmitter at this synapse is acetylcholine. The acetylcholine receptor (AchR) is present at the surface of muscle cells before synapse formation. The arrival of the nerve induces clustering of the receptors at the synapse. McMahan and Sanes showed that the synaptogenic signal is concentrated at the basal lamina. They also showed that the synaptogenic signal is produced by the nerve, and they identified the factor as Agrin. Agrin induces clustering of AchRs on the muscle surface and synapse formation is disrupted in agrin knockout mice. Agrin transuces the signal via MuSK receptor to rapsyn. Fischbach and colleagues showed that receptor subunits are selectively transcribed from nuclei next to the synaptic site. This is mediated by neuregulins.

In the mature synapse each muscle fiber is innervated by one motor neuron. However, during development many of the fibers are innervated by multiple axons. Lichtman and colleagues have studied the process of synapses elimination. This is an activity-dependent event. Partial blockage of the receptor leads to retraction of corresponding presynaptic terminals.

CNS synapses Agrin appears not to be a central mediator of CNS synapse formation and there is active interest in identifying signals that mediate CNS synaptogenesis. Neurons in culture develop synapses that are similar to those that form in vivo, suggesting that synaptogenic signals can function properly in vitro. CNS synaptogenesis studies have focused mainly on glutamatergic synapses. Imaging experiments show that dendrites are highly dynamic during development and often initiate contact with axons. This is followed by recruitment of postsynaptic proteins to the site of contact. Stephen Smith and colleagues have shown that contact initiated by dendritic filopodia can develop into synapses.

Induction of synapse formation by glial factors: Barres and colleagues made the observation that factors in glial conditioned media induce synapse formation in retinal ganglion cell cultures. Synapse formation in the CNS is correlated with astrocyte differentiation suggesting that astrocytes might provide a synaptogenic factor. The identity of the astrocytic factors is not yet known.

Neuroligins and SynCAM as synaptogenic signals: Sudhof, Serafini, Scheiffele and colleagues have shown that neuroligins and SynCAM can act as factors that will induce presynaptic differentiation. Neuroligins are concentrated at the postsynaptic site and act via neurexins concentrated in the presynaptic axons. SynCAM is a cell adhesion molecule that is present in both pre- and post-synaptic membranes.

Synapse elimination

Several motorneurones compete for each neuromuscular junction, but only one survives till adulthood. Competition *in vitro* has been shown to involve a limited neurotrophic substance that is released, or that neural activity infers advantage to strong post-synaptic connections by giving resistance to a toxin also released upon nerve stimulation. *In vivo* it is suggested that muscle fibres select the strongest neuron through a retrograde signal.

Chapter 9

Axon Guidance

Axon guidance (also called **axon pathfinding**) is a subfield of neural development concerning the process by which neurons send out axons to reach the correct targets. Axons often follow very precise paths in the nervous system, and how they manage to find their way so accurately is being researched.

Mechanisms

Growing axons have a highly motile structure at the growing tip called the growth cone, which "sniffs out" the extracellular environment for signals that instruct the axon which direction to grow. These signals, called guidance cues, can be fixed in place or diffusible; they can attract or repel axons. Growth cones contain receptors that recognize these guidance cues and interpret the signal into a chemotropic response. The general theoretical framework is that when a growth cone "senses" a guidance cue, the receptors activate various signaling molecules in the growth cone that eventually affect the cytoskeleton. If the growth cone senses a gradient of guidance cue, the intracellular signaling in the growth cone happens asymmetrically, so that cytoskeletal changes happen asymmetrically and the growth cone turns toward or away from the guidance cue.

A combination of genetic and biochemical methods (see below) has led to the discovery of several important classes of axon guidance molecules and their receptors:

- Netrins: Netrins are secreted molecules that can act to attract or repel axons by binding to their receptors, DCC and UNC5.
- Slits aka Sli: Secreted proteins that normally repel growth cones by engaging Robo (Roundabout) class receptors.
- Ephrins: Ephrins are cell surface molecules that activate Eph receptors on the surface of other cells. This interaction can be attractive or repulsive. In some cases, Ephrins can also act as receptors by transducing a signal into the expressing cell, while Ephs act as the ligands. Signaling into both the Ephrin- and Eph-bearing cells is called "bi-directional signaling."
- Semaphorins: The many types of Semaphorins are primarily axonal repellents, and activate complexes of cell-surface receptors called Plexins and Neuropilins.

In addition, many other classes of extracellular molecules are used by growth cones to navigate properly:

- Developmental morphogens, such as BMPs, Wnts, Hedgehog, and FGFs
- Extracellular matrix and adhesion molecules such as laminin, tenascins, proteoglycans, N-CAM, and L1
- Growth factors like NGF
- Neurotransmitters and modulators like GABA

Studying axon guidance

The earliest descriptions of the axonal growth cone were made by the Spanish neurobiologist Santiago Ramón y Cajal in the late 19th century. However, understanding the molecular and cellular biology of axon guidance would not begin until decades later. In the last thirty years or so, scientists have used various methods to work out how axons find their way. Much of the early work in axon guidance was done in the grasshopper, where individual motor neurons were identified and their pathways characterized. In genetic model organisms like mice, zebrafish, nematodes, and fruit flies, scientists can generate mutations and see whether and how they cause axons to make errors in navigation. In vitro experiments can be useful for direct manipulation of growing axons. A popular method is to grow neurons in culture and expose growth cones to purified guidance cues to see whether these cause the growing axons to turn. These types of experiments have often been done using traditional embryological non-genetic model organisms, such as the chicken and African clawed frog. Embryos of these species are easy to obtain and, unlike mammals, develop externally and are easily accessible to experimental manipulation.

Axon guidance model systems

Several types of axon pathways have been extensively studied in model systems to further understand the mechanisms of axon guidance. Perhaps the two most prominent of these are commissures and topographic maps. Commissures are sites where axons cross the midline from one side of the nervous system to the other. Topographic maps are systems in which groups of neurons in one tissue project their axons to another tissue in an organized arrangement such that spatial relationships are maintained; i.e. adjacent neurons will innervate adjacent regions of the target tissue.

Commissure formation: attraction and repulsion

As described above, axonal guidance cues are often categorized as "attractive" or "repulsive." This is a simplification, as different axons will respond to a given cue differently. Furthermore, the same axonal growth cone can alter its responses to a given cue based on timing, previous experience with the same or other cues, and the context in which the cue is found. These issues are exemplified during the development of commissures. The bilateral symmetry of the nervous system means that axons will encounter the same cues on either side of the midline. Before crossing (ipsilaterally), the growth cone must navigate toward and be attracted to the midline. However, after crossing (contralaterally), the same growth cone must become repelled or lose attraction to the midline and reinterpret the environment to locate the correct target tissue.

Two experimental systems have had particularly strong impacts on understanding how midline axon guidance is regulated:

The ventral nerve cord of Drosophila



Axon guidance in the Drosophila embryonic ventral nerve cord. From Sanchez-Soriano et al., 2007

The use of powerful genetic tools in *Drosophila* led to the identification of a key class of axon guidance cues, the Slits, and their receptors, the Robos (short for Roundabout). The ventral nerve looks like a ladder, with three longitudinal axon bundles (fascicles) connected by the commissures, the "rungs" of the ladder. There are two commissures, anterior and posterior, within each segment of the embryo.

The currently accepted model is that Slit, produced by midline cells, repels axons from the midline via Robo receptors. Ipsilaterally projecting (non-crossing) axons always have Robo receptors on their surface, while commissural axons have very little or no Robo on their surface, allowing them to be attracted to the midline by Netrins and, probably, other as-yet unidentified cues. After crossing, however, Robo receptors are strongly upregulated on the axon, which allows Robo-mediated repulsion to overcome attraction to the midline. This dynamic regulation of Robo is at least in part accomplished by a molecule called Comm (short for Commissureless), which prevents Robo from reaching the cell surface and targeting it for destruction.

The spinal cord of mice and chickens

In the spinal cord of vertebrates, commissural neurons from the dorsal regions project downward toward the ventral floor plate. Ipsilateral axons turn before reaching the floor plate to grow longitudinally, while commissural axons cross the midline and make their

longitudinal turn on the contralateral side. Strikingly, Netrins, Slits, and Robos all play similar functional roles in this system as well. One outstanding mystery was the apparent lack of any *comm* gene in vertebrates. It now seems that at least some of Comm's functions are performed by a modified form of Robo called Robo3 (or Rig1).

The spinal cord system was the first to demonstrate explicitly the altered responsiveness of growth cones to cues after exposure to the midline. Explanted neurons grown in culture would respond to exogenously supplied Slit according to whether or not they had contacted floor plate tissue.

Topographic maps: gradients for guidance

As described above, topographic maps occur when spatial relationships are maintained between neuronal populations and their target fields in another tissue. This is a major feature of nervous system organization, particular in sensory systems. The neurobiologist Roger Sperry proposed a prescient model for topographic mapping mediated by what he called molecular "tags." The relative amounts of these tags would vary in gradients across both tissues. We now think of these tags as ligands (cues) and their axonal receptors. Perhaps the best understood class of tags are the Ephrin ligands and their receptors, the Ephs.

In the simplest type of mapping model, we could imagine a gradient of Eph receptor expression level in a field of neurons, such as the retina, with the anterior cells expressing very low levels and cells in the posterior expressing the highest levels of the receptor. Meanwhile, in the target of the retinal cells (the optic tectum), Ephrin ligands are organized in a similar gradient: high posterior to low anterior. Retinal axons enter the anterior tectum and proceed posteriorly. Because, in general, Eph-bearing axons are repelled by Ephrins, axons will become more and more reluctant to proceed the further they advance toward the posterior tectum. However, the degree to which they are repelled is set by their own particular level of Eph expression, which is set by the position of the neuronal cell body in the retina. Thus, axons from the anterior retina, expressing the lowest level of Ephs, can project to the posterior tectum, even though this is where Ephrins are highly expressed. Posterior retinal cells express high Eph level, and their axons will stop more anteriorly in the tectum.

The retinotectal projection of chickens, frogs and fish

The large size and accessibility of the chicken embryo has made it a favorite model organism for embryologists. Researchers used the chick to biochemically purify components from the tectum that showed specific activity against retinal axons in culture. This led to the identification of Ephs and Ephrins as Sperry's hypothesized "tags."

The retinotectal projection has also been studied in *Xenopus* and zebrafish. Zebrafish is a potentially powerful system because genetic screens like those performed in invertebrates can be done relatively simply and cheaply. In 1996, large scale screens were conducted in

zebrafish, including screens for retinal axon guidance and mapping. Many of the mutants have yet to be characterized.

The Cell Biology of Axon Guidance

Genetics and biochemistry have identified a large set of molecules that affect axon guidance. How all of these pieces fit together is less understood. It is generally presumed, for good reasons, that most axon guidance receptors activate signal transduction cascades that ultimately lead to reorganization of the cytoskeleton and adhesive properties of the growth cone, which together underlie the motility of all cells. However, this raises the question of how the same cues can result in a spectrum of response from different growth cones. It may be that different receptors activate attraction or repulsion in response to a single cue. Another possibility is the receptor complexes act as "coincidence detectors" to modify responses to one cue in the presence of another. Similar signaling "cross-talk" could occur intracellularly, downstream of receptors on the cell surface.

In fact, specific instances of all these kinds have been described, and the picture that is emerging is that growth cone signaling mechanisms are highly complex. In addition to signaling to the cytoskeleton, in the past several years that guidance cues cause growth cones to locally synthesize or degrade specific proteins, independent of changes in nuclear gene expression, which occurs far away in the neuronal cell body. This type of protein regulation is involved in mediating attraction and repulsion, and has also been shown to be involved in regulating the altered responses of, for example, commissural neurons to midline cues.

Chapter 10

Neurodevelopmental Disorder

A boy with microcephaly and his schoolmates. Microcephaly is a neurodevelopmental disorder.

A **neurodevelopmental disorder**, or disorder of neural development, is an impairment of the growth and development of the brain or central nervous system. A narrower use of the term refers to a disorder of brain function that affects emotion, learning ability and memory and that unfolds as the individual grows. The term is sometimes erroneously used as an exclusive synonym for autism and autism spectrum disorders.

Disorders considered to be neurodevelopmental in origin or to have neurodevelopmental consequences when they occur in infancy and childhood include autism and autism spectrum disorders such as Asperger syndrome, traumatic brain injury (including congenital injuries such as those that cause cerebral palsy), communication, speech and

language disorders, genetic disorders such as fragile-X syndrome, and Down syndrome. Neurodevelopmental disorders are associated with widely varying degrees of mental, emotional, physical and economic burden to individuals, families and society in general.

Causes

There are many causes of neurodevelopmental disorder, which can range from deprivation, genetic and metabolic diseases, immune disorders, infectious diseases, nutritional factors, physical trauma, and toxic and environmental factors.

Some neurodevelopmental disorders such as autism and other pervasive developmental disorders are considered to be multifactorial syndromes (with many causes but more specific neurodevelopmental manifestation). However other multifactorial syndromes such as Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections (PANDAS) are presently thought to have a more specific primary causation as well as a specific neurodevelopmental manifestation.

Deprivation

Infants and children require loving emotional nurture from caregivers—there is a spectrum of problems arising from the lack of it. The most severe deprivation disorder, hospitalism, was described in 1897 as a wasting away to the point of death. A sublethal form, anaclitic depression was first described by René Spitz in the 1940s. It occurred in infants over the age of six months who suffered the loss of their mothers, who then became depressed and showed behavioral retardation (delay in reaching developmental milestones, especially as related to social behaviors). Behavioral retardation, as in the reactive attachment disorders, has been observed in emotionally deprived children living with their families. However, prominent modern thought attributes other causative mechanisms to autism and autistic spectrum disorders.

However, nurture is not the only cause of deprivation that leads to neurodevelopmental sequellae. A common example of sensory deprivation due to biologic factors is blindness. Blind infants have risk of poor developmental outcomes which, left untreated, may lead to severe, autistic-like behaviors. Despite its biologic basis, caregivers can ameliorate blindness-related sensory deprivation. This can lead to positive neurodevelopmental outcome, as in the cases of author Helen Keller, who was trained in the use of tactile sign language, and musicians such as Arthel "Doc" Watson and Ray Charles who remained emotionally connected to others via their sense of hearing.

Genetic disorders

A child with Down syndrome

A prominent example of a genetically determined neurodevelopmental disorder is Trisomy 21, also known as Down syndrome. This disorder usually results from an extra chromosome 21, although in uncommon instances it is related to other chromosomal abnormalities such as translocation of the genetic material. It is characterized by short stature, epicanthal (eyelid) folds, abnormal fingerprints and palm prints, heart defects, poor muscle tone (delay of neurological development) and mental retardation (delay of intellectual development).

Less commonly known genetically determined neurodevelopmental disorders include Fragile X syndrome, Rett syndrome and Williams syndrome. Fragile X syndrome was first described in 1943 by J.P. Martin and J. Bell, studying persons with family history of sex-linked "mental defects". Rett syndrome, another X-linked disorder, produces severe functional limitations. Williams syndrome is caused by small deletions of genetic material from chromosome 7.

Immune dysfunction

Immune reactions during pregnancy, both maternal and of the developing child can produce neurodevelopmental disorders. One typical immune reaction in infants and children is PANDAS, or *Pediatric Autoimmune Neuropsychiatric Disorders Associated*

with Streptococcal infection produce abnormal movements of the body, emotional disturbance and obsessive compulsive disorder symptoms. Another disorder is Sydenham's chorea, which results in more abnormal movements of the body and fewer psychological sequellae. Both are immune reactions against brain tissue that follow infection by *Streptococcus* bacteria. (Susceptibility to these immune diseases may be genetically determined, so sometimes several family members may suffer from one or both of them following an epidemic of Strep infection.)

Infectious diseases

A number of infectious diseases can be transmitted either congenitally or in early childhood, and can cause serious neurodevelopmental disorders, such as schizophrenia. Congenital toxoplasmosis may result in formation of cysts in the brain and other organs, causing a variety of neurological deficits. Congenital syphilis may progress to neurosyphilis if it remains untreated. Measles can progress to subacute sclerosing panencephalitis. Congenital rubella syndrome can produce schizophrenia in addition to multiple other symptoms.

Metabolic disorders

Metabolic disorders, present in either the mother or the child, can cause neurodevelopmental disorders. Two examples are diabetes mellitus (a multifactorial disorder) and phenylketonuria (an inborn error of metabolism). Many such inherited diseases may directly affect the child's metabolism and neural development but less commonly they can indirectly affect the child during gestation.

In the child, type 1 diabetes can produce neurodevelopmental damage by the effects of excessive or insufficient glucose. The problems continue and may worsen throughout childhood if the diabetes is not well controlled. Type 2 diabetes may be preceded in its onset by impaired cognitive functioning.

However a non-diabetic fetus can also be subjected to glucose effects if its mother has undetected gestational diabetes. Maternal diabetes causes excessive birth size, making it harder for the infant to pass through the birth canal without injury or it can directly produce early neurodevelopmental deficits. However usually the neurodevelopmental symptoms decrease in later childhood.

Phenylketonuria, also known as PKU is an inborn error of metabolism that can induce neurodevelopmental disorders in children. Children with PKU require a strict diet to prevent mental retardation and other disorders. In the maternal form of PKU, excessive maternal phenylalanine can be absorbed by the fetus even if the fetus has not inherited the disease. This can produce mental retardation and other disorders.

Nutrition

Nutritional deficits may cause neurodevelopmental disorders, such as spina bifida, which is common, and anencephaly, which is rare. Both disorders are neural tube defects with malformation and dysfunction of the nervous system and its supporting structures, leading to serious physical disability as well as its emotional sequellae. The most common nutritional cause of neural tube defects is maternal deficiency of folic acid, a B vitamin usually found in fruits, vegetables, whole grains and milk products. (Neural tube defects are also caused by medications and other environmental causes, many of which interfere with folate metabolism, thus they are considered to have multifactorial causes.) Another deficiency, iodine deficiency, produces a spectrum of neurodevelopmental disorders from mild emotional disturbance to severe mental retardation.

Excesses in both maternal and infant diets may cause disorders as well, with foods or food supplements proving toxic in large amounts. For instance in 1973 K.L. Jones and D.W. Smith of the University of Washington Medical School in Seattle found a pattern of "craniofacial, limb, and cardiovascular defects associated with prenatal onset growth deficiency and developmental delay" in children of alcoholic mothers. This disorder, now called fetal alcohol syndrome, has significant symptom overlap with several other entirely unrelated neurodevelopmental disorders. It has been discovered that iron supplementation in baby formula is linked to lowered I.Q. and other neurodevelopmental delays.

Trauma



CT scan showing epidural hematoma, a type of traumatic brain injury (upper left)

Brain trauma in the developing human is a common cause (over 400,000 injuries per year in the US alone, without clear information as to how many produce developmental sequellae) of neurodevelopmental syndromes. It may be subdivided into two major categories, congenital injury (including injury resulting from otherwise uncomplicated premature birth) and injury occurring in infancy or childhood. Common causes of congenital injury are asphyxia (obstruction of the trachea), hypoxia (lack of oxygen to the brain) and the mechanical trauma of the birth process itself.

Overwhelmingly, in industrial nations the most common causes of childhood brain trauma are falls and transportation-related incidents. Child maltreatment such as shaken baby syndrome can produce neurodevelopmental consequences including blindness, neuromotor deficits and cognitive impairment. According to information published by the American Association of Neurological Surgeons, sports injuries account for 21% of the US incidence, however their site includes transportation-related sports injuries. They assert that cycling produced 64,993 head injuries requiring emergency room visits in 2007 while the second most common cause, football, only produced 36,412.

Toxic and environmental factors

One well known environmental toxic cause of neurodevelopmental disorders is heavy metal poisoning, with a prominent 20th century example being Minamata disease. Developmental mercury poisoning can cause a spectrum of problems from mild impairment of emotional development to the full blown syndrome of peripheral nerve damage, visual impairment, impaired coordination and ambulation, hallucinations, mental retardation, depression and death. However other metals such as lead, manganese, arsenic, cadmium and iron, as well as pesticides, tobacco and other environmental toxins are also implicated as causative factors.

Chapter 11

Brain-Derived Neurotrophic Factor

Brain-derived neurotrophic factor



PDB rendering based on 1bnd.

Identifiers	
Symbols	BDNF; MGC34632
External IDs	OMIM: 113505 MGI: 88145 HomoloGene: 7245 GeneCards: BDNF Gene
RNA expression pattern	



Orthologs		
Species	**Human**	**Mouse**
Entrez	627	12064
Ensembl	ENSG00000176697	ENSMUSG00000048482
UniProt	P23560	Q541P3
RefSeq (mRNA)	NM_001709	NM_001048139
RefSeq (protein)	NP_001700	NP_001041604
Location (UCSC)	Chr 11: 27.63 - 27.7 Mb	Chr 2: 109.48 - 109.53 Mb

Brain-derived neurotrophic factor also known as **BDNF** is a protein that, in humans, is encoded by the *BDNF* gene. BDNF is a member of the "neurotrophin" family of growth factors, which are related to the canonical "Nerve Growth Factor", NGF. Neurotrophic factors are found in the brain and the periphery.

Function

BDNF acts on certain neurons of the central nervous system and the peripheral nervous system, helping to support the survival of existing neurons, and encourage the growth and differentiation of new neurons and synapses. In the brain, it is active in the hippocampus, cortex, and basal forebrain—areas vital to learning, memory, and higher thinking. BDNF itself is important for long-term memory. BDNF was the second neurotrophic factor to be characterized after nerve growth factor (NGF).

Although the vast majority of neurons in the mammalian brain are formed prenatally, parts of the adult brain retain the ability to grow new neurons from neural stem cells in a process known as neurogenesis. Neurotrophins are chemicals that help to stimulate and control neurogenesis, BDNF being one of the most active. Mice born without the ability to make BDNF suffer developmental defects in the brain and sensory nervous system, and usually die soon after birth, suggesting that BDNF plays an important role in normal neural development.

Tissue distribution

Despite its name, BDNF is actually found in a range of tissue and cell types, not just in the brain. It is also expressed in the retina, the central nervous system, motor neurons, the kidneys, and the prostate. BDNF is present in high concentration in hippocampus and cerebral cortex. BDNF is also found in human saliva.

Mechanism of action

BDNF binds at least two receptors on the surface of cells that are capable of responding to this growth factor, TrkB (pronounced "Track B") and the LNGFR (for *low-affinity nerve growth factor receptor*, also known as p75). It may also modulate the activity of various neurotransmitter receptors, including the Alpha-7 nicotinic receptor.

TrkB is a receptor tyrosine kinase (meaning it mediates its actions by causing the addition of phosphate molecules on certain tyrosines in the cell, activating cellular signaling). There are other related Trk receptors, TrkA and TrkC. Also, there are other neurotrophic factors structurally related to BDNF: NGF (for Nerve Growth Factor), NT-3 (for Neurotrophin-3) and NT-4 (for Neurotrophin-4). While TrkB mediates the effects of BDNF and NT-4, TrkA binds and is activated by NGF, and TrkC binds and is activated by NT-3. NT-3 binds to TrkA and TrkB as well, but with less affinity.

The other BDNF receptor, the p75, plays a somewhat less clear role. Some researchers have shown that the p75NTR binds and serves as a "sink" for neurotrophins. Cells that express both the p75NTR and the Trk receptors might, therefore, have a greater activity, since they have a higher "microconcentration" of the neurotrophin. It has also been shown, however, that the p75NTR may signal a cell to die via apoptosis; so, therefore, cells expressing the p75NTR in the absence of Trk receptors may die rather than live in the presence of a neurotrophin.

Secretion

BDNF is made in the endoplasmic reticulum and secreted from dense-core vesicles. It binds the sorting receptor carboxypeptidase E (CPE), and the disruption of this binding causes loss of sorting of BDNF into dense-core vesicles. The phenotype for BDNF knockout mice can be severe, including postnatal lethality. Other traits include sensory neuron losses that affect coordination, balance, hearing, taste, and breathing. Knockout mice also exhibit cerebellar abnormalities and an increase in the number of sympathetic neurons.

Exercise has been shown to increase the secretion of BDNF at the mRNA and protein levels in the rodent hippocampus, suggesting the potential increase of this neurotrophin after exercise in humans.

Genetics

The BDNF protein is coded by the gene that is also called *BDNF*. In humans this gene is located on chromosome 11. Val66Met (rs6265) is a single nucleotide polymorphism in the gene where adenine and guanine alleles vary, resulting in a variation between valine and methionine at codon 66.

As of 2008, Val66Met is probably the most investigated SNP of the *BDNF* gene, but, besides this variant, other SNPs in the gene are C270T, rs7103411, rs2030324, rs2203877, rs2049045 and rs7124442.

The polymorphism Thr2Ile may be linked to congenital central hypoventilation syndrome.

In 2009, variants close to the BDNF gene were found to be associated with obesity in two very large genome wide-association studies of body mass index (BMI).

Disease linkage

Various studies have shown possible links between BDNF and conditions, such as depression, schizophrenia, obsessive-compulsive disorder, Alzheimer's disease, Huntington's disease, Rett syndrome, and dementia, as well as anorexia nervosa and bulimia nervosa.

Increased levels of BDNF can induce a change to an opiate-dependent-like reward state when expressed in the ventral tegmental area in rats.

Depression

Exposure to stress and the stress hormone corticosterone has been shown to decrease the expression of BDNF in rats, and, if exposure is persistent, this leads to an eventual atrophy of the hippocampus. Atrophy of the hippocampus and other limbic structures has been shown to take place in humans suffering from chronic depression. In addition, rats bred to be heterozygous for BDNF, therefore reducing its expression, have been observed to exhibit similar hippocampal atrophy. This suggests that an etiological link between the development of depression and BDNF exists. Supporting this, the excitatory neurotransmitter glutamate, voluntary exercise, caloric restriction, intellectual stimulation, curcumin and various treatments for depression (such as antidepressants and electroconvulsive therapy and sleep deprivation) increase expression of BDNF in the brain. In the case of some treatments such as drugs and electroconvulsive therapy this has been shown to protect or reverse this atrophy.

Eczema

High levels of BDNF and Substance P have been found associated with increased itching in eczema.

Epilepsy

Epilepsy has also been linked with polymorphisms in BDNF. Given BDNF's vital role in the development of the landscape of the brain, there is quite a lot of room for influence on the development of neuropathologies from BDNF.

Levels of both BDNF mRNA and BDNF protein are known to be up-regulated in epilepsy. BDNF modulates excitatory and inhibitory synaptic transmission by inhibiting GABAA-receptor-mediated post-synaptic currents. This provides a potential mechanism for the observed up-regulation.

Alzheimer's disease

Post mortem analysis has shown lowered levels of BDNF in the brain tissues of people with Alzheimer's disease, although the nature of the connection remains unclear. Studies suggest that neurotrophic factors have a protective role against amyloid beta toxicity.

Interactions

Brain-derived neurotrophic factor has been shown to interact with TrkB. BDNF has also been shown to interact with the reelin signaling chain. The expression of reelin by Cajal-Retzius cells goes down during development under the influence of BDNF. The latter also decreases reelin expression in neuronal culture.

Chapter 12

Environmental Enrichment



A rodent is not stimulated by the environment in a wire cage, and this affects its brain negatively, particularly the complexity of its synaptic connections

Environmental enrichment concerns how the brain is affected by the stimulation of its information processing provided by its surroundings (including the opportunity to interact socially). Brains in richer, more stimulating environments, have increased numbers of synapses, and the dendrite arbors upon which they reside are more complex. This effect happens particularly during neurodevelopment, but also to a lesser degree in adulthood. With extra synapses there is also increased synapse activity and so increased size and number of glial energy support cells. Capillary vasculation also is greater to provide the neurons and glial cells with extra energy. The neuropil (neurons, glial cells, capillaries, combined together) expands making the cortex thicker. There may also exist (at least in rodents) more neurons.

Research in nonhuman animals finds that more stimulating environment could aid the treatment and recovery of a diverse variety of brain related dysfunctions, including

Alzheimer's disease and those connected to aging, whereas a lack of stimulation might impair cognitive development.

Research upon humans suggests that lack of stimulation (deprivation—such as in old-style orphanages) delays and impairs cognitive development. Research also finds that higher levels of education (which is both cognitively stimulating in itself, and associates with people engaging in more challenging cognitive activities) results in greater resilience (cognitive reserve) to the effects of aging and dementia.

Early research

Donald O. Hebb in 1947 found that rats raised as pets performed better on problem solving tests than rats raised in cages. His research, however, did not investigate the brain nor use standardized impoverished and enriched environments. Research doing this first was started in 1960 by Mark Rosenzweig who compared single rats in normal cages, and those placed in ones with toys, ladders, tunnels, running wheels in groups. This found that growing up in enriched environents affected enzyme cholinesterase activity. This work led in 1962 to the discovery that environmental enrichment increased cerebral cortex volume. In 1964, it was found that this was due to increased cerebral cortex thickness and greater synapse and glial numbers.

Also starting around 1960, Harry Harlow studied the effects of maternal and social deprivation on rhesus monkey infants (a form of environmental stimulus deprivation). This established the importance of social stimulation for normal cognitive and emotional development.

Synapses

Synaptogenesis

Rats raised with environmental enrichment have thicker cerebral cortices (3.3-7%) that contain 25% more synapses. This effect of environmental richness upon the brain occurs whether it is experienced immediately following birth, after weaning, or during maturity. When synapse numbers increase in adults, they can remain high in number even when the adults are returned to improvised environment for 30 days suggesting that such increases in synapse numbers are not necessarily temporary. However, the increase in synapse numbers has been observed generally to reduce with maturation. Stimulation affects not only synapses upon pyramidal neurons (the main projecting neurons in the cerebral cortex) but also stellate ones (that are usually interneurons). It also can affect neurons outside the brain in the retina.

Dendrite complexity

Environmental enrichment affects the complexity and length of the dendrite arbors (upon which synapses form). Higher-order dendrite branch complexity is increased in enriched environments, as can the length, in young animals, of distal branches.

Activity and energy consumption

Synapses in animals in enriched environments show evidence of increased synapse activation. Synapses tend to also be much larger. This increased energy consumption is reflected in glial and local capillary vasculation that provides synapses with extra energy.

- Glial cell numbers per neuron increase 12-14%
- The direct apposition area of glial cells with synapses expands by 19%
- The volume of glial cell nuclei for each synapse is higher by 37.5%
- The mean volume of mitochondria per neuron is 20% greater
- The volume of glial cell nuclei for each neuron is 63% higher
- Capillary density is increased.
- Capillaries are wider (4.35 μm compared to 4.15 μm in controls)
- Shorter distance exist between any part of the neuropil and a capillary (27.6 μm compared to 34.6 μm)

These energy related changes to the neuropil are responsible for increasing the volume of the cerebral cortex (the increase in synapse numbers contributes in itself hardly any extra volume).

Motor learning stimulation

Part of the effect of environmental enrichment is providing opportunities to acquire motor skills. Research upon "acrobatic" skill learning in the rat shows that it leads to increased synapse numbers.

Maternal transmission

Environmental enrichment during pregnancy has effects upon the fetus such as accelerating its retinal development.

Neurogenesis

Environmental enrichment can also lead to the formation of neurons (at least in rats) and reverses the loss of neurons in the hippocampus and memory impairment following chronic stress. However, its relevance has been questioned for the behavioral effects of enriched environments.

Mechanisms

Enriched environments affect the expression of genes in the cerebral cortex and the hippocampus that determine neuronal structure. At the molecular level, this occurs through increased concentrations of the neurotrophins NGF, NT-3, and changes in BDNF. This alters the activation of cholinergic neurons, 5-HT, and beta-adrenolin. Another effect is to increase proteins such as synaptophysin and PSD-95 in synapses. Changes in Wnt signaling have also been found to mimic in adult mice the effects of

environmental enrichment upon synapses in the hippocampus. Increase in neurons numbers could be linked to changes in VEGF.

Resilience and rehabilitation

Research (as least upon *rats*) suggests that environment enrichment might reduce the effects or ameliorate the cognitive impairments caused by a diverse variety of conditions and neurological disorders.

- Aging, (also in dogs)
- Alzheimer's disease
- Huntington's disease
- Parkinson's disease
- Stroke
- Chronic spinal cord injuries
- Amblyopia
- Rett syndrome
- Autism
- Prenatal and perinatal cocaine exposure
- Fetal alcohol syndrome
- Lead exposure
- Prenatal and maternal separation stress
- Child neglect

Humans

Though environmental enrichment research has been mostly done upon rodents, similar effects occur in primates, and are likely to affect the human brain. However, direct research upon human synapses and their numbers is limited since this requires histological study of the brain. A link, however, has been found between educational level and greater dendritic branch complexity following autopsy removal of the brain.

Localized cerebral cortex changes

MRI detects localized cerebral cortex expansion after people learn complex tasks such as mirror reading (in this case in the right occipital cortex), three-ball juggling (bilateral mid-temporal area and left posterior intraparietal sulcus), and when medical students intensively revise for exams (bilaterally in the posterior and lateral parietal cortex). Such changes in gray matter volume can be expected to link to changes in synapse numbers due to the increased numbers of glial cells and the expanded capillary vascularization needed to support their increased energy consumption.

Institutional deprivation

Children that receive impoverished stimulation due to being confined to cots without social interaction or reliable caretakers in low quality orphanages show severe delays in

cognitive and social development. 12% of them if adopted after 6 months of age show autistic or mildly autistic traits later at four years of age. Some children in such impoverished orphanages at two and half years of age still fail to produce intelligible words, though a year of foster care enabled such children to catch up in their language in most respects. Catch-up in other cognitive functioning also occurs after adoption, though problems continue in many children if this happens after the age of 6 months

Such children show marked differences in their brains, consistent with research upon experiment animals, compared to children from normally stimulating environments. They have reduced brain activity in the orbital prefrontal cortex, amygdala, hippocampus, temporal cortex, and brain stem. They also showed less developed white matter connections between different areas in their cerebral cortices, particularly the uncinate fasciculus.

Conversely, enriching the experience of preterm infants with massage quickens the maturating of their electroencephalographic activity and their visual acuity. Moreover, as with enrichment in experimental animals, this associates with an increase in IGF-1.

Cognitive reserve and resilience

Another source of evidence for the effect of environment stimulation upon the human brain is cognitive reserve (a measure of the brain's resilience to cognitive impairment) and the level of a person's education. Not only is higher education linked to a more cognitively demanding educational experience, but it also correlates with a person's generally engaging in cognitively demanding activities. The more education a person has received, the less the effects of aging, dementia, white matter hyperintensities, MRI-defined brain infarcts, Alzheimer's disease, and traumatic brain injury. Also, aging and dementia are less in those that engage in complex cognitive tasks. The cognitive decline of those with epilepsy could also be affected by the level of a person's education.

Chapter 13

Growth Cone



Image of a fluorescently-labeled growth cone extending from an axon **F-actin** (red) **microtubules** (green).

A **growth cone** is a dynamic, actin-supported extension of a developing axon seeking its synaptic target. Their existence was originally proposed by Spanish histologist Santiago Ramón y Cajal based upon stationary images he observed under the microscope. He first described the growth cone based on fixed cells as "a concentration of protoplasm of

conical form, endowed with amoeboid movements" (Cajal, 1890). Neuronal growth cones are situated on the very tips of nerve cells on structures called axons and dendrites. The sensory, motor, integrative, and adaptive functions of growing axons and dendrites are all contained within this specialized structure.

Structure



Two fluorescently-labeled growth cones. The growth cone (green) on the left is an example of a "filopodial" growth cone, while the one on the right is a "lamellipodial" growth cone. Typically, growth cones have both structures, but with varying sizes and numbers of each.

The morphology of the growth cone can be easily described by using the hand as an analogy. The fine extensions of the growth cone are known as "filopodia" or microspikes. The filopodia are like the "fingers" of the growth cone; they contain bundles of actin filaments (F-actin) that give them shape and support. Filopodia are the dominant structures in growth cones, and they appear as narrow cylindrical extensions which can extend several micrometres beyond the edge of the growth cone. The filopodia are bound by membrane which contains receptors and cell adhesion molecules that are important for axon growth and guidance.

In between filopodia--much like the webbing of the hands--are the "lamellipodia". These are flat regions of dense actin meshwork instead of bundled F-actin as in filopodia. They often appear adjacent to the leading edge of the growth cone and are positioned between two filopodia, giving them a "veil-like" appearance. In growth cones, new filopodia usually emerge from these inter-filopodial veils.

The growth cone is described in terms of three regions: the peripheral (P) domain, the transitional (T) domain, and the central (C) domain. The peripheral domain is the thin region surrounding the outer edge of the growth cone. It is composed primarily of an

actin-based cytoskeleton, and contains the lamellipodia and filopodia which are highly dynamic. Microtubules, however, are known to transiently enter the peripheral region via a process called dynamic instability. The central domain is located in the center of the growth cone nearest to the axon. This region is composed primarily of a microtubule-based cytoskeleton, is generally thicker, and contains many organelles and vesicles of various sizes. The transitional domain is the region located in the thin band between the central and peripheral domains.

There are also many cytoskeletal-associated proteins, which perform a variety of duties within the growth cone, such as anchoring actin and microtubules to each other, to the membrane, and to other cytoskeletal components. Some of these components include molecular motors that generate force within the growth cone and membrane-bound vesicles which are transported in and out of the growth cone via microtubules. Some examples of cytoskeletal-associated proteins are Fascin and Filamin (actin bundling), Talin (actin anchoring), myosin (vesicle transport), and mDia (microtubule-actin linking).

Axon branching and outgrowth

The highly dynamic nature of growth cones allows them to respond to the surrounding environment by rapidly changing direction and branching in response to various stimuli. There are three stages of axon outgrowth, which are termed: protrusion, engorgement, and consolidation. During protrusion, there is a rapid extension of filopodia and lamellar extensions along the leading edge of the growth cone. Engorgement follows when the filopodia move to the lateral edges of the growth cone, and microtubules invade further into the growth cone, bringing vesicles and organelles such as mitochondria and endoplasmic reticulum. Finally, consolidation occurs when the F-actin at the neck of the growth cone depolymerizes and the filopodia retract. The membrane then shrinks to form a cylindrical axon shaft around the bundle of microtubules. Axon branching also occurs via the same process, except that the growth cone “splits” during the engorgement phase.

Overall, axon elongation is the product of a process known as tip growth. In this process, new material is added at the growth cone while the remainder of the axonal cytoskeleton remains stationary. This occurs via two processes: cytoskeletal-based dynamics and mechanical tension. With cytoskeletal dynamics, microtubules polymerize into the growth cone and deliver vital components. Mechanical tension occurs when the membrane is stretched due to force generation by molecular motors in the growth cone and strong adhesions to the substrate along the axon. In general, rapidly growing growth cones are small and have a large degree of stretching, while slow moving or paused growth cones are very large and have a low degree of stretching.

The growth cones are continually being built up through construction of the actin microfilaments and extension of the plasma membrane via vesicle fusion. The actin filaments depolymerize and disassemble on the proximal end to allow free monomers to migrate to the leading edge (distal end) of the actin filament where it can polymerize and thus reattach. Actin filaments are also constantly being transported away from the leading edge by a myosin-motor driven process known as retrograde F-actin flow. The actin

filaments are polymerized in the peripheral region and then transported backward to the transitional region, where the filaments are depolymerized; thus freeing the monomers to repeat the cycle. This is different from actin treadmilling since the entire protein moves. If the protein was to simply treadmill, the monomers would depolymerize from one end and polymerize onto the other while the protein itself does not move.

The growth capacity of the axons lies in the microtubules which are located just beyond the actin filaments. Microtubules can rapidly polymerize into and thus “probe” the actin-rich peripheral region of the growth cone. When this happens, the polymerizing ends of microtubules come into contact with F-actin adhesion sites, where microtubule tip-associated proteins act as "ligands". Laminins of the basal membrane interact with the integrins of the growth cone to promote the forward movement of the growth cone. Additionally, axon outgrowth is also supported by the stabilization of the proximal ends of microtubules, which provide the structural support for the axon.

Axon guidance



Model of growth cone-mediated axon guidance. From left to right, this model describes how the cytoskeleton responds and reorganizes to grow towards a positive stimulus (+) detected by receptors in the growth cone or away from a negative stimulus (-).

Movement of the axons is controlled by an integration of its sensory and motor function (described above) which is established through second messengers such as calcium and cyclic nucleotides. The sensory function of axons is dependent on cues from the extracellular matrix which can be either attractive or repulsive, thus helping to guide the axon away from certain paths and attracting them to their proper target destinations. Attractive cues inhibit retrograde flow of the actin filaments and promote their assembly whereas repulsive cues have the exact opposite effect. Actin stabilizing proteins are also involved and are essential for continued protrusion of filopodia and lamellipodia in the

presence of attractive cues, while actin destabilizing proteins are involved in the presence of a repulsive cue.

A similar process is involved with microtubules. In the presence of an attractive cue on one side of the growth cone, specific microtubules are targeted on that side by microtubule stabilizing proteins, resulting in growth cone turning in the direction of the positive stimulus. With repulsive cues, the opposite is true: microtubule stabilization is favored on the opposite side of the growth cone as the negative stimulus resulting in the growth cone turning away from the repellant. This process coupled with actin-associated processes result in the overall directed growth of an axon.

Growth cone receptors detect the presence of axon guidance molecules such as Netrin, Slit, Ephrins, and Semaphorins. It has more recently been shown that cell fate determinants such as Wnt or Shh can also act as guidance cues. Quite interestingly, the same guidance cue can act as an attractant or a repellent, depending on context. A prime example of this is Netrin-1, which signals attraction through the DCC receptor and repulsion through the Unc-5 receptor. Furthermore, it has been discovered that these same molecules are involved in guiding vessel growth. Axon guidance directs the initial wiring of the nervous system and is also important in axonal regeneration following an injury.

Chapter 14

Nerve Growth Factor

Nerve growth factor, beta polypeptide



PDB rendering based on 1bet.

Identifiers	
Symbols	NGFB; Beta-NGF; HSAN5; MGC161426; MGC161428; NGF
External IDs	OMIM: 162030 MGI: 97321 HomoloGene: 1876 GeneCards: NGFB Gene

RNA expression pattern


Orthologs		
Species	**Human**	**Mouse**
Entrez	4803	18049
Ensembl	ENSG00000134259	ENSMUSG00000027859
UniProt	P01138	Q6LDU8
RefSeq (mRNA)	NM_002506	NM_013609
RefSeq (protein)	NP_002497	NP_038637
Location (UCSC)	Chr 1: 115.63 - 115.68 Mb	Chr 3: 102.6 - 102.65 Mb

Nerve growth factor (**NGF**), is a small secreted protein that is important for the growth, maintenance, and survival of certain target neurons (nerve cells). It also functions as a signaling molecule. It is perhaps the prototypical growth factor, in that it is one of the first to be described. While "nerve growth factor" refers to a single factor, "nerve growth factors" refers to a family of factors also known as neurotrophins. Other members of the neurotrophin family that are well recognized include Brain-Derived Neurotrophic Factor (BDNF), Neurotrophin-3 (NT-3), and Neurotrophin 4/5 (NT-4/5).

Function and mechanism of action

NGF is critical for the survival and maintenance of sympathetic and sensory neurons. Without it, these neurons undergo apoptosis. Nerve growth factor causes axonal growth. Studies have shown that it causes axonal branching and a bit of elongation. NGF binds with at least two classes of receptors: the p75 LNGFR (for "low-affinity nerve growth factor receptor") neurotrophin receptor (p75(NTR)) and TrkA, a transmembrane tyrosine kinase. Both are associated with neurodegenerative disorders.

NGF binds to high-affinity tyrosine kinase receptor TrkA. This phosphorylates TrkA, which leads to the activation of PI 3 Kinase, ras, and PLC signaling pathways.

There is evidence that NGF circulates throughout the entire body and is important for maintaining homeostasis.

There is also evidence that shows that the precursor to NGF, pro-NGF, may also play important roles due to its abundance. These include apoptotic and neurotrophic properties.

History

Stanley Cohen and Rita Levi-Montalcini discovered NGF in the 1950s while faculty members at Washington University in St Louis. However, its discovery, along with the discovery of other neurotrophins, was not widely recognized until 1986, when it won the Nobel Prize in Physiology or Medicine.

Studies in 1971 determined the primary structure of NGF. This eventually led to the discovery of the NGF gene.

Medical significance

NGF has the potential to help treat several diseases of the nervous system. It has shown this through numerous clinical trials. It has been shown to reduce neural degeneration. It has also been shown to promote peripheral nerve regeneration in rats.

There is strong evidence demonstrating the role of NGF as an inflammatory. This may one day be used for the treatment of Multiple Sclerosis. Also, it could possibly promote myelin repair.

Also, NGF has been shown to play a role in number cardiovascular diseases, such as coronary atherosclerosis, obesity, type 2 diabetes, and metabolic syndrome. Reduced plasma levels of NGF and BDNF have been associated with acute coronary syndromes and metabolic syndromes. NGF could also be related to various psychiatric disorders, such as dementia, depression, schizophrenia, autism, Rett syndrome, anorexia nervosa, and bulimia nervosa. NGF has also been shown to accelerate wound healing. There is evidence that it could be useful in the treatment of skin ulcers and cornea ulcers.

NGF is known to have insulinotropic, angiogenic, and antioxidant properties. NGF suppresses food intake.

It has also been tied to Alzheimer's disease.

Cultural significance

In 2005, Enzo Emanuele and coworkers at University of Pavia found that nerve growth factor (NGF) has high levels when people first fall in love, but these levels return to as they were after one year. To be specific, four neurotrophin levels, i.e., NGF, BDNF, NT-3, and NT-4, of 58 subjects who had recently fallen in love were compared with levels in a control group who were either single or already engaged in a long-term relationship. The results showed that NGF levels were significantly higher in the subjects in love than as compared to either of the control groups.

Pietro Calissano has suggested that nerve growth factor may contribute to increased longevity and mental capacity. Centenarian Rita Levi-Montalcini has been taking a daily solution in the form of eye drops, and has stated that her brain is more active now than it was four decades ago.

Interactions

Nerve growth factor has been shown to interact with TrkA and Low affinity nerve growth factor receptor.

Chapter 15

Neural Development in Humans

The study of **neural development** draws on both neuroscience and developmental biology to describe the cellular and molecular mechanisms by which complex nervous systems emerge during embryonic development and throughout life.

Some landmarks of embryonic neural development include the birth and differentiation of neurons from stem cell precursors, the migration of immature neurons from their birthplaces in the embryo to their final positions, outgrowth of axons from neurons and guidance of the motile growth cone through the embryo towards postsynaptic partners, the generation of synapses between these axons and their postsynaptic partners, the neuron pruning that occurs in adolescence, and finally the lifelong changes in synapses which are thought to underlie learning and memory.

Typically, these neurodevelopmental processes can be broadly divided into two classes: activity-independent mechanisms and activity-dependent mechanisms. Activity-independent mechanisms are generally believed to occur as hardwired processes determined by genetic programs played out within individual neurons. These include differentiation, migration and axon guidance to their initial target areas. These processes are thought of as being independent of neural activity and sensory experience. Once axons reach their target areas, activity-dependent mechanisms come into play. Neural activity and sensory experience will mediate formation of new synapses, as well as synaptic plasticity, which will be responsible for refinement of the nascent neural circuits.

Embryonic stage

Neurulation

Neurulation is the formation of the neural tube from the ectoderm of the embryo. It follows gastrulation in all vertebrates.

During gastrulation cells migrate to the interior of embryo, forming three germ layers—the endoderm (the deepest layer), mesoderm and ectoderm (the surface layer)—from which all tissues and organs will arise. In a simplified way, it can be said that the ectoderm gives rise to skin and nervous system, the endoderm to the guts and the mesoderm to the rest of the organs.

After gastrulation the notochord—a flexible, rod-shaped body that runs along the back of the embryo—has been formed from the mesoderm. During the third week of gestation the notochord sends signals to the overlying ectoderm, inducing it to become neuroectoderm. This results in a strip of neuronal stem cells that runs along the back of the fetus. This strip is called the neural plate, and is the origin of the entire nervous system. The neural plate folds outwards to form the neural groove. Beginning in the future neck region, the neural folds of this groove close to create the neural tube (this form of neurulation is called primary neuralation). The anterior (front) part of the neural tube is called the basal plate; the posterior (rear) part is called the alar plate. The hollow interior is called the neural canal. By the end of the fourth week of gestation, the open ends of the neural tube (the **neuropores**) close off.

Formation of the spinal cord



Cross-section of a developing spinal cord at four weeks

The spinal cord forms from the lower part of the neural tube. The wall of the neural tube consists of neuroepithelial cells, which differentiate into neuroblasts, forming the mantle layer (the gray matter). Nerve fibers emerge from these neuroblasts to form the marginal layer (the white matter).

The ventral part of the mantle layer (the basal plates) forms the motor areas of the spinal cord, whilst the dorsal part (the alar plates) forms the sensory areas. Between the basal and alar plates is an intermediate layer that contains neurons of the autonomic nervous system.

Formation of the brain



The embryo's brain at four weeks

Late in the fourth week, the superior part of the neural tube flexes at the level of the future midbrain—the mesencephalon. Above the mesencephalon is the prosencephalon (future forebrain) and beneath it is the rhombencephalon (future hindbrain). The optical vesicle (which will eventually become the optic nerve, retina and iris) forms at the basal plate of the prosencephalon.



The embryo's nervous system at six weeks

In the fifth week, the alar plate of the prosencephalon expands to form the cerebral hemispheres (the telencephalon). The basal plate becomes the diencephalon.

The diencephalon, mesencephalon and rhombencephalon constitute the brain stem of the embryo. It continues to flex at the mesencephalon. The rhombencephalon folds posteriorly, which causes its alar plate to flare and form the fourth ventricle of the brain. The pons and the cerebellum form in the upper part of the rhombencephalon, whilst the medulla oblongata forms in the lower part.

Human brain development



Highly schematic flowchart of human brain development

Neuronal migration

Neuronal migration is the method by which neurons travel from their origin or birth place to their final position in the brain. There are several ways they can do this, e.g. by radial migration or tangential migration.

Radial migration

Neuronal precursor cells proliferate in the ventricular zone of the developing neocortex. The first postmitotic cells to migrate form the preplate which are destined to become Cajal-Retzius cells and subplate neurons. These cells do so by somal translocation. Neurons migrating with this mode of locomotion are bipolar and attach the leading edge of the process to the pia. The soma is then transported to the pial surface by nucleokenisis, a process by which a microtubule "cage" around the nucleus elongates and contracts in association with the centrosome to guide the nucleus to its final destination. Radial fibres (also known as radial glia) can translocate to the cortical plate and differentiate either into astrocytes or neurons. Somal translocation can occur at any time during development.

Subsequent waves of neurons split the preplate by migrating along radial glial fibres to form the cortical plate. Each wave of migrating cells travel past their predecessors forming layers in an inside-out manner, meaning that the youngest neurons are the closest to the surface. It is estimated that glial guided migration represents 80-90% of migrating neurons.

Tangential migration

Most interneurons migrate tangentially through multiple modes of migration to reach their appropriate location in the cortex. An example of tangential migration is the movement of Cajal-Retzius cells from the cortical hem to the superfitial part of cortical neuroepithelium.

Others

There is also a method of neuronal migration called **multipolar migration**. This is seen in multipolar cells, which are abundantly present in the cortical intermediate zone. They do not resemble the cells migrating by locomotion or somal translocation. Instead these multipolar cells express neuronal markers and extend multiple thin processes in various directions independently of the radial glial fibers.

Neural development in the adult nervous system

Neural development in the adult nervous system includes mechanisms such as remyelination, generation of new neurons, glia, axons, myelin or synapses. Neuroregeneration differs between the peripheral nervous system (PNS) and the central nervous system (CNS) by the functional mechanisms and especially, the extent and speed.

Chapter 16

Autism

Autism

Repetitively stacking or lining up objects is a behavior occasionally associated with individuals with autism.

ICD-10	F84.0
ICD-9	299.00
OMIM	209850

DiseasesDB	1142
MedlinePlus	001526
eMedicine	med/3202 ped/180
MeSH	D001321
GeneReviews	Autism overview

Autism is a disorder of neural development characterized by impaired social interaction and communication, and by restricted and repetitive behavior. These signs all begin before a child is three years old. Autism affects information processing in the brain by altering how nerve cells and their synapses connect and organize; how this occurs is not well understood. It is one of three recognized disorders in the autism spectrum (ASDs), the other two being Asperger syndrome, which lacks delays in cognitive development and language, and Pervasive Developmental Disorder-Not Otherwise Specified (commonly abbreviated as PDD-NOS), which is diagnosed when the full set of criteria for autism or Asperger syndrome are not met.

Autism has a strong genetic basis, although the genetics of autism are complex and it is unclear whether ASD is explained more by rare mutations, or by rare combinations of common genetic variants. In rare cases, autism is strongly associated with agents that cause birth defects. Controversies surround other proposed environmental causes, such as heavy metals, pesticides or childhood vaccines; the vaccine hypotheses are biologically implausible and lack convincing scientific evidence. The prevalence of autism is about 1–2 per 1,000 people worldwide; however, the Centers for Disease Control and Prevention (CDC) reports an approximate of 9 per 1,000 children in the United States are diagnosed with ASD. The number of people diagnosed with autism has increased dramatically since the 1980s, partly due to changes in diagnostic practice; the question of whether actual prevalence has increased is unresolved.

Parents usually notice signs in the first two years of their child's life. The signs usually develop gradually, but some autistic children first develop more normally and then regress. Although there is no known cure, early behavioral or cognitive intervention can help autistic children gain self-care, social, and communication skills. Not many children with autism live independently after reaching adulthood, though some become successful. An autistic culture has developed, with some individuals seeking a cure and others believing autism should be accepted as a difference and not treated as a disorder.

Characteristics

Autism is a highly variable neurodevelopmental disorder that first appears during infancy or childhood, and generally follows a steady course without remission. Overt symptoms gradually begin after the age of six months, become established by age two or three years, and tend to continue through adulthood, although often in more muted form. It is distinguished not by a single symptom, but by a characteristic triad of symptoms:

impairments in social interaction; impairments in communication; and restricted interests and repetitive behavior. Other aspects, such as atypical eating, are also common but are not essential for diagnosis. Autism's individual symptoms occur in the general population and appear not to associate highly, without a sharp line separating pathologically severe from common traits.

Social development

Social deficits distinguish autism and the related autism spectrum disorders from other developmental disorders. People with autism have social impairments and often lack the intuition about others that many people take for granted. Noted autistic Temple Grandin described her inability to understand the social communication of neurotypicals, or people with normal neural development, as leaving her feeling "like an anthropologist on Mars".

Unusual social development becomes apparent early in childhood. Autistic infants show less attention to social stimuli, smile and look at others less often, and respond less to their own name. Autistic toddlers differ more strikingly from social norms; for example, they have less eye contact and turn taking, and do not have the ability to use simple movements to express oneself, such as the deficiency to point at things. Three- to five-year-old autistic children are less likely to exhibit social understanding, approach others spontaneously, imitate and respond to emotions, communicate nonverbally, and take turns with others. However, they do form attachments to their primary caregivers. Most autistic children display moderately less attachment security than non-autistic children, although this difference disappears in children with higher mental development or less severe ASD. Older children and adults with ASD perform worse on tests of face and emotion recognition.

Children with high-functioning autism suffer from more intense and frequent loneliness compared to non-autistic peers, despite the common belief that children with autism prefer to be alone. Making and maintaining friendships often proves to be difficult for those with autism. For them, the quality of friendships, not the number of friends, predicts how lonely they feel. Functional friendships, such as those resulting in invitations to parties, may affect the quality of life more deeply.

There are many anecdotal reports, but few systematic studies, of aggression and violence in individuals with ASD. The limited data suggest that, in children with mental retardation, autism is associated with aggression, destruction of property, and tantrums. A 2007 study interviewed parents of 67 children with ASD and reported that about two-thirds of the children had periods of severe tantrums and about one-third had a history of aggression, with tantrums significantly more common than in non-autistic children with language impairments. A 2008 Swedish study found that, of individuals aged 15 or older discharged from hospital with a diagnosis of ASD, those who committed violent crimes were significantly more likely to have other psychopathological conditions such as psychosis.

Communication

About a third to a half of individuals with autism do not develop enough natural speech to meet their daily communication needs. Differences in communication may be present from the first year of life, and may include delayed onset of babbling, unusual gestures, diminished responsiveness, and vocal patterns that are not synchronized with the caregiver. In the second and third years, autistic children have less frequent and less diverse babbling, consonants, words, and word combinations; their gestures are less often integrated with words. Autistic children are less likely to make requests or share experiences, and are more likely to simply repeat others' words (echolalia) or reverse pronouns. Joint attention seems to be necessary for functional speech, and deficits in joint attention seem to distinguish infants with ASD: for example, they may look at a pointing hand instead of the pointed-at object, and they consistently fail to point at objects in order to comment on or share an experience. Autistic children may have difficulty with imaginative play and with developing symbols into language.

In a pair of studies, high-functioning autistic children aged 8–15 performed equally well as, and adults better than, individually matched controls at basic language tasks involving vocabulary and spelling. Both autistic groups performed worse than controls at complex language tasks such as figurative language, comprehension and inference. As people are often sized up initially from their basic language skills, these studies suggest that people speaking to autistic individuals are more likely to overestimate what their audience comprehends.

Repetitive behavior

Autistic individuals display many forms of repetitive or restricted behavior, which the Repetitive Behavior Scale-Revised (RBS-R) categorizes as follows.

A young boy with autism, and the precise line of toys he made

- **Stereotypy** is repetitive movement, such as hand flapping, making sounds, head rolling, or body rocking.
- **Compulsive behavior** is intended and appears to follow rules, such as arranging objects in stacks or lines.
- **Sameness** is resistance to change; for example, insisting that the furniture not be moved or refusing to be interrupted.
- **Ritualistic behavior** involves an unvarying pattern of daily activities, such as an unchanging menu or a dressing ritual. This is closely associated with sameness and an independent validation has suggested combining the two factors.
- **Restricted behavior** is limited in focus, interest, or activity, such as preoccupation with a single television program, toy, or game.
- **Self-injury** includes movements that injure or can injure the person, such as eye poking, skin picking, hand biting, and head banging. A 2007 study reported that self-injury at some point affected about 30% of children with ASD.

No single repetitive or self-injurious behavior seems to be specific to autism, but only autism appears to have an elevated pattern of occurrence and severity of these behaviors.

Other symptoms

Autistic individuals may have symptoms that are independent of the diagnosis, but that can affect the individual or the family. An estimated 0.5% to 10% of individuals with ASD show unusual abilities, ranging from splinter skills such as the memorization of trivia to the extraordinarily rare talents of prodigious autistic savants. Many individuals with ASD show superior skills in perception and attention, relative to the general

population. Sensory abnormalities are found in over 90% of those with autism, and are considered core features by some, although there is no good evidence that sensory symptoms differentiate autism from other developmental disorders. Differences are greater for under-responsivity (for example, walking into things) than for over-responsivity (for example, distress from loud noises) or for sensation seeking (for example, rhythmic movements). An estimated 60%–80% of autistic people have motor signs that include poor muscle tone, poor motor planning, and toe walking; deficits in motor coordination are pervasive across ASD and are greater in autism proper.

Unusual eating behavior occurs in about three-quarters of children with ASD, to the extent that it was formerly a diagnostic indicator. Selectivity is the most common problem, although eating rituals and food refusal also occur; this does not appear to result in malnutrition. Although some children with autism also have gastrointestinal (GI) symptoms, there is a lack of published rigorous data to support the theory that autistic children have more or different GI symptoms than usual; studies report conflicting results, and the relationship between GI problems and ASD is unclear.

Parents of children with ASD have higher levels of stress. Siblings of children with ASD report greater admiration of and less conflict with the affected sibling than siblings of unaffected children or those with Down syndrome; siblings of individuals with ASD have greater risk of negative well-being and poorer sibling relationships as adults.

Classification

Autism is one of the five pervasive developmental disorders (PDD), which are characterized by widespread abnormalities of social interactions and communication, and severely restricted interests and highly repetitive behavior. These symptoms do not imply sickness, fragility, or emotional disturbance.

Of the five PDD forms, Asperger syndrome is closest to autism in signs and likely causes; Rett syndrome and childhood disintegrative disorder share several signs with autism, but may have unrelated causes; PDD not otherwise specified (PDD-NOS; also called *atypical autism*) is diagnosed when the criteria are not met for a more specific disorder. Unlike with autism, people with Asperger syndrome have no substantial delay in language development. The terminology of autism can be bewildering, with autism, Asperger syndrome and PDD-NOS often called the *autism spectrum disorders* (ASD) or sometimes the *autistic disorders*, whereas autism itself is often called *autistic disorder*, *childhood autism*, or *infantile autism*. Here, *autism* refers to the classic autistic disorder; in clinical practice, though, *autism*, *ASD*, and *PDD* are often used interchangeably. ASD, in turn, is a subset of the broader autism phenotype, which describes individuals who may not have ASD but do have autistic-like traits, such as avoiding eye contact.

The manifestations of autism cover a wide spectrum, ranging from individuals with severe impairments—who may be silent, mentally disabled, and locked into hand flapping and rocking—to high functioning individuals who may have active but distinctly odd social approaches, narrowly focused interests, and verbose, pedantic communication.

Because the behavior spectrum is continuous, boundaries between diagnostic categories are necessarily somewhat arbitrary. Sometimes the syndrome is divided into low-, medium- or high-functioning autism (LFA, MFA, and HFA), based on IQ thresholds, or on how much support the individual requires in daily life; these subdivisions are not standardized and are controversial. Autism can also be divided into syndromal and non-syndromal autism; the syndromal autism is associated with severe or profound mental retardation or a congenital syndrome with physical symptoms, such as tuberous sclerosis. Although individuals with Asperger syndrome tend to perform better cognitively than those with autism, the extent of the overlap between Asperger syndrome, HFA, and non-syndromal autism is unclear.

Some studies have reported diagnoses of autism in children due to a loss of language or social skills, as opposed to a failure to make progress, typically from 15 to 30 months of age. The validity of this distinction remains controversial; it is possible that regressive autism is a specific subtype, or that there is a continuum of behaviors between autism with and without regression.

Research into causes has been hampered by the inability to identify biologically meaningful subpopulations and by the traditional boundaries between the disciplines of psychiatry, psychology, neurology and pediatrics. Newer technologies such as fMRI and diffusion tensor imaging can help identify biologically relevant phenotypes (observable traits) that can be viewed on brain scans, to help further neurogenetic studies of autism; one example is lowered activity in the fusiform face area of the brain, which is associated with impaired perception of people versus objects. It has been proposed to classify autism using genetics as well as behavior.

Causes

It has long been presumed that there is a common cause at the genetic, cognitive, and neural levels for autism's characteristic triad of symptoms. However, there is increasing suspicion that autism is instead a complex disorder whose core aspects have distinct causes that often co-occur.



Deletion (1), duplication (2) and inversion (3) are all chromosome abnormalities that have been implicated in autism.

Autism has a strong genetic basis, although the genetics of autism are complex and it is unclear whether ASD is explained more by rare mutations with major effects, or by rare multigene interactions of common genetic variants. Complexity arises due to interactions among multiple genes, the environment, and epigenetic factors which do not change DNA but are heritable and influence gene expression. Studies of twins suggest that heritability is 0.7 for autism and as high as 0.9 for ASD, and siblings of those with autism are about 25 times more likely to be autistic than the general population. However, most of the mutations that increase autism risk have not been identified. Typically, autism cannot be traced to a Mendelian (single-gene) mutation or to a single chromosome abnormality like fragile X syndrome, and none of the genetic syndromes associated with ASDs have been shown to selectively cause ASD. Numerous candidate genes have been located, with only small effects attributable to any particular gene. The large number of autistic individuals with unaffected family members may result from copy number variations—spontaneous deletions or duplications in genetic material during meiosis. Hence, a substantial fraction of autism cases may be traceable to genetic causes that are highly heritable but not inherited: that is, the mutation that causes the autism is not present in the parental genome.

Several lines of evidence point to synaptic dysfunction as a cause of autism. Some rare mutations may lead to autism by disrupting some synaptic pathways, such as those

involved with cell adhesion. Gene replacement studies in mice suggest that autistic symptoms are closely related to later developmental steps that depend on activity in synapses and on activity-dependent changes. All known teratogens (agents that cause birth defects) related to the risk of autism appear to act during the first eight weeks from conception, and though this does not exclude the possibility that autism can be initiated or affected later, it is strong evidence that autism arises very early in development.

Although evidence for other environmental causes is anecdotal and has not been confirmed by reliable studies, extensive searches are underway. Environmental factors that have been claimed to contribute to or exacerbate autism, or may be important in future research, include certain foods, infectious disease, heavy metals, solvents, diesel exhaust, PCBs, phthalates and phenols used in plastic products, pesticides, brominated flame retardants, alcohol, smoking, illicit drugs, vaccines, and prenatal stress, although no links have been found, and some have been completely dis-proven.

Parents may first become aware of autistic symptoms in their child around the time of a routine vaccination. This has led to theories blaming vaccine "overload", a vaccine preservative or the MMR vaccine for causing autism. The latter theory was supported by litigation-funded study that has since been shown to have been "an elaborate fraud". Although these theories lack convincing scientific evidence and are biologically implausible, parental concern about a potential vaccine link with autism has led to lower rates of childhood immunizations, outbreaks of previously-controlled childhood diseases in some countries, and the preventable deaths of several children.

Mechanism

Autism's symptoms result from maturation-related changes in various systems of the brain. How autism occurs is not well understood. Its mechanism can be divided into two areas: the pathophysiology of brain structures and processes associated with autism, and the neuropsychological linkages between brain structures and behaviors. The behaviors appear to have multiple pathophysiologies.

Pathophysiology



Autism affects the amygdala, cerebellum, and many other parts of the brain

Unlike many other brain disorders such as Parkinson's, autism does not have a clear unifying mechanism at either the molecular, cellular, or systems level; it is not known whether autism is a few disorders caused by mutations converging on a few common molecular pathways, or is (like intellectual disability) a large set of disorders with diverse mechanisms. Autism appears to result from developmental factors that affect many or all functional brain systems, and to disturb the timing of brain development more than the final product. Neuroanatomical studies and the associations with teratogens strongly suggest that autism's mechanism includes alteration of brain development soon after conception. This anomaly appears to start a cascade of pathological events in the brain

that are significantly influenced by environmental factors. Just after birth, the brains of autistic children tend to grow faster than usual, followed by normal or relatively slower growth in childhood. It is not known whether early overgrowth occurs in all autistic children. It seems to be most prominent in brain areas underlying the development of higher cognitive specialization. Hypotheses for the cellular and molecular bases of pathological early overgrowth include the following:

- An excess of neurons that causes local overconnectivity in key brain regions.
- Disturbed neuronal migration during early gestation.
- Unbalanced excitatory–inhibitory networks.
- Abnormal formation of synapses and dendritic spines, for example, by modulation of the neurexin–neuroligin cell-adhesion system, or by poorly regulated synthesis of synaptic protein. Disrupted synaptic development may also contribute to epilepsy, which may explain why the two conditions are associated.

Interactions between the immune system and the nervous system begin early during the embryonic stage of life, and successful neurodevelopment depends on a balanced immune response. It is possible that aberrant immune activity during critical periods of neurodevelopment is part of the mechanism of some forms of ASD. Although some abnormalities in the immune system have been found in specific subgroups of autistic individuals, it is not known whether these abnormalities are relevant to or secondary to autism's disease processes. As autoantibodies are found in conditions other than ASD, and are not always present in ASD, the relationship between immune disturbances and autism remains unclear and controversial.

The relationship of neurochemicals to autism is not well understood; several have been investigated, with the most evidence for the role of serotonin and of genetic differences in its transport. Others have pointed to a role for group I metabotropic glutamate receptors (mGluR) in the pathogenesis of one type of autism, Fragile X. Some data suggest an increase in several growth hormones; other data argue for diminished growth factors. Also, some inborn errors of metabolism are associated with autism but probably account for less than 5% of cases.

The mirror neuron system (MNS) theory of autism hypothesizes that distortion in the development of the MNS interferes with imitation and leads to autism's core features of social impairment and communication difficulties. The MNS operates when an animal performs an action or observes another animal perform the same action. The MNS may contribute to an individual's understanding of other people by enabling the modeling of their behavior via embodied simulation of their actions, intentions, and emotions. Several studies have tested this hypothesis by demonstrating structural abnormalities in MNS regions of individuals with ASD, delay in the activation in the core circuit for imitation in individuals with Asperger syndrome, and a correlation between reduced MNS activity and severity of the syndrome in children with ASD. However, individuals with autism also have abnormal brain activation in many circuits outside the MNS and the MNS theory does not explain the normal performance of autistic children on imitation tasks that involve a goal or object.



Autistic individuals tend to use different areas of the brain (yellow) for a movement task compared to a control group (blue)

ASD-related patterns of low function and aberrant activation in the brain differ depending on whether the brain is doing social or nonsocial tasks. In autism there is evidence for reduced functional connectivity of the default network, a large-scale brain network involved in social and emotional processing, with intact connectivity of the task-positive network, used in sustained attention and goal-directed thinking. In people with autism the two networks are not negatively correlated in time, suggesting an imbalance in toggling between the two networks, possibly reflecting a disturbance of self-referential thought. A 2008 brain-imaging study found a specific pattern of signals in the cingulate cortex which differs in individuals with ASD.

The underconnectivity theory of autism hypothesizes that autism is marked by underfunctioning high-level neural connections and synchronization, along with an excess of low-level processes. Evidence for this theory has been found in functional neuroimaging studies on autistic individuals and by a brainwave study that suggested that adults with ASD have local overconnectivity in the cortex and weak functional connections between the frontal lobe and the rest of the cortex. Other evidence suggests

the underconnectivity is mainly within each hemisphere of the cortex and that autism is a disorder of the association cortex.

From studies based on event-related potentials, transient changes to the brain's electrical activity in response to stimuli, there is considerable evidence for differences in autistic individuals with respect to attention, orientiation to auditory and visual stimuli, novelty detection, language and face processing, and information storage; several studies have found a preference for non-social stimuli. For example, magnetoencephalography studies have found evidence in autistic children of delayed responses in the brain's processing of auditory signals.

In the genetic area, relations have been found between autism and schizophrenia based on duplications and deletions of chromosomes; research showed that schizophrenia and autism are significantly more common in combination with 1q21.1 deletion syndrome. Research on autism/schizophrenia relations for chromosome 15 (15q13.3), chromosome 16 (16p13.1) and chromosome 17 (17p12) are inconclusive.

Neuropsychology

Two major categories of cognitive theories have been proposed about the links between autistic brains and behavior.

The first category focuses on deficits in social cognition. The empathizing–systemizing theory postulates that autistic individuals can systemize—that is, they can develop internal rules of operation to handle events inside the brain—but are less effective at empathizing by handling events generated by other agents. An extension, the extreme male brain theory, hypothesizes that autism is an extreme case of the male brain, defined psychometrically as individuals in whom systemizing is better than empathizing; this extension is controversial, as many studies contradict the idea that baby boys and girls respond differently to people and objects.

These theories are somewhat related to the earlier theory of mind approach, which hypothesizes that autistic behavior arises from an inability to ascribe mental states to oneself and others. The theory of mind hypothesis is supported by autistic children's atypical responses to the Sally–Anne test for reasoning about others' motivations, and the mirror neuron system theory of autism described in *Pathophysiology* maps well to the hypothesis. However, most studies have found no evidence of impairment in autistic individuals' ability to understand other people's basic intentions or goals; instead, data suggests that impairments are found in understanding more complex social emotions or in considering others' viewpoints.

The second category focuses on nonsocial or general processing. Executive dysfunction hypothesizes that autistic behavior results in part from deficits in working memory, planning, inhibition, and other forms of executive function. Tests of core executive processes such as eye movement tasks indicate improvement from late childhood to adolescence, but performance never reaches typical adult levels. A strength of the theory

is predicting stereotyped behavior and narrow interests; two weaknesses are that executive function is hard to measure and that executive function deficits have not been found in young autistic children.

Weak central coherence theory hypothesizes that a limited ability to see the big picture underlies the central disturbance in autism. One strength of this theory is predicting special talents and peaks in performance in autistic people. A related theory—enhanced perceptual functioning—focuses more on the superiority of locally oriented and perceptual operations in autistic individuals. These theories map well from the underconnectivity theory of autism.

Neither category is satisfactory on its own; social cognition theories poorly address autism's rigid and repetitive behaviors, while the nonsocial theories have difficulty explaining social impairment and communication difficulties. A combined theory based on multiple deficits may prove to be more useful.

Screening

About half of parents of children with ASD notice their child's unusual behaviors by age 18 months, and about four-fifths notice by age 24 months. According to an article in the *Journal of Autism and Developmental Disorders*, failure to meet any of the following milestones *"is an absolute indication to proceed with further evaluations. Delay in referral for such testing may delay early diagnosis and treatment and affect the long-term outcome."*

- No babbling by 12 months.
- No gesturing (pointing, waving bye-bye, etc.) by 12 months.
- No single words by 16 months.
- No 2-word spontaneous (*not just echolalic*) phrases by 24 months.
- *Any* loss of *any* language or social skills, *at any age*.

US and Japanese practice is to screen all children for ASD at 18 and 24 months, using autism-specific formal screening tests. In contrast, in the UK, children whose families or doctors recognize possible signs of autism are screened. It is not known which approach is more effective. Screening tools include the Modified Checklist for Autism in Toddlers (M-CHAT), the Early Screening of Autistic Traits Questionnaire, and the First Year Inventory; initial data on M-CHAT and its predecessor CHAT on children aged 18–30 months suggests that it is best used in a clinical setting and that it has low sensitivity (many false-negatives) but good specificity (few false-positives). It may be more accurate to precede these tests with a broadband screener that does not distinguish ASD from other developmental disorders. Screening tools designed for one culture's norms for behaviors like eye contact may be inappropriate for a different culture. Although genetic screening for autism is generally still impractical, it can be considered in some cases, such as children with neurological symptoms and dysmorphic features.

Diagnosis

Diagnosis is based on behavior, not cause or mechanism. Autism is defined in the DSM-IV-TR as exhibiting at least six symptoms total, including at least two symptoms of qualitative impairment in social interaction, at least one symptom of qualitative impairment in communication, and at least one symptom of restricted and repetitive behavior. Sample symptoms include lack of social or emotional reciprocity, stereotyped and repetitive use of language or idiosyncratic language, and persistent preoccupation with parts of objects. Onset must be prior to age three years, with delays or abnormal functioning in either social interaction, language as used in social communication, or symbolic or imaginative play. The disturbance must not be better accounted for by Rett syndrome or childhood disintegrative disorder. ICD-10 uses essentially the same definition.

Several diagnostic instruments are available. Two are commonly used in autism research: the Autism Diagnostic Interview-Revised (ADI-R) is a semistructured parent interview, and the Autism Diagnostic Observation Schedule (ADOS) uses observation and interaction with the child. The Childhood Autism Rating Scale (CARS) is used widely in clinical environments to assess severity of autism based on observation of children.

A pediatrician commonly performs a preliminary investigation by taking developmental history and physically examining the child. If warranted, diagnosis and evaluations are conducted with help from ASD specialists, observing and assessing cognitive, communication, family, and other factors using standardized tools, and taking into account any associated medical conditions. A pediatric neuropsychologist is often asked to assess behavior and cognitive skills, both to aid diagnosis and to help recommend educational interventions. A differential diagnosis for ASD at this stage might also consider mental retardation, hearing impairment, and a specific language impairment such as Landau–Kleffner syndrome. The presence of autism can make it harder to diagnose coexisting psychiatric disorders such as depression.

Clinical genetics evaluations are often done once ASD is diagnosed, particularly when other symptoms already suggest a genetic cause. Although genetic technology allows clinical geneticists to link an estimated 40% of cases to genetic causes, consensus guidelines in the US and UK are limited to high-resolution chromosome and fragile X testing. A genotype-first model of diagnosis has been proposed, which would routinely assess the genome's copy number variations. As new genetic tests are developed several ethical, legal, and social issues will emerge. Commercial availability of tests may precede adequate understanding of how to use test results, given the complexity of autism's genetics. Metabolic and neuroimaging tests are sometimes helpful, but are not routine.

ASD can sometimes be diagnosed by age 14 months, although diagnosis becomes increasingly stable over the first three years of life: for example, a one-year-old who meets diagnostic criteria for ASD is less likely than a three-year-old to continue to do so a few years later. In the UK the National Autism Plan for Children recommends at most 30 weeks from first concern to completed diagnosis and assessment, though few cases are

handled that quickly in practice. A 2009 US study found the average age of formal ASD diagnosis was 5.7 years, far above recommendations, and that 27% of children remained undiagnosed at age 8 years. Although the symptoms of autism and ASD begin early in childhood, they are sometimes missed; years later, adults may seek diagnoses to help them or their friends and family understand themselves, to help their employers make adjustments, or in some locations to claim disability living allowances or other benefits.

Underdiagnosis and overdiagnosis are problems in marginal cases, and much of the recent increase in the number of reported ASD cases is likely due to changes in diagnostic practices. The increasing popularity of drug treatment options and the expansion of benefits has given providers incentives to diagnose ASD, resulting in some overdiagnosis of children with uncertain symptoms. Conversely, the cost of screening and diagnosis and the challenge of obtaining payment can inhibit or delay diagnosis. It is particularly hard to diagnose autism among the visually impaired, partly because some of its diagnostic criteria depend on vision, and partly because autistic symptoms overlap with those of common blindness syndromes or blindisms.

Management

A three-year-old with autism points to fish in an aquarium, as part of an experiment on the effect of intensive shared-attention training on language development.

The main goals when treating children with autism are to lessen associated deficits and family distress, and to increase quality of life and functional independence. No single treatment is best and treatment is typically tailored to the child's needs. Families and the educational system are the main resources for treatment. Studies of interventions have methodological problems that prevent definitive conclusions about efficacy. Although many psychosocial interventions have some positive evidence, suggesting that some form of treatment is preferable to no treatment, the methodological quality of systematic reviews of these studies has generally been poor, their clinical results are mostly tentative, and there is little evidence for the relative effectiveness of treatment options. Intensive, sustained special education programs and behavior therapy early in life can help children acquire self-care, social, and job skills, and often improve functioning and decrease symptom severity and maladaptive behaviors; claims that intervention by around age three years is crucial are not substantiated. Available approaches include applied behavior analysis (ABA), developmental models, structured teaching, speech and language therapy, social skills therapy, and occupational therapy.

Educational interventions have some effectiveness in children: intensive ABA treatment has demonstrated effectiveness in enhancing global functioning in preschool children and is well-established for improving intellectual performance of young children. Neuropsychological reports are often poorly communicated to educators, resulting in a gap between what a report recommends and what education is provided. It is not known whether treatment programs for children lead to significant improvements after the children grow up, and the limited research on the effectiveness of adult residential programs shows mixed results. The appropriateness of including children with varying severity of autism spectrum disorders in the general education population is a subject of current debate among educators and researchers.

Many medications are used to treat ASD symptoms that interfere with integrating a child into home or school when behavioral treatment fails. More than half of US children diagnosed with ASD are prescribed psychoactive drugs or anticonvulsants, with the most common drug classes being antidepressants, stimulants, and antipsychotics. Aside from antipsychotics, there is scant reliable research about the effectiveness or safety of drug treatments for adolescents and adults with ASD. A person with ASD may respond atypically to medications, the medications can have adverse effects, and no known medication relieves autism's core symptoms of social and communication impairments. Experiments in mice have reversed or reduced some symptoms related to autism by replacing or modulating gene function, suggesting the possibility of targeting therapies to specific rare mutations known to cause autism.

Although many alternative therapies and interventions are available, few are supported by scientific studies. Treatment approaches have little empirical support in quality-of-life contexts, and many programs focus on success measures that lack predictive validity and real-world relevance. Scientific evidence appears to matter less to service providers than program marketing, training availability, and parent requests. Some alternative treatments may place the child at risk. A 2008 study found that compared to their peers, autistic boys

have significantly thinner bones if on casein-free diets; in 2005, botched chelation therapy killed a five-year-old child with autism.

Treatment is expensive; indirect costs are more so. For someone born in 2000, a US study estimated an average lifetime cost of $3.77 million (net present value in 2011 dollars, inflation-adjusted from 2003 estimate), with about 10% medical care, 30% extra education and other care, and 60% lost economic productivity. Publicly supported programs are often inadequate or inappropriate for a given child, and unreimbursed out-of-pocket medical or therapy expenses are associated with likelihood of family financial problems; one 2008 US study found a 14% average loss of annual income in families of children with ASD, and a related study found that ASD is associated with higher probability that child care problems will greatly affect parental employment. US states increasingly require private health insurance to cover autism services, shifting costs from publicly funded education programs to privately funded health insurance. After childhood, key treatment issues include residential care, job training and placement, sexuality, social skills, and estate planning.

Prognosis

No cure is known. Children recover occasionally, so that they lose their diagnosis of ASD; this occurs sometimes after intensive treatment and sometimes not. It is not known how often recovery happens; reported rates in unselected samples of children with ASD have ranged from 3% to 25%. Most autistic children can acquire language by age 5 or younger, though a few have developed communication skills in later years. Most children with autism lack social support, meaningful relationships, future employment opportunities or self-determination. Although core difficulties tend to persist, symptoms often become less severe with age. Few high-quality studies address long-term prognosis. Some adults show modest improvement in communication skills, but a few decline; no study has focused on autism after midlife. Acquiring language before age six, having an IQ above 50, and having a marketable skill all predict better outcomes; independent living is unlikely with severe autism. A 2004 British study of 68 adults who were diagnosed before 1980 as autistic children with IQ above 50 found that 12% achieved a high level of independence as adults, 10% had some friends and were generally in work but required some support, 19% had some independence but were generally living at home and needed considerable support and supervision in daily living, 46% needed specialist residential provision from facilities specializing in ASD with a high level of support and very limited autonomy, and 12% needed high-level hospital care. A 2005 Swedish study of 78 adults that did not exclude low IQ found worse prognosis; for example, only 4% achieved independence. A 2008 Canadian study of 48 young adults diagnosed with ASD as preschoolers found outcomes ranging through poor (46%), fair (32%), good (17%), and very good (4%); 56% of these young adults had been employed at some point during their lives, mostly in volunteer, sheltered or part-time work. Changes in diagnostic practice and increased availability of effective early intervention make it unclear whether these findings can be generalized to recently diagnosed children.

Epidemiology



Reports of autism cases per 1,000 children grew dramatically in the US from 1996 to 2007. It is unknown how much, if any, growth came from changes in autism's prevalence.

Most recent reviews tend to estimate a prevalence of 1–2 per 1,000 for autism and close to 6 per 1,000 for ASD; because of inadequate data, these numbers may underestimate ASD's true prevalence. PDD-NOS's prevalence has been estimated at 3.7 per 1,000, Asperger syndrome at roughly 0.6 per 1,000, and childhood disintegrative disorder at 0.02 per 1,000. The number of reported cases of autism increased dramatically in the 1990s and early 2000s. This increase is largely attributable to changes in diagnostic practices, referral patterns, availability of services, age at diagnosis, and public awareness, though unidentified environmental risk factors cannot be ruled out. The available evidence does not rule out the possibility that autism's true prevalence has increased; a real increase would suggest directing more attention and funding toward changing environmental factors instead of continuing to focus on genetics.

Boys are at higher risk for ASD than girls. The sex ratio averages 4.3:1 and is greatly modified by cognitive impairment: it may be close to 2:1 with mental retardation and more than 5.5:1 without. Although the evidence does not implicate any single pregnancy-related risk factor as a cause of autism, the risk of autism is associated with advanced age in either parent, and with diabetes, bleeding, and use of psychiatric drugs in the mother during pregnancy. The risk is greater with older fathers than with older mothers; two potential explanations are the known increase in mutation burden in older sperm, and the hypothesis that men marry later if they carry genetic liability and show some signs of

autism. Most professionals believe that race, ethnicity, and socioeconomic background do not affect the occurrence of autism.

Several other conditions are common in children with autism. They include:

- **Genetic disorders**. About 10–15% of autism cases have an identifiable Mendelian (single-gene) condition, chromosome abnormality, or other genetic syndrome, and ASD is associated with several genetic disorders.
- **Mental retardation**. The fraction of autistic individuals who also meet criteria for mental retardation has been reported as anywhere from 25% to 70%, a wide variation illustrating the difficulty of assessing autistic intelligence. For ASD other than autism, the association with mental retardation is much weaker.
- **Anxiety disorders** are common among children with ASD; there are no firm data, but studies have reported prevalences ranging from 11% to 84%. Many anxiety disorders have symptoms that are better explained by ASD itself, or are hard to distinguish from ASD's symptoms.
- **Epilepsy**, with variations in risk of epilepsy due to age, cognitive level, and type of language disorder.
- Several **metabolic defects**, such as phenylketonuria, are associated with autistic symptoms.
- **Minor physical anomalies** are significantly increased in the autistic population.
- **Preempted diagnoses**. Although the DSM-IV rules out concurrent diagnosis of many other conditions along with autism, the full criteria for ADHD, Tourette syndrome, and other of these conditions are often present and these comorbid diagnoses are increasingly accepted.
- **Sleep problems** affect about two-thirds of individuals with ASD at some point in childhood. These most commonly include symptoms of insomnia such as difficulty in falling asleep, frequent nocturnal awakenings, and early morning awakenings. Sleep problems are associated with difficult behaviors and family stress, and are often a focus of clinical attention over and above the primary ASD diagnosis.

History

Leo Kanner introduced the label *early infantile autism* in 1943

A few examples of autistic symptoms and treatments were described long before autism was named. The *Table Talk* of Martin Luther, compiled by his notetaker, Mathesius, contains the story of a 12-year-old boy who may have been severely autistic. Luther reportedly thought the boy was a soulless mass of flesh possessed by the devil, and suggested that he be suffocated, although a later critic has cast doubt on the veracity of this report. The earliest well-documented case of autism is that of Hugh Blair of Borgue, as detailed in a 1747 court case in which his brother successfully petitioned to annul Blair's marriage to gain Blair's inheritance. The Wild Boy of Aveyron, a feral child caught in 1798, showed several signs of autism; the medical student Jean Itard treated him with a behavioral program designed to help him form social attachments and to induce speech via imitation.

The New Latin word *autismus* (English translation *autism*) was coined by the Swiss psychiatrist Eugen Bleuler in 1910 as he was defining symptoms of schizophrenia. He

derived it from the Greek word *autós* (αὐτός, meaning *self*), and used it to mean morbid self-admiration, referring to "autistic withdrawal of the patient to his fantasies, against which any influence from outside becomes an intolerable disturbance".

The word *autism* first took its modern sense in 1938 when Hans Asperger of the Vienna University Hospital adopted Bleuler's terminology *autistic psychopaths* in a lecture in German about child psychology. Asperger was investigating an ASD now known as Asperger syndrome, though for various reasons it was not widely recognized as a separate diagnosis until 1981. Leo Kanner of the Johns Hopkins Hospital first used *autism* in its modern sense in English when he introduced the label *early infantile autism* in a 1943 report of 11 children with striking behavioral similarities. Almost all the characteristics described in Kanner's first paper on the subject, notably "autistic aloneness" and "insistence on sameness", are still regarded as typical of the autistic spectrum of disorders. It is not known whether Kanner derived the term independently of Asperger.

Kanner's reuse of *autism* led to decades of confused terminology like *infantile schizophrenia*, and child psychiatry's focus on maternal deprivation led to misconceptions of autism as an infant's response to "refrigerator mothers". Starting in the late 1960s autism was established as a separate syndrome by demonstrating that it is lifelong, distinguishing it from mental retardation and schizophrenia and from other developmental disorders, and demonstrating the benefits of involving parents in active programs of therapy. As late as the mid-1970s there was little evidence of a genetic role in autism; now it is thought to be one of the most heritable of all psychiatric conditions. Although the rise of parent organizations and the destigmatization of childhood ASD have deeply affected how we view ASD, parents continue to feel social stigma in situations where their autistic children's behaviors are perceived negatively by others, and many primary care physicians and medical specialists still express some beliefs consistent with outdated autism research.

The Internet has helped autistic individuals bypass nonverbal cues and emotional sharing that they find so hard to deal with, and has given them a way to form online communities and work remotely. Sociological and cultural aspects of autism have developed: some in the community seek a cure, while others believe that autism is simply another way of being.